



EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Eventos y convocatorias.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

Eventos y convocatorias

RFPs: Innovaciones para la Preparación ante Futuras Epidemias y Pandemias

La Coalición para las Innovaciones en Preparación para Epidemias (CEPI, por sus siglas en inglés) invita a innovadores de todo el mundo a presentar sus solicitudes en su convocatoria abierta de apoyo a la investigación, el desarrollo y la fabricación de vacunas contra amenazas epidémicas y pandémicas, incluida la "Enfermedad X". La convocatoria *Innovations to Prepare for Future Epidemics and Pandemics* (Innovaciones para la Preparación ante Futuras Epidemias y Pandemias) respalda la misión de CEPI y la Misión de los 100 Días.



Resumen

- ♦ Organización financiadora: Coalición para las Innovaciones en Preparación para Epidemias (CEPI)
Tipo de oportunidad: Convocatoria de propuestas (programas científicos; innovaciones en vacunas).
- ♦ Propósito de la convocatoria: Impulsar innovaciones en el desarrollo y la fabricación de vacunas para los patógenos prioritarios de CEPI con potencial epidémico o pandémico (incluidos patógenos novedosos capaces de infectar y causar enfermedad en humanos, es decir, la Enfermedad X).
- ♦ Elegibilidad geográfica (solicitantes): Innovadores de todo el mundo (no se especifican restricciones por país en la fuente)
- ♦ Áreas de enfoque abiertas: Solo el Área de Enfoque 2 permanece abierta para recibir solicitudes.
- ♦ Fecha límite del Área de Enfoque 2: 14 de diciembre de 2026.
- ♦ Plazos de presentación y revisión: Las solicitudes pueden presentarse de forma continua y se revisarán trimestralmente, con períodos de revisión que comienzan el 13 de julio, el 12 de octubre y el 14 de diciembre.
- ♦ Método de solicitud: Se presentan a través del Portal de CEPI
- ♦ Nota adicional: Todas las propuestas presentadas en el marco de esta convocatoria pasarán por un proceso de revisión acelerado.
- ♦ URL de la fuente: <https://cepi.net/calls-for-proposals?selectedProposal=11>

Acerca de la convocatoria

El plan pandémico de CEPI tiene como objetivo reducir sustancialmente —o incluso eliminar— el riesgo futuro de pandemias y epidemias. El plan se organiza en torno a tres pilares: preparar, transformar y conectar y mejorar la colaboración global.

Dentro de esta estrategia, la convocatoria "Innovaciones para la Preparación ante Futuras Epidemias y Pandemias" está diseñada para respaldar la misión de CEPI mediante el impulso de una amplia gama de innovaciones en vacunas para patógenos con potencial epidémico/pandémico, incluidos patógenos novedosos que pueden infectar a humanos (Enfermedad X). La convocatoria también pretende contribuir a la Misión de los 100 Días, cuyo propósito es ayudar al mundo a prepararse para amenazas epidémicas y pandémicas conocidas y futuras.

Financiamiento y Beneficios

La fuente describe la intención de CEPI de apoyar:

- ♦ Innovaciones en investigación, desarrollo y fabricación de vacunas para los patógenos prioritarios de CEPI.
- ♦ Innovaciones en vacunas que contribuyan a la rapidez, escala y acceso equitativo durante la respuesta a futuros brotes.

Importante: La página proporcionada no especifica:

- ♦ El fondo total de financiamiento ni el monto por adjudicación.
- ♦ El tamaño de la subvención, los requisitos de contrapartida o los costos elegibles/no elegibles.

¿Quién es Elegible?

- ♦ Ubicación del solicitante: Innovadores de todo el mundo pueden presentar solicitudes. No se enumeran países elegibles específicos en la página proporcionada. No especificado en la fuente.
- ♦ Solicitantes elegibles (tipo): La página no especifica tipos de organizaciones (por ejemplo, instituciones académicas, industria, ONG) como criterios de elegibilidad. No especificado en la fuente.
- ♦ Alcance del Área de Enfoque 2 (lo que los solicitantes deben abordar): Desarrollar nuevos candidatos vacunales contra los patógenos prioritarios de CEPI con potencial epidémico o pandémico y familias virales.
- ♦ Requisito del portal para solicitar: Para presentar una solicitud, los solicitantes deben estar registrados como Usuario del Portal de CEPI.

Actividades Elegibles o Áreas Prioritarias

La convocatoria apoya innovaciones alineadas con el desarrollo y la fabricación de vacunas para amenazas epidémicas/pandémicas, incluida la Enfermedad X. Para el área de solicitud actualmente abierta:

- ♦ Área de Enfoque 2: Desarrollar nuevos candidatos a vacunas contra los patógenos prioritarios de CEPI con potencial epidémico o pandémico y familias virales.
- ♦ Podrán introducirse y actualizarse Áreas de Enfoque adicionales con el tiempo a medida que se identifiquen brechas y necesidades de I+D. Los solicitantes deben consultar periódicamente las actualizaciones.

Por qué es importante esta oportunidad

Esta convocatoria está dirigida a organizaciones que trabajan en candidatos a vacunas de próxima generación y enfoques de fabricación habilitantes para patógenos que representan riesgos epidémicos o pandémicos. Al enfocarse en los patógenos prioritarios de CEPI y hacer énfasis en la Misión de los 100 Días, la oportunidad se posiciona en torno a acelerar el camino desde la innovación en vacunas hacia una respuesta a brotes más rápida, escalable y equitativa.

Para obtener más información sobre cómo aplicar, consejos para la solicitud o errores comunes, preguntas frecuentes y próximos pasos:

<https://www2.fundsforngos.org/innovation/cepi-innovations-to-prepare-for-future-epidemics-and-pandemics-call-for/amp/>



Noticias en la Web

Se han añadido cuatro vacunas más al Programa Ampliado de Inmunización: ¿Cuándo se implementarán?

1 oct. Según la hoja de ruta aprobada por el Gobierno en la Resolución N° 104/NQ-CP del 15 de agosto de 2022, el Programa Ampliado de Inmunización para el período 2021-2030 incorporará cuatro vacunas: la vacuna contra el rotavirus para la diarrea, la vacuna neumocócica, la vacuna contra el VPH humano y la vacuna contra la influenza estacional.

“El Programa Ampliado de Inmunización está incorporando gradualmente nuevas vacunas, ampliando así el alcance de la prevención de enfermedades para la población.”

En declaraciones a un reportero de la revista *Tri Thuc & Cuoc Song* (Conocimiento y Vida), el Sr. Phi Van Kien, Jefe del Departamento de Gestión de Vacunación del Departamento de Prevención de Enfermedades del Ministerio de Salud, afirmó que la vacuna contra el rotavirus que previene la diarrea se ha incluido en el Programa Ampliado de Inmunización y se implementará en todo el país a partir de principios de 2026. Anteriormente, esta vacuna se había implementado a pequeña escala en algunas provincias desde 2024.

En cuanto a la vacuna neumocócica, el Ministerio de Salud planea implementarla a pequeña escala en 10 provincias a partir de finales de 2026. El Ministerio de Salud está tramitando actualmente los procedimientos de adquisición de la vacuna contra el VPH para su implementación en el Programa, prevista para el período 2026-2027.

En concreto, la vacuna contra la gripe estacional se incluirá en el Programa Ampliado de Inmunización para el año 2030, según una hoja de ruta aprobada por el Gobierno.

Cabe destacar que, a partir del 1 de julio de 2026, las enfermedades relacionadas con el VPH humano se incluyeron en la lista de enfermedades que requieren vacunación obligatoria a través del Programa Ampliado de Inmunización. Sin embargo, la implementación de las vacunas contra el VPH aún se ajusta al calendario y los recursos asignados.

Hasta la fecha, el Programa Nacional Ampliado de Inmunización ha proporcionado 12 tipos de vacunas de forma gratuita, entre ellas la vacuna contra la hepatitis B, la vacuna contra la tuberculosis, la vacuna contra la difteria, la tos ferina y el tétanos (DPT), la vacuna combinada DPT-VGB-Hib, la vacuna oral contra la poliomielitis (OPV), la vacuna inyectable contra la poliomielitis (IPV), la vacuna contra el sarampión, la vacuna contra el sarampión y la rubéola (MR), la vacuna contra la encefalitis japonesa B, la vacuna contra el tétanos para mujeres embarazadas y adultos, la vacuna Td y la vacuna contra la diarrea por rotavirus.

Según el Dr. Duong Chi Nam, subdirector del Departamento de Prevención de Enfermedades del Ministerio de Salud, en los primeros ocho meses de 2026, el progreso en la distribución de vacunas en el marco del Programa a nivel nacional cumplió con los objetivos del plan para 2026, incluyendo la vacuna contra la hepatitis B para recién nacidos y la vacuna contra el tétanos para mujeres embarazadas.

El Programa Ampliado de Inmunización se ha implementado en Vietnam durante más de 40 años, contribuyendo a la reducción de la incidencia y la mortalidad por varias enfermedades infecciosas peligrosas en niños. Vietnam ha mantenido y protegido sus logros en la erradicación de la poliomielitis desde el año 2000 y la eliminación del tétanos neonatal desde 2005.

La ampliación del catálogo de vacunas en el marco del Programa Ampliado de Inmunización se está llevando a cabo en el contexto de la entrada en vigor de la Ley de Prevención de Enfermedades el 1 de julio de 2026 y de la implementación por parte del Ministerio de Salud del Plan Ampliado de Inmunización para el período 2026-2028.

La implementación gradual de las vacunas requiere una preparación coordinada, desde la selección, adquisición y suministro de las vacunas hasta la organización de la vacunación y la garantía de su seguridad. Para la población,

cuando se introducen nuevas vacunas, es necesario seguir las directrices oficiales del sector salud con respecto a los grupos objetivo, los calendarios de vacunación y el alcance de la implementación, evitando confusiones entre las vacunas que ya figuran en la lista y las que ya se utilizan ampliamente en la práctica.

Fuente: VIETNAM.VN. Disponible en <https://n9.cl/vo2j10>



Egypt's GennVax, China's Minhai sign deal to transfer pneumococcal vaccine technology

Oct 1. EDA Chairman Ali El-Ghamrawy witnessed the signing during a visit to Minhai's facilities in China, where he explored cooperation in vaccine development and manufacturing.

The agreement aims to localize the production of priority vaccines and strengthen Egypt's manufacturing capabilities, the authority said. Egypt has adopted a national vaccine manufacturing strategy covering 2024–2030.



During the visit, El-Ghamrawy toured Minhai's PCV-13 pneumococcal vaccine production line, reviewing manufacturing stages and the technical equipment and technologies used in production.

Discussions also covered potential cooperation in manufacturing technology transfer and the exchange of technical expertise between the Egyptian and Chinese pharmaceutical sectors.

El-Ghamrawy stressed the importance of expanding partnerships with specialist vaccine manufacturers to transfer knowledge, develop local production capabilities, and strengthen the sustainability and competitiveness of Egypt's vaccine industry.

The focus on manufacturing partnerships comes alongside investment in new facilities. Egypt began construction of a \$220 million vaccine complex in the Suez Canal Economic Zone in December 2025.

The talks with Minhai also addressed opportunities to develop production capacity and technical expertise, strengthen the security of pharmaceutical supplies, and expand cooperation with regional and international markets, the EDA said.

Separately, the European Investment Bank announced a €750,000 technical assistance package in June for studies supporting VACSERA's planned €50 million vaccine facility.

In September, the cabinet approved a draft presidential decree concerning the VACSERA cooperation agreement underpinning those preparatory studies.

The EDA said the Minhai visit forms part of its efforts to expand international partnerships, support technology transfer and attract investment into Egypt's pharmaceutical industry.

Egypt attained WHO maturity level 3 for medicines and vaccine regulation in December 2024, recognizing the stability and effectiveness of its regulatory system.

Fuente: AHARAM ONLINE. Disponible en <https://n9.cl/kcragc>

Cultivating HPV to Improve Vaccine Development

Oct 1. It's recommended that all adolescents get vaccinated against human papilloma virus (HPV), as the infection can cause cancer. HPV causes nearly all cases of cervical cancer and about 70% of some forms of head and neck cancers. While some regions of the United States have relatively high rates of HPV vaccination, there are major vaccine shortages in much of the world.

A new Yale study, published Sept. 30 in Science Advances, introduces a genetic platform that could be used to boost future HPV vaccine development.



"The current vaccine is great, there's just not enough of it," says Daniel DiMaio, MD PhD, Waldemar Von Zedtwitz Professor of Genetics at Yale School of Medicine (YSM). "There are persistent vaccine shortages that are anticipated to continue for the foreseeable future. Therefore, there would be a real advantage to coming up with ways to make more vaccines or make them more efficiently."

Growing HPV in bulk

To create a better vaccine, DiMaio and his lab members homed in on a molecule—called the L1 protein—that's part of the virus-like particle used in the HPV vaccine. They reasoned that they could look for and isolate different versions of the L1 protein that might enable better vaccines. But there was a problem—there were no methods that allowed them to do that. So, they set about to develop a technique to isolate better versions of the L1 protein. The first step was to overcome how difficult HPV is to cultivate.

“For other viruses, like influenza or SARS, we can cultivate a virus stock by letting the viruses reproduce in host cells we grow in the laboratory,” says DiMaio, a member of Yale Cancer Center. “But HPV will not reproduce in these simulated conditions. That has hindered the study of HPV, and that’s one of the barriers we had to overcome.”

To address these challenges, DiMaio and his lab first set out to develop a procedure to cultivate and manipulate large quantities of the HPV virus. Luckily, the researchers had two advantages, says DiMaio: a long-term grant from the National Cancer Institute, which gave them time to explore, and Yuka Takeo, PhD, a postdoctoral researcher and the paper’s first author.

“When we started this project, we didn't know if it would work,” says Takeo. “As a researcher, it's risky to have a project that might not produce a result. But we cared about this.”

For several years, DiMaio and Takeo looked for ways to overcome HPV's unique biology in order to grow it in culture. HPV is composed of DNA packaged in a protein shell consisting of L1 and L2 proteins. When the researchers tried to grow the virus with L1 and L2 expressed from the same piece of DNA, called a plasmid, the plasmid was unstable and could not produce a virus. One of their breakthroughs came when they realized that if they expressed L1 and L2 from different plasmids, the plasmid stabilized and they could grow the virus.

“The size of the plasmid was very important because HPV can only package small pieces of DNA,” says Takeo. “It was a breakthrough for us to have L1 and L2 on their own, small plasmids.”

Developing a library of HPV mutants

Being able to cultivate HPV solved one of the challenges in vaccine development. Having a version of HPV that doesn't require refrigeration or that assembles more efficiently would solve others. But that would require different HPV variants than those currently used in the vaccine.

To find a virus variant with a particular characteristic, such as being shelf-stable, researchers create thousands of random mutants and put them through a selection process.

HPV mutants are made by adding mutated plasmids to cells. This introduces mutations to the virus population, but it does so randomly; most viruses will contain a mutated piece of DNA that does not match the mutant L1 protein in that same virus. DiMaio and Takeo needed a way to ensure a match between the mutation in the packaged DNA and the mutant L1 protein within the virus particle.

“If the mutant protein and the mutated DNA in the virus particle do not match, you can't select for that mutant,” explains DiMaio. “We had to partition each one of these thousands or millions of mutations into the appropriate virus so that we could evaluate each mutation separately.”

After close to five years of tests, the team found a way to ensure that each mutant virus contained only the matched mutant DNA. First, they exposed HPV to thousands of pieces of DNA, each with a different mutation, and the viruses took in the mutant DNA randomly.

Then, they introduced the virus to cultures of human kidney cells in small enough amounts that each kidney cell could be infected by only a single virus. The virus would then undergo its natural life cycle, reproducing within the kidney cell.

“We infected cells, and we recovered viruses that we hoped were enriched for particular mutants,” says DiMaio.

Pulling one mutant from the library

Through this work, the researchers built a library of mutants. The next step was to demonstrate that they could pull just one mutant out of their library. This test would help them determine if they could someday pull a mutant out to use in a vaccine.

For the test, they aimed to show that they could select a mutant with a specific characteristic, in this case antibiotic resistance. When they modified the HPV plasmids, they attached a gene that would make the virus resistant to specific antibodies. Then they exposed the mutant library to the antibodies and infected cells. Rare mutant viruses survived, and further testing confirmed they were indeed mutants resistant to those specific antibodies. This confirmed to Takeo and DiMaio that they could select mutant with desired properties from their library.

There is a long way to go before this technology can be used to develop the next HPV vaccine. But this new platform pushes the boundaries of what was previously thought possible and establishes the first system to use genetic selection for HPV. The lab is now working to select mutants that make more stable vaccines.

“We began this work because we wanted to study how the virus grows,” says DiMaio. “Now that we have developed a way to select mutants, this approach could eventually lead to more or better vaccines or even antiviral agents.”

Fuente: Newswise. Disponible en <https://n9.cl/6tz7m>

Suvoda Expands Unified Clinical Trial Platform With AI-Powered Capabilities

Oct 2. Suvoda, a global clinical trial technology company, announced a new release of important advancements since unifying the market-leading Suvoda and Greenphire products on one platform. Innovations in AI and new product functionality are expanding the platform's capabilities, reducing manual work for users, and giving patients, sites, and sponsors more choices in how to engage with their trial technology worldwide.

The Suvoda Platform connects technology and services across the mission-critical, time-sensitive moments in a clinical trial, so that sponsors, CROs, sites, and patients have



the insight to make smarter decisions and the ease to move faster. It solves a longstanding challenge in clinical trials: study teams have had to stitch together technology that was never built to work together, with separate vendors, logins, and support teams in order to handle randomization, drug supply, questionnaire completion, payments, travel, and patient consent. Suvoda is turning that patchwork experience into a single platform the industry has not seen before.

Advancements include:

AI built into the platform. Suvoda is bringing AI capabilities across its unified platform, beginning with RTSM and eCOA and expanding into financial services such as patient payments. The results are significant. Suvoda's agentic RTSM capability is demonstrating up to an 80% reduction in kickoff-to-UAT timelines. Sofia, Suvoda's conversational AI assistant, lets sponsors and sites find information and take permissioned action across multiple languages, with every action logged and auditable. Humans retain sign-off authority at every step.

One login for eight connected products. The new Product Launchpad, rolling out across global trials, lets study teams move between RTSM/IRT, eCOA, eConsent, Scheduling, Patient Payments, Travel, Site Payments, and Budgeting & Benchmarking without switching systems. A unified data layer means participant data entered once in RTSM can flow automatically across products, eliminating re-entry.

Faster, more confident sponsor and CRO decisions. New reporting and self-service enhancements give sponsors and CROs more choice and control. Examples include a finance and travel reporting portal that enables self-service access to the study data they need when they need it. The Budgeting & Benchmarking solution now allows negotiations to happen right in the platform rather than offline, and payment data feeds back to sharpen fair-market value benchmarks in real time.

A better patient experience. The award-winning Suvoda App gives patients a single place to track visits, book rides, complete questionnaires, and receive micropayments upon task completion. Sites can conduct video calls for at-home patient visits and provide their schedule availability for easier appointment scheduling. Patients across the globe can receive reimbursement through the payment method that works for them such as digital wallet payments, including Alipay in China. For sites, this means fewer inbound calls on payment and travel status and fewer manual handoffs.

"This release shows what a platform-based and AI-enabled product suite makes possible. Sites can spend less time reconciling systems, patients can have an easier clinical trial experience wherever they are, and sponsors get faster answers to their important questions. I'm immensely proud of our teams. They have embraced a bold vision for the future and have brought it to life through innovative technology designed to make clinical trial work better for everyone involved," said Jagath Wanninayake, CEO, Suvoda.

Suvoda is a global clinical trial technology company with a market-leading, real-time software platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools.

Fuente: BioPharma APAC. Disponible en <https://n9.cl/wvefo>

In 1963, Maurice Hilleman swabbed his 5-year-old daughter's throat after she caught mumps; four years later, the vaccine built from her virus strain was licensed in the US and remains in use

Oct 4. In 1963, vaccine researcher Dr Maurice Hilleman was working to develop a safe and effective vaccine against mumps when his five-year-old daughter, Jeryl Lynn, developed the disease. One night, Jeryl Lynn woke Hilleman and showed him her swollen cheeks, a characteristic sign of mumps. He then swabbed her throat to collect a sample of the virus and drove it to his laboratory.



Hilleman was the chief virologist at Merck Research Laboratories in the 1960s and had set out to create a mumps vaccine. At the time, mumps was considered a common childhood illness, and many parents underestimated its dangers. According to the Smithsonian's National Museum of American History, scientists had already tried to develop a vaccine, but earlier attempts had problems. Some vaccines caused too many mumps symptoms, while others did not provide enough immunity. Jeryl Lynn's infection gave Hilleman a chance to try a different approach. He suspected that he needed to work with another strain of the virus. After collecting the sample from his daughter, he began trying to weaken the virus, a process known as attenuation. The aim was to make the virus weak enough that it would not cause mumps, while still allowing it to produce immunity. Hilleman achieved this by introducing the virus to generations of chicken embryo cells. With each generation, the virus changed. It became better at attacking the chick cells and less able to attack human cells. The resulting vaccine strain was officially named the Jeryl Lynn Strain, after the child whose infection provided the original virus sample.


From Jeryl Lynn's infection to a vaccine

Human testing showed that the Jeryl Lynn Strain vaccine could produce strong immunity without causing the disease in vaccinated children. The work then moved towards clinical use, including a remarkable connection within the Hilleman family.

Jeryl Lynn herself could not benefit directly from the vaccine that carried her name. Her younger sister, Kirsten Jeanne Hilleman, did. In 1966, Kirsten was immunised with the investigational vaccine. A photograph from that year shows Jeryl Lynn comforting her younger sister as Kirsten received the vaccine from Dr Robert Weibel.

The Smithsonian says the vaccine was developed from the virus collected from Jeryl Lynn's mumps infection. Its collection also includes vials of the investigational vaccine used to immunise Kirsten.

In 1967, the US Food and Drug Administration approved Merck's mumps vaccine. The vaccine developed by Hilleman remains in use today and is still derived from the Jeryl Lynn strain. The Smithsonian also notes that doctors began administering the Jeryl Lynn Strain mumps vaccine to the American public in early 1968.



Why the mumps vaccine mattered

The vaccine was developed against a disease that could cause more than the familiar swelling of the jaw and cheeks. Most people who contract mumps recover fully, but the disease can also lead to serious and sometimes permanent complications.

These include inflammation of the testicles and ovaries, encephalitis, which is swelling of the brain, meningitis, which is infection of the tissue around the brain and spinal cord, seizures and deafness. Before vaccination, mumps was also a significant cause of acquired deafness in childhood in the United States. The Smithsonian noted that the disease was once so common that it was often treated as a normal part of growing up, even though it could have serious consequences.

The museum marked 50 years of mumps vaccination in America in 2018. It described how the vaccine helped make the swollen cheeks associated with mumps a thing of the past for many Americans.

The change was also reflected in popular culture. The Smithsonian holds two Norman Rockwell prints from around 1972 that were commissioned by Merck Research Laboratories to celebrate vaccination and the changing American experience of childhood disease. One of the works shows a family having to cancel a fishing trip after their son develops mumps.

The virus sample was kept for decades

The story of the Jeryl Lynn Strain did not end with the vaccine's development. The Smithsonian later acquired an object connected to the preservation of the virus stock used for vaccine production.

The museum acquired a shiny stainless-steel 15-litre canister that had stored part of the frozen Jeryl Lynn virus "seed stock". It was one of five canisters used to keep the entire supply safe and pure. According to the Smithsonian, the stock kept in the canister could produce 3.26 billion doses of vaccine.

The container had protected the stock for years, but its green neoprene stopper eventually began to fail. That created a problem because the virus stock had to be moved without becoming contaminated or losing its potency.

In 2015, Merck scientists undertook the task of thawing and transferring the precious seed stock into new containers. The Smithsonian said that if the stock had lost its potency or become contaminated during the transfer, it could have taken five to seven years to produce new stock.

The transfer was successful. The Jeryl Lynn stock was moved into a more secure type of container, while the old stainless-steel canister became part of the Smithsonian's collection.

Fuente: THE TIMES OF INDIA. Disponible en <https://n9.cl/ohkt4i>

Los ensayos clínicos en el Instituto de Hematología e Inmunología

5 oct. Los ensayos clínicos (EC) realizados en el Instituto de Hematología e Inmunología en los últimos 12 años permitieron evaluar terapéuticas o intervenciones en pacientes (participantes voluntarios) y contribuyeron al registro sanitario de medicamentos cubanos como la vacuna anti SARS-CoV-2, Soberana Plus.

Actualmente, optan por la Certificación en Buenas Prácticas Clínicas, según la Lic. Laura Ruiz Villegas, coordinadora de Ensayos Clínicos en el IHI Dr. José M. Ballester Santovenia que el primero de diciembre celebrará al aniversario 60 de fundada.

Un ensayo clínico es una investigación determinante en la evaluación de un producto, sustancia, medicamento, técnica diagnóstica o terapéutica para su aplicación en humanos.

Durante la pandemia, el IHI colaboró con otras instituciones en cuatro EC que comprobaron eficacia y seguridad de esquemas terapéuticos para incrementar la inmunidad contra el virus y fueron el sitio clínico de tres ensayos, donde se demostró la eficacia de un tratamiento y un candidato vacunal.

Laura Ruiz explica que el Instituto promovió la investigación en la cual se demostró seguridad y efectividad para el tratamiento de lesiones pulmonares con células madre autólogas en pacientes recuperados de COVID-19, así como la disminución de varios biomarcadores inflamatorios.

El IHI fue el sitio clínico seleccionado por el Instituto Finlay de Vacunas para probar el candidato vacunal FINLAY-FR-1A, que se convirtió en la vacuna SOBERANA®Plus.



Los EC con Soberana Plus demostraron que es muy segura, bien tolerada, con pocos eventos adversos (por lo general leves y locales) y que con una dosis estimula fuertemente la inmunidad humoral y celular en individuos con inmunidad natural preexistente.

También comprobaron que induce anticuerpos neutralizantes contra diferentes variantes del virus, incluyendo la Delta, que es la más transmisible.




Los resultados de los ensayos con Soberana Plus fueron publicados en revistas nacionales (Anales de la Academia de Ciencias de Cuba) e internacionales de alto impacto (entre ellas *The Lancet Regional Health–Americas* y *The Lancet Respiratory Medicine*).

Todos los ensayos durante la pandemia se realizaron en corto tiempo, con una gran rapidez e incluyendo un número importante de sujetos, sin violar las regulaciones nacionales ni internacionales para la investigación con seres humanos.

Otro EC muy importante realizado en el IHI, promovido por el Centro de Biopreparados (BIOCEN) y monitoreado por el CENCEC, está relacionado con la aplicación de un esquema de tratamiento con Biomodulina T en niños de 1 a 5 años con hipoplasia de timo. Fue un EC desarrollado durante 5 años (sin detenerse por la pandemia) y con el que se demostró la seguridad y eficacia de este esquema de tratamiento para la cura de la hipoplasia de timo en los niños estudiados.

Los resultados de éste EC fueron publicados en varias revistas nacionales e internacionales y recientemente galardonado con el Premio Anual de la Academia de Ciencias de Cuba.

Otro EC en el que intervino el IHI fue en el de Neumo11 en una primera etapa donde vacunaron un centenar de participantes, en su mayoría trabajadores del propio instituto, mientras la siguiente etapa fue en tres policlínicos del municipio Plaza.

Se estudió la seguridad y eficacia del candidato vacunal conjugado antineumocócico de 11 valencias del Instituto Finlay de Vacunas, en adultos de 50 a 74 años.

La coordinadora de EC expresó que la labor del sexagenario centro en el registro sanitario de los productos, ha tenido un impacto directo en los indicadores de salud, modificados por la introducción de nuevos productos o indicaciones.

Además, explicó que los resultados repercuten en la posible comercialización fuera del país, con el consiguiente beneficio económico para el desarrollo integral de la sociedad.

Los impactos indirectos han sido mejor organización y coordinación entre los servicios, aseguramiento de insumos médicos, así como el perfeccionamiento de los recursos humanos que participan en las investigaciones científicas.

Fuente: TRABAJADORES. Disponible en <https://n9.cl/qs1vi>

Vacuna VAX-31 de Vaxcyte cumple objetivos en ensayo fase 3

5 oct. Vaxcyte Inc. (NASDAQ:PCVX) anunció hoy que su candidata a vacuna neumocócica conjugada VAX-31 cumplió todos los criterios de valoración primarios preestablecidos en el ensayo pivotal de fase 3 OPUS-1, que evalúa la seguridad e inmunogenicidad en adultos.



El ensayo inscribió a 4,047 participantes en aproximadamente 30 sitios en Estados Unidos, según un comunicado de prensa. Los participantes de 50 años o más fueron asignados aleatoriamente para recibir VAX-31, Prevnar 20 de Pfizer o Capvaxive de Merck. Una cohorte separada incluyó adultos de entre 18 y 49 años.

VAX-31 cumplió los criterios de no inferioridad para los 28 serotipos compartidos con las vacunas comparadoras en adultos de 50 años o más, con el límite inferior del intervalo de confianza del 95% superando 0.667. Los tres serotipos únicos de VAX-31 y el serotipo 20B de reactividad cruzada cumplieron los criterios de superioridad.

En comparaciones individuales, VAX-31 alcanzó el umbral de no inferioridad de 0.667 para 20 de 20 serotipos compartidos con Prevnar 20 y 17 de 19 compartidos con Capvaxive. Los serotipos 3 y 12F comparados con Capvaxive no alcanzaron el umbral de 0.667, pero sí cumplieron el umbral histórico de 0.5.

La vacuna demostró un perfil de seguridad similar al de las vacunas comparadoras en todos los grupos de edad estudiados. Las reacciones solicitadas fueron generalmente leves a moderadas y se resolvieron en un plazo de 48 horas. Ningún evento adverso grave fue considerado relacionado con la vacuna.

VAX-31 es una candidata a vacuna 31-valente diseñada para prevenir la enfermedad neumocócica invasiva y la neumonía neumocócica. La compañía recibió la designación de Terapia Innovadora de la FDA para la vacuna en mayo de 2025.

Vaxcyte espera reportar resultados de dos ensayos adicionales de fase 3 en adultos en la primera mitad de 2027. La compañía planea presentar una Solicitud de Licencia Biológica en la primera mitad de 2028.

La candidata a vacuna también está siendo evaluada en un programa clínico de fase 2 en lactantes, con resultados esperados para finales de la primera mitad de 2027.

Fuente: Investing.com. Disponible en <https://n9.cl/4i7zz>

Uganda launches Phase I clinical study of Bundibugyo virus disease vaccine

Oct 7. The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

Conducted in partnership with the Oxford Vaccine Group and Pandemic Science Institute, at the University of Oxford, the study will evaluate the safety of a ChAdOx-based Bundibugyo Ebola vaccine candidate, ChAdOx BDBV, and its ability to stimulate an immune response in healthy adult volunteers.

The first participants were vaccinated today, Monday 5th October 2026, in Masaka City, and follows the launch of a first-in-human Phase I trial in the United Kingdom evaluating the same vaccine candidate.

Both trials are funded by the Coalition for Epidemic Preparedness Innovations (CEPI), as part of a programme to advance the development of the vaccine candidate.

The ChAdOx BDBV vaccine candidate was developed by scientists at the University of Oxford, with production and quality-testing of the viral seed stock that formed the starting material for large-scale vaccine manufacture carried out onsite by the Clinical Biomanufacturing Facility.

The Serum Institute of India (SII), based in Pune, India, has collaborated to manufacture and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate in two weeks for potential future use. SII has supplied 300 vials to UK and additionally ~3000 investigational doses for this Phase I trial in Uganda.

The Uganda study is led by Professor Eugene Ruzagira, Head of Clinical Research and Trials at the MRC/UVRI&LSHTM Uganda Research Unit, and will be conducted at the Unit's internationally recognized clinical research site in Masaka City, southwestern Uganda. With more than three decades of experience in vaccine research and clinical trials, the site combines state-of-the-art laboratory and clinical infrastructure, and long-standing community partnerships, providing an ideal setting for conducting early-phase clinical studies to the highest scientific, ethical and regulatory standards.

The study launches at a critical time as countries in the region respond to the ongoing Bundibugyo virus disease outbreak. While Uganda has contained local transmission through rapid surveillance and response measures, Ugandan scientists and public health experts continue to support regional efforts to control the outbreak in the Democratic Republic of the Congo.

Bundibugyo virus was first identified during an outbreak in western Uganda in 2007 and remains one of the Ebola virus species for which no licenced vaccine is currently available. Developing an effective vaccine against Bundibugyo virus is therefore an important priority for global epidemic preparedness.

The study further strengthens the MRC/UVRI& LSHTM Uganda Research Unit's longstanding contribution to research on emerging infectious diseases and reinforces Uganda's role as a trusted partner in international efforts to develop vaccines and other interventions against epidemic-prone diseases.

The study is sponsored by the University of Oxford and implemented in Uganda by the MRC/UVRI & LSHTM Uganda Research Unit. It will be conducted in accordance with Uganda's regulatory requirements and international standards for ethical clinical research.

If early-stage trials are successful, CEPI anticipates working with the University of Oxford and SII to support late-stage trials to generate data for emergency use authorisation or licensure.



CEPI, SII and the University of Oxford are committed to enabling rapid, affordable supply of Bundibugyo virus vaccines to affected countries and to the populations that need them.

ChAdOx1 BDBV uses the same vaccine technology as the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved around six million lives during its first year of use.

Fuente: FIRSTWORDPHARMA. Disponible en <https://n9.cl/ihvrb>


Nasal vaccine additive improves flu survival in mice even 100 days after treatment

Oct 9. The COVID-19 pandemic showed the challenges of protecting populations when a new respiratory virus emerges. Although vaccines were developed at unprecedented speed, there was still a period when vaccines were not yet available, and people remained vulnerable to infection. This raises an important question: Could the body's natural defenses be temporarily strengthened without knowing which virus will emerge?

One possible answer lies in innate immunity, the body's first line of defense. Unlike adaptive immunity, which learns to recognize specific targets, innate immunity can respond to threats without prior exposure. Some studies have shown that certain stimuli can leave innate immune cells more responsive through a phenomenon called trained immunity. However, questions remain about how long this protection can last and which cells are responsible for maintaining it in the respiratory tract.

To bridge these knowledge gaps, a research team led by professor Ken Ishii from the Division of Vaccine Science, Department of Microbiology and Immunology at The Institute of Medical Science, The University of Tokyo, Japan, investigated how the vaccine adjuvant K3-SPG modulates innate immunity. The study was co-authored by Ph.D. candidate Asuka Joy Tobuse of The University of Tokyo and associate project scientist Kouji Kobiyama of the University of California San Diego, U.S., formerly a member of Ishii's laboratory at The University of Tokyo.

Their study is published in *Science Advances*.



K3-SPG activates innate immunity and offers temporary defense against respiratory viruses. Credit: Professor Ken Ishii from The University of Tokyo, Japan. Created with BioRender.com

Nasal treatment limits damage in mice

K3-SPG is a nanosized adjuvant that combines a short piece of synthetic DNA called CpG oligodeoxynucleotide, which activates the immune sensor toll-like receptor 9 (TLR9), with a β -glucan called schizophyllan. The researchers first tested whether a single dose given through the nose could protect mice against influenza A virus. Treated mice lost less weight and had higher survival rates than control mice. Protection was still detectable 100 days after treatment, although it waned over time. The treatment also protected mice against SARS-CoV-2 in a susceptible mouse model.



The route of administration was important. Nasal treatment produced stronger protection than treatment given under the skin or into the bloodstream. Despite improving survival and reducing lung damage, however, K3-SPG did not substantially reduce the amount of virus in the lungs. The findings suggest that the treatment mainly helped the host tolerate the infection and limit tissue damage rather than directly preventing viral replication.

A two-stage immune response

The team then investigated how this protection developed. Using several analytical approaches, including single-cell RNA sequencing, they found evidence of a two-stage response. Macrophages were important during the early phase, while innate lymphoid cells became important later. Some of the innate lymphoid cells showed changes at the level of chromatin, the DNA–protein structure that helps regulate gene activity, suggesting longer-lasting changes in their function.

The team also found that the response depended on TLR9, an immune receptor activated by K3-SPG, as well as the inflammatory signaling molecule TNF- α . "Our research has identified unique mechanisms by which vaccine adjuvants can induce protective innate immunity against respiratory viral infections, suggesting that adjuvants may have potential applications beyond their traditional role in enhancing vaccine responses," says Ishii.

Human protection remains unproven

The researchers caution that these findings were demonstrated primarily in mice and do not establish that K3-SPG can protect people from respiratory viral infections. Further studies are needed to assess its safety, effectiveness and suitability for human use, including differences in TLR9 biology and respiratory delivery.

"Because an adjuvant-based preventive approach may not require prior knowledge of the specific pathogen, it could potentially provide an additional layer of protection while pathogen-specific vaccines are being developed and manufactured," explains Ishii. Such an approach could potentially complement pandemic preparedness efforts such as the 100 Days Mission by providing temporary protection while targeted vaccines are being developed.

Fuente: Medical Xpress. Disponible en <https://n9.cl/0uwqf6>

Vietnam está investigando diversas plataformas para vacunas de próxima generación.

9 oct. El Instituto de Vacunas y Productos Médico-Biológicos (IVAC) de Nha Trang, en colaboración con la Universidad Nacional de Vietnam en Ciudad Ho Chi Minh, organizó un taller titulado "Orientación para la investigación y el desarrollo de vacunas al servicio de la salud pública en Vietnam". El taller reunió a científicos, instituciones de investigación y fabricantes de vacunas, centrándose en debates sobre nuevas tecnologías y la dirección del desarrollo de productos nacionales.



En el taller, el Dr. Huynh Tan Dung, de la Facultad de Medicina de la Universidad de Ciencias de la Salud de la Universidad Nacional de Vietnam en Ciudad Ho Chi Minh, presentó una línea de investigación sobre la base de las vacunas de biopartículas, utilizando vesículas de la membrana externa bacteriana e inclusiones de proteínas para presentar antígenos.

Esta línea de investigación tiene como objetivo desarrollar soluciones para prevenir la propagación de patógenos, incluidos aquellos asociados con la resistencia a los antibióticos.

Investigación sobre un preparado dirigido contra el virus que causa la enfermedad de manos, pies y boca.

Uno de los temas más destacados del taller fue la investigación y el desarrollo de una preparación granular que contiene la bacteria *Lactiplantibacillus plantarum* portadora del receptor SCARB2, destinada a capturar el virus EV71, el agente causal de la enfermedad de manos, pies y boca, que puede provocar complicaciones graves en los niños.

Según un equipo de investigación de la Facultad de Ciencias de la Universidad Nacional de Vietnam en Ciudad Ho Chi Minh, las bacterias modificadas genéticamente expresaban el receptor SCARB2 en la superficie de sus células. Las pruebas iniciales demostraron que las bacterias eran capaces de unirse al virus EV71 y capturarlo.

El equipo de investigación planea continuar evaluando la toxicidad y la capacidad de atrapar virus en modelos celulares y animales. Esta es una línea de investigación en curso que requiere una evaluación adicional antes de determinar su aplicación práctica.

Además, IVAC se centra en el desarrollo de nuevas plataformas tecnológicas, incluidas vacunas producidas mediante cultivo celular, proteínas recombinantes y ARNm-LNP. Se espera que estas tecnologías reduzcan el tiempo de desarrollo de productos, amplíen la escala de producción y mejoren la capacidad de respuesta ante nuevos brotes de enfermedades.

El Dr. Duong Huu Thai, director de IVAC, también presentó información sobre las tecnologías clave para el desarrollo de vacunas que prevengan pandemias.

Ampliación de la tecnología de producción nacional de vacunas

Además de la investigación que se lleva a cabo en IVAC y en la Universidad Nacional de Vietnam en Ciudad Ho Chi Minh, el Centro de Investigación, Producción de Vacunas y Productos Médicos Biológicos (POLYVAC) participa en un programa de transferencia de tecnología para la producción de vacunas de ARNm a escala de laboratorio. La unidad también se centra en el desarrollo de vacunas de nueva generación, incluidas las vacunas de partículas similares a virus (VLP).

En Pasteur Dalat Vaccine Company Limited (DAVAC), otra línea de investigación se centra en el desarrollo de una vacuna conjugada contra la fiebre tifoidea. Según un informe presentado en la conferencia, el producto cumple con los estándares básicos reconocidos y ha mostrado resultados prometedores en las evaluaciones preclínicas iniciales.

La investigación está sentando las bases científicas para los ensayos clínicos y también está explorando la posibilidad de desarrollar una producción a escala industrial.

Según los documentos de la conferencia, para julio de 2026, Vietnam podrá producir 10 de los 14 tipos de vacunas incluidos en el Programa Ampliado de Inmunización. Los cuatro tipos restantes, entre ellos la vacuna pentavalente, la vacuna antipoliomielítica inactivada (VPI), la vacuna neumocócica y la vacuna contra el VPH, deberán importarse.

El objetivo para 2030 es dominar la tecnología para producir 15 tipos de vacunas, incluyendo la producción nacional de al menos 5 de ellas.

Se espera que la diversificación de las plataformas tecnológicas, desde el ARNm y las proteínas recombinantes hasta las vacunas conjugadas y las vacunas de partículas, proporcione una base científica más sólida para la investigación y el desarrollo de nuevos productos en Vietnam.

Sin embargo, los productos que aún se encuentran en fase de investigación necesitan mayor perfeccionamiento, evaluaciones de seguridad y eficacia, y deben someterse a los procedimientos de prueba y concesión de licencias exigidos por la normativa antes de que puedan utilizarse de forma generalizada.

Fuente: VIETNAM.VN. Disponible en <https://n9.cl/0qlk0>

AI Companies Predict Pharmaceutical Pivotal Trial Results Through Virtual Clinical Trials

Oct 11. An article reported by Reuters on October 7, 2026, regarding AI companies beginning to offer virtual clinical trials for pharmaceuticals to pharmaceutical companies is intriguing. According to the article, regarding the failure of Novartis's rare muscle disease treatment in a later-stage trial in September, the Copenhagen-based AI company BioinvestGPT is said to have run a virtual trial two months prior and predicted that the clinical added benefit would be minimal.

The Novartis trial in question was the Phase III HARBOR trial of del-desiran (delpacibart etedesiran) for myotonic dystrophy type 1 (DM1), a 54-week placebo-controlled study involving approximately 150 patients, which failed to show a statistically significant improvement over placebo in its primary endpoint. Del-desiran is one of the pipelines the company acquired from Avidity Biosciences in a major acquisition worth approximately \$12 billion on February 27, 2026.



Following this announcement, the company's stock price fell by 11% at one point, and in the same week, it was also announced that eight CAR-T therapy trials were temporarily suspended on September 2, and that the Phase III trial of pelacarsen, co-developed with Ionis, had failed on September 4.

BioinvestGPT, which is attracting attention for these virtual clinical trials, is a Copenhagen-based company founded in 2024 that can generate virtual human bodies that meet trial eligibility criteria using DNA sequence data and run virtual trials by administering models of the test drugs. While human trials take several years, some simulations can be completed in less than a month. The founder states that this allows them to identify why a drug is effective and safe, and in many cases, why it is not.

In addition to this, the article introduces QuantHealth, a company based in Tel Aviv. The company uses real-world data and AI to simulate treatment responses for individual patients, and announced in August 2024 that it had simulated over 100 clinical trials with an accuracy rate of 85% (88% for Phase II, 83.2% for Phase III). (This is based solely on the company's own reporting and has not been externally verified).

AI companies state that such simulations can be used to decide which development products to advance to the next stage and to evaluate acquisition candidates. In July 2026, BioinvestGPT shared predictions for several high-profile trials with Reuters and stated that 5 out of 6 were correct. The correct predictions were cited as the failure of del-desiran, the success of Merck and Moderna's personalized cancer vaccine for melanoma, the weak clinical effect in the cardiomyopathy trial of AstraZeneca and Ionis's Wainua, the first trial failure of Novo Nordisk's ziltivekimab, and the success of Vaxcyte's pneumococcal vaccine.

They have also provided predictions for trials with unannounced results: one is the Phase III TOPAZ-2 trial of Biogen's litifilimab for systemic lupus erythematosus (SLE), and the other is the Phase II trial of Takeda's zasocitinib for Crohn's disease and ulcerative colitis, both of which are predicted to fail. The AI model is said to have evaluated both drugs as not optimal for these patient populations. The results of the litifilimab SLE Phase III TOPAZ-1 and TOPAZ-2 trials are scheduled for the fourth quarter of 2026, so that will be the time for verification.

Also, since zasocitinib is considered Takeda's next-generation blockbuster and the FDA has accepted the application for priority review for plaque psoriasis, it will be interesting to see if the prediction for Crohn's disease and ulcerative colitis is correct.

Furthermore, on the regulatory side, the Advanced Research Projects Agency for Health (ARPA-H) of the U.S. Department of Health and Human Services (HHS) announced SURPASS on September 30, 2026, as a new clinical trial initiative. It consists of a design engine that simulates results before the start of a trial using predictive calculation models and digital twins, an inference engine that analyzes data as it accumulates, and a layer that automates operational tasks, aiming for phaseless trials that eliminate the divisions between Phase I and Phase III. In addition, three other projects were announced: STACK, which speeds up the setup of clinical trial sites; COMMONS, which establishes a nationwide consent and data infrastructure; and CINCH, which allows patients to provide their own data and connect to appropriate trials. The potential for this initiative to pave the way for the use of predictive AI in clinical development was also mentioned.

The aforementioned QuantHealth poses the question, "Is it still ethical in 2026 to enroll patients in trials that are highly likely to fail?" If the high accuracy of these AI predictions is truly proven, it is possible that trials with low success probabilities will not even be considered for investment.

Fuente: NOTE. Disponible en <https://n9.cl/dabkk>

La OMS aplaude la adopción de la declaración política de las Naciones Unidas sobre prevención, preparación y respuesta frente a pandemias

12 oct. La Organización Mundial de la Salud (OMS) aplaude la adopción, hoy, por la Asamblea General de las Naciones Unidas de la declaración política sobre prevención, preparación y respuesta frente a pandemias. La declaración supone una reafirmación contundente de la solidaridad mundial y el compromiso necesarios para proteger a las generaciones futuras de los efectos devastadores de las pandemias.



**World Health
Organization**

«La OMS aplaude este firme compromiso de los Estados Miembros de las Naciones Unidas para seguir trabajando al unísono en la prevención, preparación y respuesta frente a pandemias», señaló el Dr. Tedros Adhanom Ghebreyesus, Director General de la OMS. «El mundo ha recorrido un largo camino desde la COVID-19. Instamos a los países a que cumplan ahora los compromisos asumidos, especialmente el de finalizar las negociaciones sobre el anexo del Sistema de Acceso a los Patógenos y Participación en los Beneficios (Sistema PABS), para que el Acuerdo de la OMS sobre Pandemias pueda abrirse para su firma, se inicie el proceso de ratificación y el texto entre en vigor en el marco del derecho internacional».

Los Estados Miembros examinaron la declaración durante la segunda reunión de alto nivel de la Asamblea General de las Naciones Unidas sobre prevención, preparación y respuesta, celebrada el 25 de septiembre de 2026, y la remitieron al pleno de la Asamblea General para su adopción hoy.

Partiendo de los importantes avances en investigación y coordinación logrados desde la pandemia de COVID-19, en particular la adopción del Acuerdo de la OMS sobre Pandemias, la declaración de la Asamblea General de las Naciones Unidas hace un llamamiento a la inversión sostenida y la toma de medidas para fortalecer las capacidades de prevención, detección y respuesta frente a las amenazas pandémicas a escala nacional, regional y mundial.

En la declaración se subraya la necesidad de adoptar un enfoque holístico que considere la preparación frente a pandemias como un imperativo en materia de salud, desarrollo, economía y seguridad que requiere una acción intersectorial coordinada.

Los Estados Miembros subrayaron especialmente la urgente necesidad de concluir las negociaciones sobre el anexo PABS como componente fundamental del Acuerdo de la OMS sobre Pandemias. El resultado de las negociaciones sobre el anexo PABS se examinará en la próxima Asamblea Mundial de la Salud, en mayo de 2027, o antes, en una reunión extraordinaria de la Asamblea. Su adopción permitiría que el Acuerdo sobre Pandemias entrara en vigor y contribuiría a ofrecer una respuesta mundial más equitativa, coordinada y eficaz frente a futuras amenazas pandémicas.

La declaración política de la Asamblea General de las Naciones Unidas define con claridad una agenda para fortalecer la seguridad sanitaria mundial. Sus prioridades principales son mejorar los sistemas de seguimiento, invertir en las capacidades nacionales y aplicar el Reglamento Internacional de Salud (2005) enmendado. En la declaración se insta también a empoderar a las comunidades, garantizar el acceso oportuno a los patógenos y la participación equitativa en los beneficios, ampliar la capacidad local y regional de fabricación y de investigación y desarrollo, y garantizar una financiación sostenible. Tales acciones combinadas inevitablemente impulsarán la cooperación internacional y desembocarán en mayor solidaridad y equidad.

Acerca de la OMS

Dedicada al bienestar de todas las personas y guiada por la ciencia, la OMS lidera y defiende los esfuerzos mundiales por dar a todas las personas, en todas partes, las mismas oportunidades de disfrutar de una vida segura y saludable. Como organismo de las Naciones Unidas para la salud, conecta a naciones, asociados y personas en más de 150 lugares, liderando la respuesta mundial a las emergencias sanitarias, previniendo las enfermedades, abordando las causas profundas de los problemas de salud y ampliando el acceso a los medicamentos y la atención de salud. Nuestra misión es apoyar a todos los países para promover, procurar y proteger la salud. «Juntos por la salud. Apoyemos la ciencia», el lema del Día Mundial de la Salud 2026, marca el inicio de una campaña de un año de duración destinada a poner de relieve que la ciencia es la base para proteger la salud y el bienestar en todo el mundo.

Fuente: ORGANIZACIÓN MUNDIAL DE LA SALUD. Disponible en <https://n9.cl/kw486w>



VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:



Síguenos en redes sociales



@vaccimonitor



@finlayediciones

EBSCO
Information Services



DOAJ DIRECTORY OF
OPEN ACCESS
JOURNALS



reDalyC.org



HINARI
Research in Health

latindex
Sistema Regional de Información en Línea para
Revistas Científicas de América Latina, el Caribe,
España y Portugal

SeCiMed

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/10/01"[Date - Publication] : "2026/10/12"[Date - Publication])) 640 records

[Streptococcus pneumoniae: Pathogenesis, virulence factors, antimicrobial resistance mechanisms, and therapeutic strategies.](#)

Woodard GE. *Diagn Microbiol Infect Dis.* 2026 Oct;116(2):117459. doi: 10.1016/j.diagmicrobio.2026.117459. Epub 2026 May 12. PMID: 42160795

[Congenital Measles: A Review.](#)

McCay A, Bichianu D. *Neoreviews.* 2026 Oct 1;27(10):e626-e633. doi: 10.1542/neo.27-10-054. PMID: 42815925

[Andes Virus - A Clinical Review.](#)

Harris GH, Sinchi A, Lawler J, Frank M. *N Engl J Med.* 2026 Oct 1;395(13):1310-1317. doi: 10.1056/NEJMr2606651. Epub 2026 Jul 15. PMID: 42456129

[Novel immunotherapies for prostate cancer.](#)

Mo G, Narayan V. *Urol Oncol.* 2026 Oct;44(10):709-719. doi: 10.1016/j.urolonc.2026.111092. Epub 2026 Apr 16. PMID: 41991381 **Free PMC article.**

[\[Vaccine prevention of HPV-associated diseases\].](#)

Wieland U, Kreuter A. *Dermatologie (Heidelb).* 2026 Oct;77(10):666-672. doi: 10.1007/s00105-026-05786-z. Epub 2026 Sep 11. PMID: 42726205

[Brain Tumor Vaccines: Next Steps.](#)

Santos A, Chiocca EA. *Hematol Oncol Clin North Am.* 2026 Oct 6:S0889-8588(26)00106-1. doi: 10.1016/j.hoc.2026.08.005. Online ahead of print. PMID: 42838832

[Promoters and Barriers of Vaccine Hesitancy.](#)

Duradoni M, Tosti AE, Colombini G, Masti F, Licata AL, Zanobini P, Materassi L, Guazzini A. *Psychol Rep.* 2026 Oct;129(5):3583-3661. doi: 10.1177/00332941241302266. Epub 2024 Nov 25. PMID: 39587437

[Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.](#)

Lassen MCH, Christensen SH, Yafasov M, Pareek M, Johansen ND, Rudolph AE, R-T Sánchez C, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Lenz IT, Christensen J, Simonsen JØ, Afzal M, Bartholdy KV, Langhoff ACF, Køber L, Solomon SD, Jensen JUS, Martel CJ, Giné-Vázquez I, Duran-Parrondo C, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, Mirás-Carballal S, González-Pérez JM, Gessner BD, Aliabadi N, Schwarz C, Skovdal M, Moulton LH, Zhang P, López-Gómez V, Welsh S, Anatale-Tardiff L, Cane A, Hayford K, Martínón-

Torres F, Begier E, Biering-Sørensen T. NEJM Evid. 2026 Oct;5(10):EVIDoa2600272. doi: 10.1056/EVIDoa2600272. Epub 2026 Aug 29. PMID: 42666095

[Colorectal cancer and tumor vaccines \(Review\).](#)

Ma J, Xiang C, Xia D. Oncol Lett. 2026 Aug 21;32(4):472. doi: 10.3892/ol.2026.15827. eCollection 2026 Oct. PMID: 42741532

[Effectiveness of respiratory syncytial virus vaccination in solid organ transplant recipients in the United States.](#)

Hasan L, Sharath DB, Lum J, Tsuang W, Rivard K, Yetmar ZA. Am J Transplant. 2026 Oct;26(10):2374-2382. doi: 10.1016/j.ajt.2026.05.2302. Epub 2026 Jun 5. PMID: 42250880

[Monocyte-derived galectin-1^{hi} cells provide innate immune help in the generation of functional memory CD8⁺ T cells.](#)

Lim K, Dahal A, Lv X, Kim KD, Evans BA, Li H, Steiner LA, Kim M. Nat Immunol. 2026 Oct;27(10):2102-2116. doi: 10.1038/s41590-026-02638-9. Epub 2026 Aug 31. PMID: 42675114

[Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice.](#)

Kim BK, Park JH, Choi WS, Oh S, An SH, Lee GC, Chokkakula S, Kim CU, Jeong JH, Min SC, Lee DG, Lee JR, Yoon SW, Kim DJ, Mahony TJ, Webby RJ, Choi YK, Baek YH, Song MS. Mol Ther. 2026 Oct 7;34(10):6007-6027. doi: 10.1016/j.ymthe.2026.07.047. Epub 2026 Jul 29. PMID: 42528137

[Why does rotavirus vaccine effectiveness vary around the globe?](#)

Woodyear S, Binti NN, Caddy SL. PLoS Pathog. 2026 Oct 9;22(10):e1014670. doi: 10.1371/journal.ppat.1014670. eCollection 2026 Oct. PMID: 42853809

[Dengue and chikungunya vaccines past, present and future: implications for travelers.](#)

Norman FF, McGuinness SL, Chen LH. Curr Opin Infect Dis. 2026 Oct 1;39(5):404-414. doi: 10.1097/QCO.0000000000001211. Epub 2026 Jun 10. PMID: 42296464

[The return of measles: a dangerous comeback.](#)

Halabi KC. Curr Opin Infect Dis. 2026 Oct 1;39(5):500-504. doi: 10.1097/QCO.0000000000001222. Epub 2026 Jul 22. PMID: 42502260

[Roles of the M2 protein of influenza A virus.](#)

Ren W, Wang Q, Yi Y, Li J. Virus Genes. 2026 Oct;62(5):561-575. doi: 10.1007/s11262-026-02243-w. Epub 2026 May 20. PMID: 42162513

[Recent progress in the rational design of mRNA vaccines.](#)

Guo Z, Fu J, Ran L, Bao N, Wang Y, Dong H, Yang X, Jin Y. Mol Ther. 2026 Oct 7;34(10):5652-5674. doi: 10.1016/j.ymthe.2026.07.020. Epub 2026 Jul 13. PMID: 42444130

[Vaccination in pediatric transplantation-General recommendations. A position paper by the European Reference Network TransplantChild.](#)

Casotti V, Saglio F, Balduzzi A, Barany P, Christensen VB, Buelli S, Donà D, Klaudel-Dreszler M, Mosca S, Pietrobbattista A, Pinon M, Ranucci G, Wennberg L, D'Antiga L; ERN TransplantChild Working Group. *J Pediatr Gastroenterol Nutr.* 2026 Oct;83(4):624-636. doi: 10.1002/jpn3.70523. Epub 2026 Aug 7. PMID: 42563542

[Recent developments in typhoidal and non-typhoidal Salmonella vaccines.](#)

Blank M, Rydlova A, Gibani MM. *Curr Opin Infect Dis.* 2026 Oct 1;39(5):450-457. doi: 10.1097/QCO.0000000000001230. Epub 2026 Aug 5. PMID: 42566676

[Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine.](#)

Yang Q, Wang T, Zhang H, Xu Y, Huang S, He Y, Wei R, Yin N, Gao Y, Yang L, Jin S, Mi L, Chao R, Li M, Feng M, Guo L. *Bioact Mater.* 2026 May 9;64:410-430. doi: 10.1016/j.bioactmat.2026.05.005. eCollection 2026 Oct. PMID: 42181167

[Cross-reactive immunity against orthopoxviruses after monkeypox virus infection or smallpox vaccination.](#)

Trovato M, Accordini S, Giancesini N, Chesini LM, Cheri S, Cotugno G, Matucci A, Donini A, Mantovani RP, Cassaniti I, Rovida F, Ferrari A, Mazzi C, Tacconelli E, Baldanti F, Capobianchi MR, Caro AD, De Berardinis P, D'Apice L, Castilletti C. *Int J Infect Dis.* 2026 Oct;171:109047. doi: 10.1016/j.ijid.2026.109047. Epub 2026 Aug 16. PMID: 42604648

[Pediatric Vaccination and Pandemic Preparedness in Humanitarian Settings.](#)

Pickering A, Wise PH, Maldonado YB. *Pediatr Clin North Am.* 2026 Oct;73(5):953-964. doi: 10.1016/j.pcl.2026.04.006. Epub 2026 Jul 28. PMID: 42711057

[Vaccine ethics: Balancing individual liberty with protecting the vulnerable.](#)

Buckey TM, Gutshall M, Whitehorn G, Spergel JM. *Ann Allergy Asthma Immunol.* 2026 Oct;137(4):413-414. doi: 10.1016/j.anai.2026.05.001. Epub 2026 May 8. PMID: 42107493

[Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1\(+\)CD8\(+\) T cells.](#)

Noblecourt L, Wicki A, Jainarayanan A, Pereira-Almeida V, McAuliffe J, Steffke E, Panetti S, Fuchs H, Ramirez-Valdez RA, Chandrasekar V, Cai Y, Boekstijn S, Hill AVS, Gerard A, Welters MJP, Van der Burg SH, Pedroza-Pacheco I, Van den Eynde BJ, Leung CSK. *Cancer Cell.* 2026 Oct 12;44(10):2083-2099.e9. doi: 10.1016/j.ccell.2026.09.006. Epub 2026 Oct 2. PMID: 42826713

[Optimized Lipid Nanoparticles with Tail-Modified Ionizable Lipids for Safer mRNA Delivery.](#)

Bae SH, Lee J, Ahn JH, Choi H, Choi H, Kim J, Kang M, Oh HR, Park SH, Oh EY, Jeon S, Lee Y, Lee YS, Lee NY, Bae HJ, Kwak J, Kim J, Lee N, Kang B, Kim JH, Song E, Song D, Yoon H, Lee SM, Youn H, Lee K, Kang BC, Nam JH. *Adv Sci (Weinh).* 2026 Oct;13(55):e76539. doi: 10.1002/adv.76539. Epub 2026 Jul 14. PMID: 42446186

[mRNA vaccines targeting HPV E6/E7: A new frontier in cervical cancer immunotherapy.](#)

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

Aftabsavad S, Arashkia A, Shokrgozar MA, Rahimi AA, Karimipoor M. Crit Rev Oncol Hematol. 2026 Oct;226:105520. doi: 10.1016/j.critrevonc.2026.105520. Epub 2026 Aug 5. PMID: 42556594

[The human gut microbiome primes fever after vaccination.](#)

Huus KE; µHEAT Study Group†; Abo H, Tan YH, Atay E, Rytter H, Keller R, Dauser S, Vu DL, Azad MB, Knight R, Ke A, Lotoski L, Langlois MA, Liu R, Tyakht AV, Youngblut N, Kang SM, Parsonnet J, Maier L, Chassaing B, Kremsner PG, Gewirtz AT, Esen M, Ley RE, Gabor JJ, Gaile JM, Fleischmann WA, Siebner AS, Smeenk G, Flügge J, De Moraes RA, Jakob D, Prokipchuk A, Wilhelm C. Science. 2026 Oct 8;394(6820):eaea7733. doi: 10.1126/science.aea7733. Epub 2026 Oct 8. PMID: 42848888

[Salmonella vaccines in poultry: An update on the current status.](#)

Prakasan L, Nair SS, Pal S, Arun TR, Athira V, Abdel-Glil MY, Mukherjee A, Abhishek, Kumar B, Dandapat P, Thomas P. Res Vet Sci. 2026 Oct;210:106327. doi: 10.1016/j.rvsc.2026.106327. Epub 2026 Jul 16. PMID: 42486020

[Malaria Vaccine Rollout in Nigeria: Current Status and Challenges.](#)

Oyegbade SA, Adeboye SO, Oni GJ, Oyegbade AP, Oziohu JJ, Duyann ZY, Owoyemi OC. Am J Trop Med Hyg. 2026 Aug 27;115(4):702-708. doi: 10.4269/ajtmh.26-0371. Print 2026 Oct 7. PMID: 42660112

[Unresolved questions in pediatric dengue: from disease mechanisms to prevention.](#)

Lopez-Medina E. Curr Opin Infect Dis. 2026 Oct 1;39(5):480-490. doi: 10.1097/QCO.0000000000001219. Epub 2026 Jul 22. PMID: 42470689

[EVOLVE-HBV: A cross-sectional study of HBV seroepidemiology in a rural population in South Africa.](#)

Anderson M, Mazibuko L, Sukali G, Maponga TG, Delphin M, Waddilove E, Upton J, Naidoo VG, Olivier S, Ording-Jespersen G, Gareta D, Martyn E, Gunda R, Herbst K, Hanekom WA, Msomi N, Mthethwa L, Ellapen M, Smit T, Ndung'u T, Wong EB, Siedner MJ, Khoza T, Baisley K, Iwuji C, Matthews PC. Int J Infect Dis. 2026 Oct;171:108998. doi: 10.1016/j.ijid.2026.108998. Epub 2026 Jul 23. PMID: 42492834

[Serological correlates of disseminated *Borrelia burgdorferi* infection in mouse models of tick challenge.](#)

Freeman-Gallant G, Shrestha M, You S, Silva-Valenzuela CA, Carfi A, Finn MB, Dold C, Hu LT, Mantis N. Microbiol Spectr. 2026 Oct 6;14(10):e0144626. doi: 10.1128/spectrum.01446-26. Epub 2026 Aug 28. PMID: 42663471

[Real-world effectiveness and impact of human papillomavirus vaccination in males: a comprehensive review.](#)

Manrique AF, Tadese BK, Huang Y, Rohlwing K, Lou X, Li A, Tota JE, Saraiya M, Guo Y, Wang WV. Int J Infect Dis. 2026 Oct;171:109052. doi: 10.1016/j.ijid.2026.109052. Epub 2026 Aug 20. PMID: 42624282

[Vaccination-related worsening of disease in patients with immune-mediated inflammatory diseases.](#)

Meiszl K, Denz R, Tokic MC, Basten J, Lauer R, Sand HV, Oganowski T, Grüter T, Stock S, Simic D, Shukri A, Kiltz U, Zacharopoulou M, Vollmar HC, Otte IC, Flemm C, Suslow A, Stallmach A, Franz A, Marschall U, Saam J, Tiemann C, Reeb K, Heinen C, Meyer I, Hellwig K, Timmesfeld N; VAC-MAC Consortium. Int J Infect Dis. 2026 Oct;171:109012. doi: 10.1016/j.ijid.2026.109012. Epub 2026 Jul 25. PMID: 42501818

[CRISPR-Cas and Infectious Diseases: A Decade of Translational Advances in Molecular Biotechnology.](#)

Mayuri K, Saravanan KM, Somala CS, Selvaraj C, Anand T, Vickram S. *Biochem Genet.* 2026 Oct;64(5):6292-6318. doi: 10.1007/s10528-026-11391-5. Epub 2026 May 19. PMID: 42154426

[Update on the Pathophysiology of Yellow Fever Intoxication.](#)

Duarte-Neto AN, Ho YL, Kallas EG, Bailey AL. *Am J Trop Med Hyg.* 2026 Aug 11;115(4):694-701. doi: 10.4269/ajtmh.26-0276. Print 2026 Oct 7. PMID: 42580329

[Advancing immunization research in the Eastern Mediterranean Region: Launch of the Regional Research Working Group.](#)

Anwari P, Dbaiibo GS, Alsuwaidi AR, Hasan Q, Mere O, Altaf A, Singh A, Memish ZA. *New Microbes New Infect.* 2026 Jun 18;73:101798. doi: 10.1016/j.nmni.2026.101798. eCollection 2026 Oct. PMID: 42861301

[A Brief Review of Vaccine History, Hesitancy, and Education Today.](#)

Youssef AS, Gupta A, Gollamudi S, Moore KT. *J Clin Pharmacol.* 2026 Oct;66(10):e70302. doi: 10.1002/jcph.70302. PMID: 42836464

[A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.](#)

Liu S, Zhu Y, Chen T, Liu X, Lai J, Hu M, Liu Y, Rao H, Zhang B, Xiao S, Peng H, Liang T, Xie L, Qiu G, Li S, Ma X. *Mater Today Bio.* 2026 Aug 3;40:103524. doi: 10.1016/j.mtbio.2026.103524. eCollection 2026 Oct. PMID: 42602399

[AS04-adjuvanted semisynthetic glycoconjugate vaccine against *Pseudomonas aeruginosa*.](#)

Wang X, Ji X, Zheng H, Ru M, Zhang J, Zhang Y, Zhang L, Li S, Zhao L, Yu B, Yang Y. *Vaccine.* 2026 Oct 3;91:129066. doi: 10.1016/j.vaccine.2026.129066. Epub 2026 Aug 19. PMID: 42617357

[Bioengineering strategies for improving the immunogenicity of mRNA vaccines.](#)

Wang H, Zhuo R, Wu J, Ouyang S. *Signal Transduct Target Ther.* 2026 Oct 8;11(1):430. doi: 10.1038/s41392-026-02991-z. PMID: 42844249

[Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.](#)

Callens S, Dambre C, De Schryver A, Desmet S, Flamaing J, Peeters M, Vigneron L, Van Laethem Y. *Acta Clin Belg.* 2026 Oct;81(5):441-451. doi: 10.1080/17843286.2026.2671079. Epub 2026 May 9. PMID: 42105330

[Immuno-Oncology: New Insights into Targets and Therapies.](#)

Schokrpur S, White MG, Roland CL, Patel SP. *Hematol Oncol Clin North Am.* 2026 Oct;40(5):751-764. doi: 10.1016/j.hoc.2026.05.020. PMID: 42686326

[Engineered exosome-lymphotropic mRNA vaccine encoding series-connected antigens elicits potent antitumor immunity in pancreatic cancer.](#)

Li Y, Jin J, Chen K, Yao S, Yang L, Lin Y, Dai W, Zhang H, He B, Miao L, Zhang Q, Wang X. *Int J Pharm.* 2026 Oct 5;703:127327. doi: 10.1016/j.ijpharm.2026.127327. Epub 2026 Aug 21. PMID: 42628816

[Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis.](#)

Chen WG, Li L, Dai GD, Wu YD, Zhu CG, Zhang H, Li XR, Li L, Zhang NZ, Wang LQ, Li GC, Ma WL, Pan JT, Tan ML, Da FL, Yin H, Fu BQ, Luo XN, Yan HB, Jia WZ. *PLoS Pathog.* 2026 Oct 9;22(10):e1014659. doi: 10.1371/journal.ppat.1014659. Online ahead of print. PMID: 42853894

[Transient hypogammaglobulinemia of infancy: revisiting an old entity.](#)

Genç Ozbay Z, Esenboga S. *Expert Rev Clin Immunol.* 2026 Oct 4:1-9. doi: 10.1080/1744666X.2026.2742255. Online ahead of print. PMID: 42820937

[Vaccine Injury Compensation, COVID-19 Vaccine Claim Migration, and Public Trust.](#)

Yang YT. *Am J Public Health.* 2026 Oct 8:e1-e9. doi: 10.2105/AJPH.2026.308790. Online ahead of print. PMID: 42848992

[NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity.](#)

Lee S, Kim S, Kim S, Kyung K, Kim G, Nam J, Lee J, Jeong S, Seo G, Cho H. *J Control Release.* 2026 Oct 10;398:115176. doi: 10.1016/j.jconrel.2026.115176. Epub 2026 Jul 18. PMID: 42471060

[Durability of RSV Prefusion F Vaccine Protection across Two RSV Seasons.](#)

Lassen MCH, Johansen ND, Christensen SH, Rudolph AE, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Yafasov M, Pareek M, Køber L, Solomon SD, Jensen JUS, Martel CJ, Aliabadi N, Gessner BD, Schwarz C, Skovdal M, Zhang P, Welsh S, Begier E, Biering-Sørensen T. *NEJM Evid.* 2026 Oct;5(10):EVIDoa2600242. doi: 10.1056/EVIDoa2600242. Epub 2026 Aug 29. PMID: 42666088

[Metal-organic framework nanovaccines for systemic tumour regression.](#)

Jiang X, Wang C, Yang K, Tillman L, Lin EJ, Piffkó A, Wen C, Germanas T, Li J, Ma X, Liang HL, Weichselbaum RR, Lin W. *Nat Biomed Eng.* 2026 Oct 6. doi: 10.1038/s41551-026-01786-5. Online ahead of print. PMID: 42839014

[Sequence-Aware Antigenic Alignment and SRID Potency Interpretation in Influenza Vaccines.](#)

Jeong O, Kim PK, Oh H, Lee K, Nam JH. *Vaccine.* 2026 Oct 7;93:129191. doi: 10.1016/j.vaccine.2026.129191. Online ahead of print. PMID: 42843286

[Preclinical and clinical trials for vaccine induction of CD4-binding site neutralizing antibodies.](#)

Mendes Silva C, Sanders RW, Caniels TG. *Curr Opin HIV AIDS.* 2026 Nov 1;21(6):433-441. doi: 10.1097/COH.0000000000001065. Epub 2026 Oct 1. PMID: 42636339

[A leap forward in vaccination - a molecular process of epigenetic silencing to the virus.](#)

Zhang J, Askenase P, Crumpacker C. *Vaccine*. 2026 Oct 3;91:129119. doi: 10.1016/j.vaccine.2026.129119. Epub 2026 Sep 1. PMID: 42679650

[Vaccination perspectives among nurses in a rural, frontier state.](#)

Larson M, Brunsvold A, Schmitz K, Orr M, Riasat N. *Nurs Outlook*. 2026 Oct 7;74(6):102894. doi: 10.1016/j.outlook.2026.102894. Online ahead of print. PMID: 42842976

[Circular RNA-based therapeutic vaccine elicits potent antigen-specific antitumor immunity and remodels tumor microenvironment in lung cancer.](#)

Chen S, Weng L, Liu X, Sun Z, Bai J, Wang J, Chen K, Qiu M. *Cancer Lett*. 2026 Oct 10;658:218743. doi: 10.1016/j.canlet.2026.218743. Epub 2026 Jul 20. PMID: 42476285

[Involvement of immunomodulators in the development of cancer vaccines.](#)

Bibi R, Swayamsiddhi, Saishree S, Sobti M, Reddy S, Sarkar K. *Biochim Biophys Acta Mol Basis Dis*. 2026 Oct;1872(7):168321. doi: 10.1016/j.bbadis.2026.168321. Epub 2026 Jun 9. PMID: 42263891

[Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.](#)

Chumbe AL, van den Aardweg SMD, Boyd A, Grobden M, Koekkoek SM, Zon I, Prins M, Sliepen K, van Gils MJ, Schinkel J. *Gut*. 2026 Oct 7;75(11):2256-2266. doi: 10.1136/gutjnl-2025-336302. PMID: 41136184

[Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials.](#)

Ruhwald M, Dagnev AF, Churchyard G, Penn-Nicholson A, Dewan P, Garcia-Basteiro AL, Wong EB, Hanekom WA, Hatherill M, van Crevel R, den Boon S, Hall-Eidson P, Houben RMGJ, Ginsberg AM, Cobelens F, Horton KC, White RG. *Lancet Glob Health*. 2026 Oct 1:104079. doi: 10.1016/j.langlo.2026.104079. Online ahead of print. PMID: 42822494

[Treatment of clonal hematopoiesis associated atherosclerosis via vaccine-based clearance of the mutant cells.](#)

Liang S, Tao W, Qu D, Ji P, Hao Z, Wei M, Yang G, Zhou X, Wang C, Yuan L. *J Adv Res*. 2026 Oct;88:335-347. doi: 10.1016/j.jare.2026.01.040. Epub 2026 Jan 18. PMID: 41558605

[COVID-19 Vaccination Refusal and Non-Uptake Among People Living with HIV in the United States.](#)

Khubchandani J, Prabhu N, Craig K, Wiblishauser M, Mustapha T, Srejon RR, Batra K. *J Community Health*. 2026 Oct;51(5):896-904. doi: 10.1007/s10900-026-01596-5. Epub 2026 Jul 23. PMID: 42493748

[Economic Impact of Delaying the Infant Hepatitis B Vaccination Schedule.](#)

Hall EW, Gounder P, Bradley H, Nelson NP. *JAMA Pediatr*. 2026 Oct 1;180(10):1136-1146. doi: 10.1001/jamapediatrics.2026.1221. PMID: 42043804

[Ethics as if Your Life Depended on It.](#)

Pearce JM. *J Empir Res Hum Res Ethics*. 2026 Oct;21(4):395-400. doi: 10.1177/15562646261453477. Epub 2026 May 26. PMID: 42186370

[Rotavirus vaccine effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of pooled case-control studies from the MNSSTER-V dataset.](#)

Moran MC, Burnett E, Groome MJ, Michael F, Breiman RF, Robinson AL, Iniguez V, Mujuru HA, Goldfarb DM, Lungayo CL, Mandomando I, Bonkougou IJO, Anwari P, Contreras-Roldán I, Enweronu-Laryea C, N'Zue K, Nalunkuma C, Trang NV, Gheorghita S, Sahakyan G, Nazurdinov A, Latipov R, Uwimana J, Rey-Benito G, Weldegebriel G, Mwenda JM, Parashar UD, Tate JE; Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) project working group. *Lancet Child Adolesc Health*. 2026 Oct;10(10):699-709. doi: 10.1016/S2352-4642(26)00158-6. Epub 2026 Aug 12. PMID: 42586106

[The role of vaccinating pharmacists in public health advancement in Nigeria.](#)

McKeirnan K, Alhayek J, Truter I, Fogarty TL, Akunne O. *Curr Pharm Teach Learn*. 2026 Oct;18(10):102725. doi: 10.1016/j.cptl.2026.102725. Epub 2026 Jun 20. PMID: 42322768

[Vaccine hesitancy in conflict-affected Ukraine: An agent-based analysis of survey data.](#)

Naeem A, Sikder IU, Pangallo M, Pavlova I, Lapii F, Zarubina V, Rahman MS, Haque U. *Health Policy*. 2026 Oct;172:105705. doi: 10.1016/j.healthpol.2026.105705. Epub 2026 Jul 17. PMID: 42508188

[Vaccination status of patients undergoing HIV treatment in a hospital in Madrid.](#)

Alcaide-Jiménez A, Losa JE, Hernández-Múgica V, Sánchez JG, Rodríguez-Caravaca G, Cárdenas-Soriano P, Pedraza-Flechas AM. *Rev Clin Esp (Barc)*. 2026 Oct;226(8):502597. doi: 10.1016/j.rceng.2026.502597. Epub 2026 Jun 10. PMID: 42269924

[Vaccinations in pregnancy: An update for a changing time.](#)

Hodge W, Bhuienneáin M, Goba G, Labovsky M, Amaral E, Khalil A, Lissauer D, Divakar H, McAuliffe FM, Money D, Pasupathy D; FIGO Committee on Infections During Pregnancy. *Int J Gynaecol Obstet*. 2026 Oct 7. doi: 10.1002/ijgo.71273. Online ahead of print. PMID: 42841243

[Antigen-specific messenger RNA lipid nanoparticle therapy with mTOR inhibition promotes regulatory T cells and limits allergy.](#)

Rochman Y, Melamed JR, Klingler AM, Kotliar M, Rochman M, Caldwell JM, Felton JM, Osswald GA, Muscat-Rivera J, Kegel M, Barski A, Lewkowich IP, Weissman D, Rothenberg ME. *J Allergy Clin Immunol*. 2026 Oct;158(4):1058-1072. doi: 10.1016/j.jaci.2026.05.023. Epub 2026 Jun 9. PMID: 42263787

[Development and protection evaluation of a nanoparticle vaccine against transferrin-binding protein TbpB\(Y167A\) of *Glaesserella parasuis*.](#)

Chao L, Zhang B, Cai Y, Zhu C, Li Y. *Vet Microbiol*. 2026 Oct;321:111172. doi: 10.1016/j.vetmic.2026.111172. Epub 2026 Aug 6. PMID: 42567121

[Improvements to pharmaceutical manufacturing capacity, Ethiopia.](#)

Hagos KT, Gebre-Mariam T, Woo D, Kahsay AG, Teferi MW, Dong J. *Bull World Health Organ*. 2026 Oct 1;104(10):705-710. doi: 10.2471/BLT.25.295594. Epub 2026 Sep 1. PMID: 42820195

[Population-Based First Estimates of the Effect of HPV Vaccination in Three Italian Areas Covered by Organised Cervical Screening.](#)

Amaroli P, Zappa M, Giorgi Rossi P, Carozzi FM, Rizzolo R, Visioli CB, De Marco L, Bisanzi S, Del Mistro A, Iossa A, Bonelli L, Venturino E, Camussi E, Viti J, Ronco G. *Int J Cancer*. 2026 Oct 1;159(7):1686-1696. doi: 10.1002/ijc.70536. Epub 2026 May 5. PMID: 42084786

[Pentavalent Recombinant Vaccine Using Escherichia coli Bacterins Against Major Clostridium Toxins in Ruminants.](#)

Conceição FR, Rodrigues RR, Motta JF, Moreira Júnior C, Alves MLF, de Castro ELA, Martins FMS, de Moraes WMP, Sott CH, Salvarani FM, Ferreira MRA. *Mol Biotechnol*. 2026 Oct 7. doi: 10.1007/s12033-026-01610-0. Online ahead of print. PMID: 42842087

[Contriving multiepitope vaccine for breast cancer by targeting the estrogen receptor using in-silico method.](#)

Shah FH, Cho JS, Na JU, Chung HJ, Jeong NY, Jung J. *Comput Biol Chem*. 2026 Oct;124(Pt 1):109141. doi: 10.1016/j.compbiolchem.2026.109141. Epub 2026 May 27. PMID: 42214855

[Parameters Affecting Dengue Virus Replication in Vero Cells.](#)

Asim MMH, Khan AM, Susmi TF, Mahmud FMA, Zubayer A, Mozid MT, Rayhan R, Ashik MMR, Nasrin S, Khan I, Karim M, Muktedir H, Muktedir A, Whitehead SS, Ahasan MM. *Vaccine X*. 2026 Oct;32:100894. doi: 10.1016/j.jvacx.2026.100894. Epub 2026 Aug 17. PMID: 42713220

[Changes in HPV Vaccine Uptake after the COVID Vaccine.](#)

Harlow S, Anderson E, Cass I. *J Pediatr Adolesc Gynecol*. 2026 Oct;39(5):602-608. doi: 10.1016/j.jpag.2026.01.045. Epub 2026 Jan 29. PMID: 41619921

[Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.](#)

Conde L, Monteiro V, Freitas JCR, Crandell J, Lawres L, Tana F, Breban MI, Akther F, Polster J, Porzucek A, Ramiro TM, de Oliveira AB, Nogueira ML, Martinez DR, Grubaugh ND, Almeida PRJ, Weiskopf D, Teixeira MM, Lucas C. *J Exp Med*. 2026 Oct 5;223(10):e20261126. doi: 10.1084/jem.20261126. Epub 2026 Sep 2. PMID: 42684715

[A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.](#)

Suzuki Y, Arita T, Shirakura M, Kishida N, Sano K, Watanabe S, Nagata N, Sakai Y, Iwata-Yoshikawa N, Suzuki T, Hasegawa H, Asanuma H. *Vaccine*. 2026 Oct 3;91:129048. doi: 10.1016/j.vaccine.2026.129048. Epub 2026 Aug 17. PMID: 42607626

[Toward broad-spectrum coronavirus vaccines: navigating viral evolution from past epidemics to future resilience.](#)

Wang M, Wang W, Chen Z, Lu L, Liu Z, Jiang S. *Microbiol Mol Biol Rev*. 2026 Oct 6:e0010025. doi: 10.1128/mmbr.00100-25. Online ahead of print. PMID: 42836613

[Emergence of Macrolide-Resistant Bordetella pertussis, Peru, 2025.](#)

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

Juscamayta-López E, Valdivia F, Rodríguez-Cueva C, Horna H, Quispe Y, Soto MP, Torres S, Solórzano VF, Yagui M, Cantarelli VV, Montilla-Escudero E, Silva V, Da Costa AR. *Emerg Infect Dis.* 2026 Oct;32(10):1702-1706. doi: 10.3201/eid3210.251477.PMID: 42811428

[Influenza vaccine refusal among healthcare workers: A cross-sectional study.](#)

Cesaro E, Daicampi C, Degan M, Cozza A, Cocchio S, Baldo V. *Int J Nurs Stud.* 2026 Oct 2;185:105710. doi: 10.1016/j.ijnurstu.2026.105710. Online ahead of print.PMID: 42849113

[MTB-KB: A Curated Knowledgebase of Mycobacterium tuberculosis Related Studies.](#)

Li P, Li C, Zhu R, Sun W, Zhou H, Fan Z, Yue L, Zhang S, Jiang X, Luo Q, Han J, Huang H, Shen A, Tuohetaerbaik B, Wang J, Zhang W, Wen H, Niu H, Bu C, Zhang Z, Xiao J, Gao R, Chen F. *Genomics Proteomics Bioinformatics.* 2026 Oct 1;qzag102. doi: 10.1093/gpbjnl/qzag102. Online ahead of print.PMID: 42820792

[Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.](#)

Alami A, Lewis M, El-Chaâr D, Walker M, Wen SW, Krewski D. *Vaccine.* 2026 Oct 3;91:129070. doi: 10.1016/j.vaccine.2026.129070. Epub 2026 Aug 29.PMID: 42667900

[Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management.](#)

Li Y, Wu Z, Xiang T, Duan B, Liu Z, Liu P, Wei Y, Ling P. *Infection.* 2026 Oct 9. doi: 10.1007/s15010-026-02990-w. Online ahead of print.PMID: 42853493

[Questing for sustainable control of cattle ticks: bottlenecks in developing efficacious vaccines.](#)

de Miranda Santos IKF, Charlier J, Nene V, Entrican G, Elhachimi L, Goddeeris B, Baldwin C. *Trends Parasitol.* 2026 Oct;42(10):992-1003. doi: 10.1016/j.pt.2026.08.005. Epub 2026 Aug 31.PMID: 42674912

[Mobile-app-based cohort event monitoring study \(CEM\) of COVID-19 vaccines.](#)

Kopp L, Hofner B, Mentzer D. *Vaccine.* 2026 Oct 7;93:129219. doi: 10.1016/j.vaccine.2026.129219. Online ahead of print.PMID: 42843285

[Pre-existing cross-subtype serological responses against H5Nx in health care workers.](#)

Dionne K, Bélanger É, Benlarbi M, Beaudoin-Bussièrès G, Saenz CS, Ding S, Bourassa C, Medjahed H, Jennings M, Laroche G, Carbonneau J, Haddad E, Durand M, Boivin G, Côté M, Finzi A. *J Virol.* 2026 Oct 7:e0131026. doi: 10.1128/jvi.01310-26. Online ahead of print.PMID: 42841622

[ACCP Call to Action-The Need for Vaccine Education.](#)

Moore KT, Gollamudi S, Youssef AS. *J Clin Pharmacol.* 2026 Oct;66(10):e70301. doi: 10.1002/jcph.70301.PMID: 42836469

[Promoting health information-seeking behaviour prior to vaccination decisions.](#)

Gross R, Sievert EDC, Korn L, Santana AP, Betsch C, Böhm R. Psychol Health. 2026 Oct 5;1-23. doi: 10.1080/08870446.2026.2739472. Online ahead of print. PMID: 42832247

[Humoral immune profiling of endemic schistosome-exposed individuals reveals epitopes associated with resistance to reinfection.](#)

Khouri MI, Carvalho FML, da Silva Neto AP, da Silva CP, Alves Dos Santos R, Souza BOL, de Souza Fialho TR, Casaes AC, de Siqueira IC, Leite LCC, Wilson RA, Oliveira RR, Farias LP. Int J Infect Dis. 2026 Oct;171:108892. doi: 10.1016/j.ijid.2026.108892. Epub 2026 Jul 28. PMID: 42521117

[Safety and Immunogenicity of Varicella Vaccination in Children and Adolescents Living With HIV: A Systematic Review.](#)

Marin M, Raparti L, Leung J, Oliver SE, Levin MJ. Pediatr Infect Dis J. 2026 Oct 1;45(10):916-924. doi: 10.1097/INF.0000000000005264. Epub 2026 May 11. PMID: 42108526

[Biphasic phenotypic adaptation of sheeppox virus consequent to serial passaging in heterologous host cell type.](#)

Gupta T, Chahota R. Arch Virol. 2026 Oct 8;171(11):294. doi: 10.1007/s00705-026-06752-9. PMID: 42844458

[An epigenetically enhanced whole-cell vaccine in a stimulatory hydrogel for robust antitumor immunity.](#)

Li X, Zong X, Yuan P, Yan X, Yang C, Chen X, Wei S, Wen Y, Du J, Liu X, Liu F, Dai J. Biomaterials. 2026 Oct;333:124173. doi: 10.1016/j.biomaterials.2026.124173. Epub 2026 Mar 28. PMID: 41931965

[Evaluation of mass dog vaccination campaign in Techiman, Ghana.](#)

Dwaah PK, Squire SA, Awua-Boateng NY, Yar DD, Kando D, Num A, Amisah P, Djang-Fordjour H. PLoS Negl Trop Dis. 2026 Oct 5;20(10):e0014080. doi: 10.1371/journal.pntd.0014080. eCollection 2026 Oct. PMID: 42832606

[Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.](#)

Crodel CC, Gork L, Göpel W, Linke P, Sinn K, Miethke J, Hochhaus A, Hilgendorf I. J Cancer Res Clin Oncol. 2026 Oct 1;152(10):191. doi: 10.1007/s00432-026-06632-4. PMID: 42828557

[Impact and cost-effectiveness of national implementation of rotavirus vaccination in Vietnam: A modeling study.](#)

Dang HTT, Clark A, Nguyen ALT, Duong HT, Nguyen TT, Tran TT, Cu LNT, Tham DC, Nguyen NT, Debellut F. Vaccine. 2026 Oct 6;93:129220. doi: 10.1016/j.vaccine.2026.129220. Online ahead of print. PMID: 42837896

[Meningococcal B vaccination for gonorrhoea prevention in men who have sex with men - time to revisit the recommendation?](#)

Lee SS, Al-Abri S. Int J Infect Dis. 2026 Oct;171:109033. doi: 10.1016/j.ijid.2026.109033. Epub 2026 Aug 4. PMID: 42551585

[Immunogenicity and protective efficacy of a Toxoplasma gondii glycoprotein-enriched fraction in mice.](#)

El Shanawany EE, Abdel-Rahman EH, Hassan SE, Desouky HM, Nofal AE, Shaapan RM, Younis SS. *Acta Trop.* 2026 Oct;282:108245. doi: 10.1016/j.actatropica.2026.108245. Epub 2026 Jul 24. PMID: 42492874

[Pharmacists' contribution to improving vaccination uptake among children: A systematic review.](#)

Amare SN, Leung M, Yee KC, Naunton M, Bushell M. *Res Social Adm Pharm.* 2026 Oct;22(10):908-920. doi: 10.1016/j.sapharm.2026.05.007. Epub 2026 May 19. PMID: 42167984

[Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.](#)

Campbell Statler M, Bishop-Royse J, Sampson AT, Martin M. *Vaccine.* 2026 Oct 3;91:129024. doi: 10.1016/j.vaccine.2026.129024. Epub 2026 Aug 19. PMID: 42617355

[Alarmin cues and regulated cell death calibrate mucosal immunoglobulin A responses and virologic control after intranasal whole-virion inactivated influenza vaccination.](#)

Sasaki E, Asanuma H, Takahashi Y, Hasegawa H. *Int Immunol.* 2026 Oct 1;38(10):626-644. doi: 10.1093/intimm/dxag023. PMID: 42128806

[Incentivizing Immunity: Black and Latinx Individuals' Attitudes About COVID-19 Vaccine Incentives.](#)

Cross FL, Williams CE, Esqueda AP, Hunt R, Ku CP, Lucio J, Bailey S, Williamson S, Marsh EE, Resnicow K. *J Racial Ethn Health Disparities.* 2026 Oct;13(5):3975-3987. doi: 10.1007/s40615-025-02550-2. Epub 2025 Jul 22. PMID: 40696108

[Immune reset in rheumatic autoimmune disease: from a tantalising metaphor to a measurable therapeutic state.](#)

Dörner T, Schrezenmeier E, Daamen AR, Lipsky PE. *Ann Rheum Dis.* 2026 Oct 1:S0003-4967(26)00552-2. doi: 10.1016/j.ard.2026.09.002. Online ahead of print. PMID: 42823266

[Limited G-dependent residual infectivity of G gene-deleted vesicular stomatitis virus.](#)

Sun K, Li L, Yang J, Xu F, Jia F. *Virus Res.* 2026 Oct;372:199792. doi: 10.1016/j.virusres.2026.199792. Epub 2026 Aug 18. PMID: 42612733

[Gaps in Routine Childhood Immunization Among Low-Income Children at 24 Months \(2019-2024\).](#)

Stange KC, Goueth R, Templeton AR, Jones MWH, Der-Martirosian C, Navale SM, Crist R, Cook N. *AJPM Focus.* 2026 May 8;5(5):100510. doi: 10.1016/j.focus.2026.100510. eCollection 2026 Oct. PMID: 42541274

[Rotavirus vaccine success and the challenge of vaccine equity.](#)

Hungerford D, Ndeketa L. *Lancet Child Adolesc Health.* 2026 Oct;10(10):688-689. doi: 10.1016/S2352-4642(26)00215-4. Epub 2026 Aug 12. PMID: 42586105

[Area-Level Disparities in Pneumococcal Vaccination Among Publicly Insured US Adults: 2016-2019.](#)

Mohanty S, Chatrath S, Shanmugam P, Cossrow N, Fiduccia PC, Cassell K, Smith-Howell E, McGuinn VC, Zurovac J, Delannoy C, Evans A, Barna M, Keshaviah A, Feemster KA. *Public Health Rep.* 2026 Oct 11:333549261488379. doi: 10.1177/00333549261488379. Online ahead of print. PMID: 42860546

[HPV vaccine coverage among adults aged 27-45: Implications for oropharyngeal cancer prevention.](#)

Jiang R, Gao MZ, D'Anniballe VM, Lu M, Watts TL, Zimet GD, Weatherspoon DJ, Thompson EL, Osazuwa-Peters N. Hum Vaccin Immunother. 2026 Dec;22(1):2739672. doi: 10.1080/21645515.2026.2739672. Epub 2026 Oct 5. PMID: 42834027

[Cell culture-derived vaccine for rabbit haemorrhagic disease virus 2.](#)

Smertina E, Rutherford M, Pavy M, Huang N, O'Connor T, Jenckel M, Smith IL, Strive T. Vaccine. 2026 Oct 3;91:129067. doi: 10.1016/j.vaccine.2026.129067. Epub 2026 Aug 19. PMID: 42617358

[Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.](#)

Itou H, Sano K, Aina A, Otsuki K, Inoue T, Hemmi T, Hasegawa H, Suzuki T. Protein Sci. 2026 Oct;35(10):e70795. doi: 10.1002/pro.70795. PMID: 42742346

[Timeliness of measles vaccination in selected districts of Oromia Region, Ethiopia - 2021.](#)

Shah MP, Woyessa AB, Matanock AM, Azmeraye BM, Lisanwork L, Yimer G, Wang SH, Pan X, Samuel P, Tolera B, Sori BK, Bekele A, Deti T, Wako G, Shiferaw A, Tefera YL, Kokebie MA, Anbessie TB, Wubie HT, An Q, Wallace A, Sugerman CE. Vaccine X. 2026 Oct;32:10.1016/j.jvacx.2026.100892. doi: 10.1016/j.jvacx.2026.100892. PMID: 42788099

[Real-world safety of dengue vaccines in Brazil: A pharmacovigilance study.](#)

Boschiero MN, Sansone NMS, Marson FAL. Vaccine. 2026 Oct 3;93:129178. doi: 10.1016/j.vaccine.2026.129178. Online ahead of print. PMID: 42828936

[HPV vaccine series completion in a midwestern HIV/PrEP population.](#)

Nguyen K, Bernhard S, Bares SH, Davis JM, Henry J, Havens JP, Sunagawa SW. AIDS Care. 2026 Oct 4:1-7. doi: 10.1080/09540121.2026.2734033. Online ahead of print. PMID: 42829990

[Polysaccharide hydrogels as immunologically active vaccine depots for cancer immunotherapy.](#)

Borralho MJ, Barreira MJ, Ferreira E, Ferreira JA. Carbohydr Polym. 2026 Oct 1;389:125663. doi: 10.1016/j.carbpol.2026.125663. Epub 2026 Jul 20. PMID: 42586689

[Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission.](#)

Kunkeaw N, Nguitragool W, Thosapornvichai T, Buasri N, Hongeng S, Takashima E, Tsuboi T, Wongtrakoongate P, Sattabongkot J. Vaccine. 2026 Oct 8;94:129221. doi: 10.1016/j.vaccine.2026.129221. Online ahead of print. PMID: 42849225

[Societies Release Vaccine Recommendations for Respiratory Virus Season.](#)

Anderer S. JAMA. 2026 Oct 2. doi: 10.1001/jama.2026.20006. Online ahead of print. PMID: 42826041

[Recent advances in coated and dissolving microneedle technologies for clinical translation.](#)

Wanichwecharungruang S, Ampawa S. Expert Opin Drug Deliv. 2026 Oct;23(10):1877-1888. doi: 10.1080/17425247.2026.2723071. Epub 2026 Aug 25. PMID: 42633536

[Metabolically engineered chimeric probiotic-cancer vesicles orchestrate anti-tumor systemic immunity.](#)

Duong VH, Bui VD, Ghosh T, Kim J, Jang WH, Shin S, Kim CH, Wooram U, Cho S, Lee C, Chung CH, Son S, Park JH. *J Control Release*. 2026 Oct 7;115442. doi: 10.1016/j.jconrel.2026.115442. Online ahead of print. PMID: 42843530

[Rickettsial Diseases and Vaccines: Is There an Opportunity for Plant-Made Vaccine Technology?](#)

Monreal-Escalante E, León-Montoya H, Ramos-Vega A, Trujillo E, Angulo M, Guerra K, Reyes-Becerril M, Angulo C. *Biotechnol Bioeng*. 2026 Oct;123(10):2587-2604. doi: 10.1002/bit.70296. Epub 2026 Jul 5. PMID: 42402151

[Scaling up vaccination for people living in prisons: a global person-centred need for public health.](#)

Thanasi E, McGregor-Harper J, Tramonti Fantozzi MP, Cocco N, Ranieri R, Plugge E, De Vita E, Tavoschi L. *Vaccine*. 2026 Oct 3;91:129039. doi: 10.1016/j.vaccine.2026.129039. Epub 2026 Aug 22. PMID: 42628197

[8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal \(TyVOID\): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.](#)

Pant D, Zhang Y, Basile FW, Shakya M, Kelly S, Gurung M, Subhani H, Shrestha S, Mujadidi YF, Dongol S, Haque N, Joshi M, Maharjan A, Dahal A, Karkey A, Rijal S, Rajkarnikar S, Nepal J, Ghimire S, Curtis B, Kim YC, Voysey M, Basnyat B, Shrestha S, Pollard AJ, Liu X; TyVAC/TyVOID Nepal study team. *Lancet Glob Health*. 2026 Oct;14(10):104009. doi: 10.1016/j.langlo.2026.104009. Epub 2026 Aug 10. PMID: 42575113

[High Rates of Seroprotection for Measles in Pediatric Patients With Inflammatory Bowel Disease.](#)

Caldera F, Hayney MS, Strople JA, Kastl AJ, Adler J, Boccieri M, Zhang X, Long MD, Kappelman MD. *Am J Gastroenterol*. 2026 Oct 1;121(10):2581-2584. doi: 10.14309/ajg.0000000000004050. Epub 2026 May 20. PMID: 42159717

[Immune responses induced by a subunit vaccine against *Mycoplasma gallisepticum*.](#)

Miller JM, Mara AB, Ozyck RG, Savoie R, Hernandez EF, Lee K, Hunte ML, Malek JB, Tulman ER, Szczepanek SM, Geary SJ. *Infect Immun*. 2026 Oct 7:e0030526. doi: 10.1128/iai.00305-26. Online ahead of print. PMID: 42841775

[Safety of Rotavirus Vaccination in a Growing Care Unit \(Intermediate-care Neonatal Unit\) in Japan.](#)

Miura H, Manabe M, Ihira M, Kozawa K, Miyata M, Kawamura Y, Kondo Y, Kawada JI, Komoto S, Yoshikawa T. *Pediatr Infect Dis J*. 2026 Oct 1;45(10):911-915. doi: 10.1097/INF.0000000000005251. Epub 2026 Apr 22. PMID: 42014964

[Simultaneous Administration of Human Papillomavirus \(HPV\) Vaccine With Other Recommended Vaccines Among Adolescents Aged 13-17 years, National Immunization Survey-Teen \(NIS-Teen\), United States, 2023.](#)

Pingali C, Yankey D, Chen M, Elam-Evans LD, Markowitz LE, DeSisto CL, Stefanos R, Singleton JA. *J Adolesc Health*. 2026 Oct;79(4):600-602. doi: 10.1016/j.jadohealth.2026.06.014. Epub 2026 Aug 7. PMID: 42565767

[Effectiveness of the 2025-2026 seasonal influenza vaccine among U.S. veterans: an observational study.](#)

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

Xie Y, Choi T, Al-Aly Z. *EClinicalMedicine*. 2026 Sep 10;100:104183. doi: 10.1016/j.eclinm.2026.104183. eCollection 2026 Oct. PMID: 42761462

[Mucosal BCG vaccination reprograms lung interstitial macrophages and enhances antimicrobial defense in mice.](#)

Forde AJ, Esposito M, Kerschbamer E, Schreiner D, Moreo E, Pantouloufos N, Camarasa TMN, de Lima J, Soliman H, Erber M, Depew CE, Naderi W, King CG. *Mucosal Immunol*. 2026 Oct;19(5):100391. doi: 10.1016/j.mucimm.2026.100391. Epub 2026 Jul 26. PMID: 42503329 **Free article.**

Bacille Calmette-Guerin (BCG) is the only licensed vaccine against tuberculosis (TB) but provides inconsistent protection against disease. ...Collectively, these findings identify IM as key mediators of mucosal vaccine-induced protection and highlight macrophage sub ...

127

Cite

[Projected effects of removing school-entry vaccination requirements on measles transmission in Florida.](#)

Oveson A, Gumel AB. *Proc Natl Acad Sci U S A*. 2026 Oct 6;123(40):e2610455123. doi: 10.1073/pnas.2610455123. Epub 2026 Sep 28. PMID: 42804627

[Robust Alpha Spending for Unstable Data.](#)

Silva IR, Maro JC. *Stat Med*. 2026 Oct;45(23-24):e70760. doi: 10.1002/sim.70760. PMID: 42853134

[Association of In-Hospital Influenza Vaccination With Reduced 1-Year Mortality in Critically Ill Patients With Chronic Pulmonary Disease: A Real-World Target Trial Emulation.](#)

Feng J, Xi F, Sun C, Tan S, Wang X. *Chest*. 2026 Oct;170(4):1037-1048. doi: 10.1016/j.chest.2026.04.022. Epub 2026 Apr 28. PMID: 42061701

[Wastewater Surveillance to Track Resurgent Measles Outbreak, Ontario, Canada, 2025.](#)

Corchis-Scott R, Mercier É, Mejia EM, Geng Q, Harrop E, Podadera A, Fong J, Lewoc N, Ng KKS, Santiago N, Knox N, Goodridge L, Mangat CS, Landgraff C, Riddell KB, Aloosh M, Delatolla R, McKay RM. *Emerg Infect Dis*. 2026 Oct;32(10):1667-1676. doi: 10.3201/eid3210.260092. PMID: 42811349

[Targeting Amastigote and Trypomastigote Phases: Multi-Epitope Vaccine Strategy Against *Trypanosoma cruzi*.](#)

Silva MKD, Sena CPS, Vieira DS, Zaki MEA, Yee LC, Akter S, Fulco UL, Oliveira JIN, Rodrigues-Neto JF. *Biotechnol Appl Biochem*. 2026 Oct;73(5):2457-2481. doi: 10.1002/bab.70185. Epub 2026 May 29. PMID: 42216423

[Deletion of *ppe27* in *Mycobacterium bovis* BCG augments macrophage immune responses during infection.](#)

Guo T-C, Seto S, Hijikata M, Keicho N. *Microbiol Spectr*. 2026 Oct 6:e0091526. doi: 10.1128/spectrum.00915-26. Online ahead of print. PMID: 42836644

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

[Recombinant *Fasciola gigantica* tegumental calcium binding protein-4 modulates host peripheral blood mononuclear cell immune responses in vitro.](#)

Yousaf A, Shahzad MI, Ehsan M, Hu RS, Shahid K, Rashid M, Malik MI, Khan MI. *Acta Trop.* 2026 Oct;282:108282. doi: 10.1016/j.actatropica.2026.108282. Epub 2026 Aug 12. PMID: 42586466

[Validation of electrochemiluminescent \(ECL\)-based immunoassay to determine the levels of antibodies against *Escherichia coli* O-lipopolysaccharide antigens.](#)

Kamdar M, Shah V, Janssen S, Dominguez EG, Davies T, van den Dobbelsteen G. *Microbiol Spectr.* 2026 Oct 6;14(10):e0086326. doi: 10.1128/spectrum.00863-26. Epub 2026 Sep 8. PMID: 42708599

[A novel recombinant serotype 4 fowl adenovirus expressing HA of H3N8 avian influenza virus.](#)

Jiang W, Wang W, Chu X, Zhao Z, Cao X, Yin X, Li T, Shao H, Wan Z, Qin A, Xie Q, Ye J. *Vet Microbiol.* 2026 Oct 1;322:111238. doi: 10.1016/j.vetmic.2026.111238. Online ahead of print. PMID: 42826490

[Acute symptoms and subsequent post-acute symptoms following COVID-19 vaccination: A Danish population-based study.](#)

Jensen CB, Sørensen AS, Hansen KT, Hansen SN, Josiasen M, Le Marc AH, Gram SA, Fahnøe CL, Nielsen H, Rask CU, Fink P, Dantoft TM, Jørgensen T, Thysen SM, Bech BH, Rytter D. *Public Health.* 2026 Oct;259:106429. doi: 10.1016/j.puhe.2026.106429. Epub 2026 Jul 28. PMID: 42520426

[Factors associated with measles infection during the 2025-6 outbreak in Burao, Somaliland: a case-control study.](#)

Yosef DK, Farah MO, Ahmed FO. *Int Health.* 2026 Oct 9;ihag102. doi: 10.1093/inthealth/ihag102. Online ahead of print. PMID: 42852487

[Development and validation of a high-throughput agglutination assay for O-serogrouping clinical *Escherichia coli* isolates.](#)

Shastri R, Shang W, Janssen S, Tete S, Dominguez EG, van den Dobbelsteen G, Davies T, Morrow B. *Microbiol Spectr.* 2026 Oct 6;14(10):e0099126. doi: 10.1128/spectrum.00991-26. Epub 2026 Aug 21. PMID: 42627174

[Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire.](#)

Chen H, Zhang Z, Wen Z, Yang Z, Li L, Wang S, Gao Q, Liu H, Liu L, Chen Y. *J Control Release.* 2026 Oct 10;398:115262. doi: 10.1016/j.jconrel.2026.115262. Epub 2026 Aug 13. PMID: 42595179

[Superior in-vivo efficacy of integrated tumor neoantigen vaccination with adoptive neoantigen-reactive T-cell therapy in solid tumor.](#)

Liang G, Zhang B, Chen D, Chen Q, Lai L, Su Z, Ruan Q, Ruan R. *Transl Oncol.* 2026 Oct;72:102984. doi: 10.1016/j.tranon.2026.102984. Epub 2026 Aug 20. PMID: 42623869

[Trends in Selective Childhood Measles-Mumps-Rubella \(MMR\) Vaccine Nonreceipt Surrounding the MMR-Autism Controversy: National Immunization Survey Analyses, 1996-2019.](#)

Shapiro T, Kuperstein H, MacPherson C.J Community Health. 2026 Oct;51(5):838-843. doi: 10.1007/s10900-026-01598-3. Epub 2026 Jul 15.PMID: 42458106

[Implementing School-Associated Vaccination Events in Colorado Public Schools: A Statewide Survey of Nurses.](#)

Nienstedt L, Gromis A, Faherty LJ, Korn AR.J Sch Health. 2026 Oct;96(10):e70232. doi: 10.1111/josh.70232.PMID: 42740714

[Expression and immunogenicity of a rabies virus glycoprotein-HSV-2 ICP35 fusion antigen delivered by an mRNA-LNP formulation.](#)

Li X, Niu Z, Mou T, Gao Y, Wang L, Zhang Y, Chen H, Tan S, Liu J, Li J, Li Q.Virus Res. 2026 Oct;372:199785. doi: 10.1016/j.virusres.2026.199785. Epub 2026 Aug 12.PMID: 42586214

[Powassan virus LB neuroinvasion and lethality are determined by envelope protein domain III residues.](#)

Lindner MR, Gorbunova EE, de Souza MRM, Himmler GE, Kim HK, Mackow ER.J Virol. 2026 Oct 8:e0096326. doi: 10.1128/jvi.00963-26. Online ahead of print.PMID: 42847708

[Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.](#)

Kim SJ, Kim HW, Son SE, Song JH, Ahn SM, Lim SJ, Park HN, Sa HJ, Kim NY, Kim JJ, Kim YB, Kwon HJ, Choi KS.Vaccine. 2026 Oct 3;91:129059. doi: 10.1016/j.vaccine.2026.129059. Epub 2026 Aug 20.PMID: 42623712

[Efficacy of a composite aluminum adjuvant containing inulin in protecting turbot \(*Scophthalmus maximus*\) against *Aeromonas salmonicida* infection.](#)

Wu Y, Qian W, Liu Q, Liu X.Dev Comp Immunol. 2026 Oct;183:105719. doi: 10.1016/j.dci.2026.105719. Epub 2026 Aug 20.PMID: 42624186

[HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.](#)

Burmann SN, Wieland U, Silling S, Oellig F, Chromy D, Hyun J, Gambichler T, Kreuter A.J Dtsch Dermatol Ges. 2026 Oct;24(10):1412-1416. doi: 10.1111/ddg.15981. Epub 2025 Oct 6.PMID: 41047841

[A pragmatic randomized trial to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine for preventing RSV hospitalizations in adults \(DAN-RSV\): Trial design update.](#)

Lassen MCH, Christensen SH, Johansen ND, Yafasov M, Pareek M, Rudolph AE, Tenreiro-Sánchez CR, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Køber L, Solomon SD, Jensen JUS, Martel CJ, Aliabadi N, Schwarz C, Skovdal M, Zhang P, López-Gómez V, Welsh S, Gessner BD, Martínón-Torres F, Begier E, Biering-Sørensen T.Am Heart J. 2026 Oct;300:107497. doi: 10.1016/j.ahj.2026.107497. Epub 2026 Jun 1.PMID: 42219049

[Respiratory Syncytial Virus Immunization Disparities in Mothers and Infants at the Birth Hospitalization: A Cross-Sectional Study.](#)

Cheung A, Jain A, Bernstein S, Sarathy L.J Pediatr. 2026 Oct;297:115219. doi: 10.1016/j.jpeds.2026.115219. Epub 2026 Jul 2.PMID: 42392501

[Genetic analysis of inflammatory proteins following BCG vaccination in Danish children.](#)

Boahen CK, Nissen TN, Birk NM, Netea MG, Benn CS, Kumar V.Biomed Pharmacother. 2026 Oct;203:119848. doi: 10.1016/j.biopha.2026.119848. Epub 2026 Aug 13.PMID: 42594746

[Central nervous system safety risks and evaluation strategies for mucosal vaccines: A review.](#)

Li Q, Bai G.Vaccine. 2026 Oct 3;91:129084. doi: 10.1016/j.vaccine.2026.129084. Epub 2026 Aug 27.PMID: 42659918

[Gut microbiome-enteric virus interactions: mechanisms, clinical implications, and translational directions.](#)

Saxena A, Javed M, Trehanpati N.J Gastroenterol. 2026 Oct 6. doi: 10.1007/s00535-026-02524-z. Online ahead of print.PMID: 42836953

[CTH522/CAF01 vaccination elicits clonally related Th17 subsets that mediate IL-17A-dependent protection against Chlamydia trachomatis.](#)

Nguyen NDNT, Guleed S, Subratheepam S, Marcos-Lopez E, Van Tilbeurgh M, Leonec M, Galloüet AS, Wørzner K, Woodworth J, Lindenstrøm T, Melchior KM, Hu T, Hallstrøm S, Le Grand R, Pedersen GK, Mortensen R, Christensen JP, Follmann F, Dietrich J.J Immunol. 2026 Oct 1;215(10):vkag265. doi: 10.1093/jimmun/vkag265.PMID: 42823065

[Vaccine adherence among adult cancer survivors in the United States.](#)

Feng K, Zhang C, Mukamal KJ.J Natl Cancer Inst. 2026 Oct 1;118(10):1831-1835. doi: 10.1093/jnci/djag118.PMID: 41975248

[Online Information as a Double-Edged Sword: A Multilevel Analysis of Vaccination Skepticism Based on ISSP 2021.](#)

Helbing A, Heise J, Redlin S, Kriwy P.J Community Health. 2026 Oct;51(5):844-853. doi: 10.1007/s10900-026-01599-2. Epub 2026 Jul 16.PMID: 42461515

[Guillain-Barré syndrome temporally associated with respiratory syncytial virus vaccination.](#)

Hreiz S, Abu Zaher M, Thyparambil VK, Bettany K.BMJ Case Rep. 2026 Oct 1;19(10):e276086. doi: 10.1136/bcr-2026-276086.PMID: 42823139

[Engineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine.](#)

Xu H, Kamei C, Gökbuget D, Du J, Barrero M, Wang L, Iwamoto Y, Soriano JM, Godding K, Wang B, Kwek SS, Nistor GI, Keirstead HS, Fong L, Kaneko S, Gaensler KML, Blelloch R.Cell Stem Cell. 2026 Oct 1;33(10):1625-1642.e10. doi: 10.1016/j.stem.2026.07.017. Epub 2026 Aug 25.PMID: 42641609

[Leveraging ligand density and multivalent binding for optimal mannose targeting of APCs in precision vaccines.](#)

Luo JR, Chai ZL, Li C, Shi J, Zhu YJ, Zhang FB. Eur J Pharm Biopharm. 2026 Oct;227:115210. doi: 10.1016/j.ejpb.2026.115210. Epub 2026 Aug 7. PMID: 42567423

[Targeting strategies of lipid nanoparticles for RNA therapeutics: From hepatic tropism to extrahepatic precision delivery.](#)

Zhu X, Sun H, Cao X, Xia J. Crit Rev Oncol Hematol. 2026 Oct;226:105448. doi: 10.1016/j.critrevonc.2026.105448. Epub 2026 Jun 24. PMID: 42342140

[Zika virus-like particles' production lab protocol in chemically defined medium using quality by design.](#)

Aragão Tejo Dias V, Consoni Bernardino T, Moraes Octaviano AL, Leme J, Correia Barrence FA, Taniwaki NN, Attie Calil Jorge S, Mancini Astray R, Fernández Núñez EG. Prep Biochem Biotechnol. 2026 Oct 8:1-16. doi: 10.1080/10826068.2026.2739398. Online ahead of print. PMID: 42850960

[Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.](#)

Kalsoom A, Aleem Z, Rehman HM, Sajjad M, Shabbir G, Khan MS, Altaf A, Rahman IU, Alharbi M, Alasmari AF. Naunyn Schmiedebergs Arch Pharmacol. 2026 Oct 3. doi: 10.1007/s00210-026-05944-z. Online ahead of print. PMID: 42827179

[Acceptability of a Prospective Chlamydia Vaccine in Sexually Active Young Adults: A Descriptive Survey.](#)

Griner SB, Garza SR, Akpan IN, Footman A, Brosnan A, Thompson EL, Neelamegam M, Hubach RD. Sex Transm Dis. 2026 Oct 6. doi: 10.1097/OLQ.0000000000002421. Online ahead of print. PMID: 42841258

[Anesthesia as a Partner in Public Health: Enabling National Pediatric SARS-CoV-2 Serosurveillance in Australia.](#)

Koirala A, Attard C, Skowno J. Anesthesiology. 2026 Oct 6. doi: 10.1097/ALN.0000000000006317. Online ahead of print. PMID: 42837490

[Heterogeneity of baseline immune activation and SARS-CoV-2 vaccine responses in people with HIV: a multicenter prospective study.](#)

El Moussaoui M, Ladang A, Maes N, Cavalier E, Genderini F, Dahma H, Martin C, Dauby N, Darcis G. AIDS. 2026 Oct 1;40(10):1480-1487. doi: 10.1097/QAD.0000000000004557. Epub 2026 Jun 1. PMID: 42227026

[Vaccinating women across the life course: Gendered social norms, obligations and vaccine uptake.](#)

Wiley K, Divakar H, Pasupathy D; FIGO Committee on Infections During Pregnancy. Int J Gynaecol Obstet. 2026 Oct 7. doi: 10.1002/ijgo.71338. Online ahead of print. PMID: 42841246

[Vaccine Policy in the Face of Low Hepatitis B Immunity.](#)

Wang M, Inouye SK, Durant RW. JAMA Intern Med. 2026 Oct 1;186(10):1200-1201. doi: 10.1001/jamainternmed.2026.3838. PMID: 42606882

[Engineering Antibody Evolution: Germline-Targeting HIV Vaccines Reach a Turning Point.](#)

Bull RA, Burnett DL. Immunol Cell Biol. 2026 Oct 6. doi: 10.1111/imcb.70169. Online ahead of print. PMID: 42836702

[Adult vaccination coverage and missed preventive care opportunities among Filipino adults with diabetes: A cross-sectional study.](#)

Jacobo RJB, Villa ML, Isidro MJC, Paragas SMO. Hum Vaccin Immunother. 2026 Dec;22(1):2742630. doi: 10.1080/21645515.2026.2742630. Epub 2026 Oct 2. PMID: 42826175

[H5 influenza virus mRNA-lipid nanoparticle \(LNP\) vaccination elicits adaptive immune responses in Holstein calves.](#)

Souza CK, Santos JJS, Boggiatto P, Sterle H, Arruda B, Palmer MV, Campos A, Liu J, Ye N, Weissmann D, Hensley SE, Baker AL. J Virol. 2026 Oct 8:e0128926. doi: 10.1128/jvi.01289-26. Online ahead of print. PMID: 42847707

[Nationwide Surveillance and Control Measures during Large Measles Outbreak, Bangladesh, 2026.](#)

Rabbi MF, Muztahid P, Al Mahdi F. Emerg Infect Dis. 2026 Oct 2;32(11). doi: 10.3201/eid3211.260996. Online ahead of print. PMID: 42826219

[Comparative Toll-like receptor profiling reveals breed-specific innate immune architecture following Newcastle disease vaccination.](#)

Nikunj Kumar P, Kolluri G, Kaliappan A, Kurva SK, Vats A, Ramakrishnan S, Tyagi JS. Poult Sci. 2026 Oct 5;105(12):107908. doi: 10.1016/j.psj.2026.107908. Online ahead of print. PMID: 42854492

[Multivalent DNA vaccines induce potent cellular responses and prolong BCG-mediated control of Mycobacterium tuberculosis.](#)

Parzych EM, Bah MA, Tursi NJ, Gary EN, Ali AR, Chu JD, Esquivel RN, Duso DK, Cole M, Kummer L, Roberts A, Hart T, Muncil SE, Smith TRF, Patel A, Reiley WW, Weiner DB. Mol Ther. 2026 Oct 7;34(10):5993-6006. doi: 10.1016/j.ymthe.2026.07.029. Epub 2026 Jul 14. PMID: 42452836

[Impact of general anaesthesia on immune response to first rabies vaccination in seronegative domestic cats.](#)

Bessière P, Breyse R, Chrétien M, Hayes B, Boullier S, Labadie A, Rieder J, Wasniewski M, Jourdan G. Vet Rec. 2026 Oct 3;199(7):e331-e336. doi: 10.1002/vetr.70223. Epub 2025 Dec 26. PMID: 41450168

[Knowledge, attitudes and practices of vaccination among older adults in Brunei Darussalam: a convergent mixed-method study.](#)

Matsamri SAM, Teo SP, Suryono S, Sharbini S, Abdul-Mumin KH, Chaw L. BMJ Open. 2026 Oct 9;16(10):e120792. doi: 10.1136/bmjopen-2026-120792. PMID: 42855239

[Vaccine attitudes among rural community college students: The impact of the COVID-19 pandemic on routine childhood vaccinations.](#)

Mashinini DP, Kelly NK, Bancroft NM, McLarney-Vesotski A, Delamater PL. J Am Coll Health. 2026 Oct;74(8):2232-2238. doi: 10.1080/07448481.2026.2649527. Epub 2026 Apr 24. PMID: 42030195

[A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice.](#)

Wang X, Wang A, Huang W, Tian P, Cao L, Xiao B, Han J, Huang Z, Jiang L. *Acta Pharmacol Sin.* 2026 Oct;47(10):2983-2995. doi: 10.1038/s41401-026-01850-5. Epub 2026 Jun 16. PMID: 42304102

[Mandates or "Medical Freedom"? What Florida parents' attitudes suggest about the future of childhood vaccination.](#)

Jamison AM, Saiyed S, Gardner LM. *Vaccine.* 2026 Oct 3;91:129060. doi: 10.1016/j.vaccine.2026.129060. Epub 2026 Aug 22. PMID: 42628196

[Spike antibody Fc is associated with protection from SARS-CoV-2 challenge in macaques.](#)

Brady C, Govender M, Mellors J, Tipton T, Gooch K, Tomic A, Carroll MW. *Vaccine.* 2026 Oct 2;93:129192. doi: 10.1016/j.vaccine.2026.129192. Online ahead of print. PMID: 42826689

[Cross-Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses.](#)

Marchand S, Taouli S, McIlroy D. *Eur J Immunol.* 2026 Oct;56(10):e70290. doi: 10.1002/eji.70290. PMID: 42847337

[Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAbs induction in SHIV-infected rhesus macaques.](#)

Hogarty MP, Li H, Zhao C, Martella CL, Skelly AN, Habib R, Connell AJ, Bibollet-Ruche F, Liu W, Carey JW, Ayyanathan K, Ding W, Lora J, Park Y, Lewis E, Rando J, Chohan N, Singh A, Wang S, Murphy A, Akeley MJ, Mansouri K, Spence TN, Wiehe KJ, Williams WB, Saunders KO, Wagh K, Seaman MS, Edwards RJ, Haynes BF, Hahn BH, Shaw GM. *Proc Natl Acad Sci U S A.* 2026 Oct 6;123(40):e2620354123. doi: 10.1073/pnas.2620354123. Epub 2026 Sep 29. PMID: 42809389

[Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides.](#)

Kakinami A, Oitate S, Mochizuki S. *ACS Appl Bio Mater.* 2026 Oct 2. doi: 10.1021/acsabm.6c01600. Online ahead of print. PMID: 42826501

[Antibody-associated responses are linked to increased susceptibility to *Rhodococcus equi* infection in mice.](#)

Suzuki Y, Fujiwara S, Sugiyama M, Takai S. *Microbiol Spectr.* 2026 Oct 6;14(10):e0230226. doi: 10.1128/spectrum.02302-26. Epub 2026 Sep 2. PMID: 42684935

[Bridging the intention–behavior gap in herpes zoster vaccination: A nationwide survey in a self-payment setting.](#)

Liou FY, Chen CY, Chang YF, Wang RH, Shen WC, Huang CK, Chang CS, Wu CH. *Hum Vaccin Immunother.* 2026 Dec;22(1):2741764. doi: 10.1080/21645515.2026.2741764. Epub 2026 Oct 7. PMID: 42842236

[KP.2-Adapted BNT162b2 COVID-19 Vaccine Uptake and Effectiveness in Children.](#)

Andersen KM, Ahi T, McColgan MD, Mateus JS, Yu T, Zhou A, Puzniak L, Lopez SMC. *J Pediatr.* 2026 Oct;297:115221. doi: 10.1016/j.jpeds.2026.115221. Epub 2026 Jul 3. PMID: 42398805

[Bacterial surface layer - Properties, role, applications and challenges - A review of the next-generation nanotechnological tool.](#)

Kumar A, Rana A, Kumar A, Tyagi A. J Microbiol Methods. 2026 Oct;249:107648. doi: 10.1016/j.mimet.2026.107648. Epub 2026 Aug 1. PMID: 42542137

[Adverse Events Following Immunization: Mechanisms, Clinical Manifestations, Surveillance, and Public Health Management-A Narrative Review.](#)

Patrick T, John OB, Dominique BB, Raoul RZ. Infect Drug Resist. 2026 Oct 2;19:642114. doi: 10.2147/IDR.S642114. eCollection 2026. PMID: 42841057

[Formulation and stability design spaces for a new yellow fever vaccine.](#)

Clénet D, Mansois N, Guo Y, Dos Ramos BA, Bertaux L, Vangelisti M. Eur J Pharm Biopharm. 2026 Oct;227:115177. doi: 10.1016/j.ejpb.2026.115177. Epub 2026 Jul 10. PMID: 42431558

[Validation of self-reported mpox vaccination in men who have sex with men.](#)

Mozaffari F, Aung ET, Soe NN, Wijekoon D, Towns JM, Latt PM, Chow EPF. Vaccine. 2026 Oct 1;93:129193. doi: 10.1016/j.vaccine.2026.129193. Online ahead of print. PMID: 42822177

[Nutritional modulation of biochemical stress using *Azolla pinnata* in *E. coli*-challenged broiler chickens vaccinated with IBDV.](#)

Barak M, Kajal S, Lather D, Gupta S, Nehra V, Sharma N. Avian Pathol. 2026 Oct 2;1-14. doi: 10.1080/03079457.2026.2699975. Online ahead of print. PMID: 42417604

[COVID-19 vaccine may protect older patients against major adverse CV events.](#)

Roush K. Am J Nurs. 2026 Oct 1;126(10):13. doi: 10.1097/AJN.000000000000388f. Epub 2026 Sep 24. PMID: 42779059

[Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted Staphylococcus aureus Vaccine in Adults With Recent Skin and Soft Tissue Infections: An Observer-Blind, Randomized, Placebo-Controlled, Multinational Phase 1/2 Trial.](#)

Athan E, Greenberg RN, Baker DA, Shah R, Dubhashi S, Badat A, Thurlow C, Schlessinger J, Wronski A, Zakrzewski M, Turner D, Bindi I, Basile V, Galletti B, Spensieri F, Brazzoli M, Zigon G, Cilio GL, Ranzato G, Lattanzi M, Pellegrini M; Staph aureus 208833 study group. Clin Infect Dis. 2026 Oct 7;83(3):e569-e577. doi: 10.1093/cid/ciag162. PMID: 41800789

[Review on anticoccidial vaccine development for chickens: Past progress, modern methods, and production bottlenecks.](#)

Yismaw M, Terefe G. Poult Sci. 2026 Oct 5;105(12):107875. doi: 10.1016/j.psj.2026.107875. Online ahead of print. PMID: 42854494

[Phenotypic and functional characterization of porcine T follicular helper and regulatory cells.](#)

Zaki D, Schmidt S, Wells J, Borrow P, Gerner W, Graham SP, Edwards JC. *J Immunol.* 2026 Oct 1;215(10):vkag264. doi: 10.1093/jimmun/vkag264.PMID: 42837425

[The Dunning-Kruger effect does not account for Covid-scepticism or vaccine hesitancy.](#)

McIntosh RD, Claydon J, Booth T, Della Sala S. *R Soc Open Sci.* 2026 Oct 7;13(10):260147. doi: 10.1098/rsos.260147. eCollection 2026 Oct 7.PMID: 42841132

[A recombinant attenuated PRRSV vaccine expressing the PCV2 capsid protein confers protective immunity in pigs.](#)

Gao SL, Yan JC, Wang J, Liu QY, Rong XL, Xing YR, Chen RL, Fei WH, Shan TL, Zhou YJ, Tong W, Zheng H, Kong N, Tong GZ, Yu H. *Vaccine.* 2026 Oct 3;91:129106. doi: 10.1016/j.vaccine.2026.129106. Epub 2026 Aug 31.PMID: 42673712

[Protecting newborns and infants before birth: Accelerating equitable maternal vaccine introduction in low- and middle-income countries.](#)

Nakimuli A, Fay K, Groome MJ, Barsosio H, Nakabembe E, Habib SS, Oyarzo-Torres S, Seale AC, Pasupathy D, Galadanci HS. *Int J Gynaecol Obstet.* 2026 Oct 7. doi: 10.1002/ijgo.71381. Online ahead of print.PMID: 42841270

[Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis.](#)

Seaman C, Bailie C, Spearman CW, Sonderup M, Howell J, Hellard M, Scott N. *Lancet Glob Health.* 2026 Oct;14(10):103975. doi: 10.1016/j.langlo.2026.103975. Epub 2026 Sep 2.PMID: 42685764

[Muscle size matters: making paediatric vaccination safe for all - a pilot study.](#)

Mackenzie LJ, Bousie JA, Newman P, Preston P, Cunningham JE, Fleming C, Leary K, Bushell MA. *Vaccine.* 2026 Oct 3;91:129076. doi: 10.1016/j.vaccine.2026.129076. Epub 2026 Aug 26.PMID: 42659919

[Identification of expressed endogenous retroviral element associated long terminal repeats in devil facial tumour cells.](#)

Kruawan A, Stammnitz MR, Wilson R, Ramarathinam SH, Ong CEB, Fairfax KA, Patchett AL, Lyons AB, Flies A. *Open Biol.* 2026 Oct 7;16(10):250430. doi: 10.1098/rsob.250430.PMID: 42838533

[Recent advances in antituberculosis drugs and therapeutics: from mechanistic breakthroughs to clinical translation.](#)

Pan Z, Liu G, Li Y, Yan H, Peng Y, Wang Y, Gong H, Du J, Wei S. *Mol Biomed.* 2026 Oct 10;7(1):203. doi: 10.1186/s43556-026-00610-5.PMID: 42859361

[From target engagement to translational disconnect: A systematic review and narrative synthesis of direct tau-targeted clinical trials in Alzheimer's disease and primary tauopathies.](#)

Yin L, Ren R, Leo C, Lu Y. *Pharmacol Res.* 2026 Oct;232:108439. doi: 10.1016/j.phrs.2026.108439. Epub 2026 Sep 6.PMID: 42702342

[Sense-Making During the RTS,S Malaria Vaccine Pilot Implementation in Ghana.](#)

Tani-Eshon ET. Qual Health Res. 2026 Oct;36(12):1284-1297. doi: 10.1177/10497323251347922. Epub 2025 Jun 13. PMID: 40512580

[Dual-Pathogen Defense: Engineering an ExPEC Ghost to Display Protective Epitopes of Streptococcus suis.](#)

Liu J, Pan X, Zhang Z, Liang S, Zhang S, Li C, Lv S, Chen Z, Zhu Y, Bao Y, Huang C, Huang J, Ma J. Adv Healthc Mater. 2026 Oct 12:e71838. doi: 10.1002/adhm.71838. Online ahead of print. PMID: 42864825

[Long-term trends in pediatric intussusception in Hokkaido, Japan, 2007-2024 across the rotavirus vaccination era.](#)

Fukuda Y, Araki Y, Kizawa T, Kondo K, Ikemoto W, Nishino K, Sato T, Kikuchi M, Nagai K, Kihara M, Ito T, Kabutoya H, Asakura H, Sasaoka Y, Adachi N, Nishida T, Tsugawa T. J Pediatr Gastroenterol Nutr. 2026 Oct 12. doi: 10.1002/jpn3.70599. Online ahead of print. PMID: 42865132

[Dual-glycolipid engineered vaccine platform empowers delivery route customization to intercept tumor lung metastasis.](#)

Wei L, Xu W, Zhang T, Zhao X, Zhao Y, Zhang J, Sun S, Wu L, Yang M, Cun D. J Control Release. 2026 Oct 2;399(Pt B):115429. doi: 10.1016/j.jconrel.2026.115429. Online ahead of print. PMID: 42826903

[Cognitive and behavioral determinants of HPV vaccination willingness and Behavior among female university students in Karnataka, India.](#)

Thomas Gil M, Gopal S, Oduro Owusu S. Hum Vaccin Immunother. 2026 Dec;22(1):2738253. doi: 10.1080/21645515.2026.2738253. Epub 2026 Oct 8. PMID: 42847160

[Platform-Specific Immunoassay Development and Orthogonal Characterization for Improved Host Cell Protein Control in Vero Cell-Derived Vaccines.](#)

Patel S, Zhang Y, Guan H, Groegler E, Yin K, Raffaele J, Rustandi RR, Stiving AQ, Gillespie PF, Wang Y, Driscoll D, Li X, Wang F. Biotechnol Bioeng. 2026 Oct 6. doi: 10.1002/bit.70401. Online ahead of print. PMID: 42834805

[Recent insights from prophylactic passive immunization trials of HIV-1 broadly neutralizing antibodies: implications for vaccine design.](#)

Moore PL. Curr Opin HIV AIDS. 2026 Nov 1;21(6):410-415. doi: 10.1097/COH.0000000000001064. Epub 2026 Oct 1. PMID: 42817199

[Vaccine data suggest immunity could mitigate dementia. What's the biology behind these apparent effects?](#)

Madhusoodanan J. Proc Natl Acad Sci U S A. 2026 Oct 13;123(41):e2633554123. doi: 10.1073/pnas.2633554123. Epub 2026 Oct 7. PMID: 42842397

[From Ebola response to adaptable preparedness beyond a single virus.](#)

Kambale Kahingi J, Mbokolo Bolima C, Belanga Bola J, Bebedi Nkamba B, Ilonga Mpeti E, Mbanda Mpunza C, Bekoka Wanga H, Mpembe Ngila R, Belito Nyimi J, Okasuma Djela R, Mungolongolo Mabaya J, Ndjate Olongo P, Kanjinga Ngoyi A, Shotsha Asambo L, Bongo Ngjala G, Nkayilu Tungulo Y, Kola Nsimba N,

Mubindikila Nzamba R, Seke Vangu M, Nzundu Mbo JP, Inia Aluna S, Tangou Tabou T. *Trop Med Health*. 2026 Oct 10;54(1):219. doi: 10.1186/s41182-026-01094-3. PMID: 42859161

[Development and protective efficacy of a live attenuated vaccine candidate against goose astrovirus.](#)

Qin Y, Wei X, Cui C, Ouyang K, Chen Y, Wei Z, Huang W. *Vet Microbiol*. 2026 Oct;321:111206. doi: 10.1016/j.vetmic.2026.111206. Epub 2026 Aug 24. PMID: 42641448

[The Impermanence of Public Health Gains-Lessons Learned from Measles Resurgence, Bangladesh, 2026.](#)

Bhuiya S, Shuvo TA, Hassan MZ, Aleem MA, Mamun GMS, Zakaria AFM, Rahman M, Chowdhury F. *Emerg Infect Dis*. 2026 Oct 2;32(11). doi: 10.3201/eid3211.261019. Online ahead of print. PMID: 42826220

[Integrated molecular and pathobiological evaluation of three live infectious bursal disease vaccines reveals differential replication, immunogenicity and genetic stability.](#)

Muneeb JM, Gul I, Hassan A, Akram T, Wani BM, Khan AA, Haq Z, Kamil SA, Shah RA, Ahmad SM, Ganai NA, Chikan NA, Abdul Careem MF, Shabir N. *Avian Pathol*. 2026 Oct;55(5):661-676. doi: 10.1080/03079457.2026.2690228. Epub 2026 Jul 13. PMID: 42324932

[Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study.](#)

Crandell J, Fantin RF, de Araújo LP, Lawres L, Pischel L, Monteiro VS, Conde L, Kottkamp AC, Samanovic MI, Cordeiro R, Póvoas D, Melo M, Castineiras TM, Vale AM, Yildirim I, Mulligan MJ, de Almeida LA, Omer SB, Coelho CH, Lucas C. *Lancet Infect Dis*. 2026 Oct;26(10):1058-1069. doi: 10.1016/S1473-3099(26)00173-8. Epub 2026 Jun 18. PMID: 42314719

[Safety and immunogenicity of one or two doses of the rVSVdeltaG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.](#)

Tremblay C, Valea I, Ndiaye BP, Barry H, ElSherif M, Cooper C, Breeze JL, Cai Y, Ye L, Omole T, Halperin SA, Mboup S, Langley JM. *Lancet HIV*. 2026 Oct;13(10):e689-e701. doi: 10.1016/S2352-3018(26)00118-9. Epub 2026 Aug 7. PMID: 42567171

[Long-term effectiveness of typhoid conjugate vaccine in Nepal.](#)

Chaudhary S, Uranw S. *Lancet Glob Health*. 2026 Oct;14(10):104045. doi: 10.1016/j.langlo.2026.104045. Epub 2026 Aug 10. PMID: 42575115

[Genetic diversity of clinical Mycobacterium bovis BCG isolates from an immunocompromised patient with BCG infection.](#)

Sawaswong V, Premchaiporn P, Wongjarit K, Prammananan T, Petsong S, Srichomthong C, Anugulruengkitt S, Payungporn S, Shotelersuk V, Rotcheewaphan S. *Infect Genet Evol*. 2026 Oct;144:106014. doi: 10.1016/j.meegid.2026.106014. Epub 2026 Aug 25. PMID: 42641843

[Adjuvant HPV Vaccination and Survival in Oropharyngeal Squamous Cell Carcinoma: An Exploratory Analysis of a Real-World Database.](#)

Kim ME, Herrera K, Han A, Hur K, Kokot N, Swanson MS. Laryngoscope Investig Otolaryngol. 2026 Sep 29;11(5):e70573. doi: 10.1002/lio2.70573. eCollection 2026 Oct. PMID: 42818876

[Ethical considerations of incentive structures in vaccine acceptance research.](#)

Musrati MA, Shenaisheh S, Elemraid MA. Vaccine. 2026 Oct 3;91:129102. doi: 10.1016/j.vaccine.2026.129102. Epub 2026 Aug 30. PMID: 42669239

[A staged clinical development and evidence-generation framework for Group A Streptococcus vaccines.](#)

Cagigi A, Kraus A, Wartel TA, Steer A, Carapetis J, Fulurija A, Kim JH. NPJ Vaccines. 2026 Oct 11;11(1):189. doi: 10.1038/s41541-026-01607-5. PMID: 42860434

[An effective combined vaccine against vibriosis and typical and atypical furunculosis in Atlantic salmon \(*Salmo salar*\).](#)

Park Y, Han HJ, Kim MS, Woo SJ, Park MC, Hong S. Fish Shellfish Immunol. 2026 Oct;177:111511. doi: 10.1016/j.fsi.2026.111511. Epub 2026 Jun 24. PMID: 42341863

[Evaluation of transduction properties and vaccine efficacy of a simian adenovirus type 25-based vector.](#)

Okumura F, Tokuoka S, Nagata N, Onishi R, Shiota A, Sakurai F, Shimizu K, Mizuguchi H. Eur J Pharm Sci. 2026 Oct 1;225:107619. doi: 10.1016/j.ejps.2026.107619. Epub 2026 Jul 24. PMID: 42492663

[Vaccine Performance Helps Explain Heterogeneity in Indirect Protection Across Influenza Vaccine Trials.](#)

Tuite AR, Warshawsky BF, Friedman L, Kwong JC, Dick DW. Clin Infect Dis. 2026 Oct 7;83(3):e673-e675. doi: 10.1093/cid/ciag260. PMID: 41995713

[Dispensing Patterns of Influenza and Pneumococcal Vaccines in the Private Healthcare Sector in South Africa for 2017 to 2021: A Longitudinal Study.](#)

Truter I, Hugo J, Smith H, Bansal S, Vira A. Pharmacoepidemiol Drug Saf. 2026 Oct;35(10):e70477. doi: 10.1002/pds.70477. PMID: 42764173

[Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity.](#)

Wiest MJ, Laghlali G, d'Acunzo J, Chung C, Karadag D, Yan V, Park SC, Nouredine M, Janczak KW, Chen C, Farazuddin M, O'Konek JJ, García-Sastre A, Baker JR Jr, Schotsaert M, Wong PT. EMBO Mol Med. 2026 Oct 12. doi: 10.1038/s44321-026-00539-w. Online ahead of print. PMID: 42864420

[Beyond the traveller: immunocompromised residents as a blind spot in the South American yellow fever resurgence.](#)

Faico-Filho KS. New Microbes New Infect. 2026 Aug 19;73:101830. doi: 10.1016/j.nmni.2026.101830. eCollection 2026 Oct. PMID: 42643869

[Association of gut microbiota and regulatory T cells with vaccine immunogenicity in HIV-exposed uninfected and HIV-unexposed infants: a longitudinal cohort study.](#)

Johnson MJ, Frank DN, Salazar AT, Nunes MC, Madhi SA, Weinberg A. EBioMedicine. 2026 Oct 1;132:106500. doi: 10.1016/j.ebiom.2026.106500. Online ahead of print. PMID: 42822324

[RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.](#)

Reimer Jensen AM, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Janstrup KH, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Stæhr Jensen JU, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Zhang P, Begier E, Biering-Sørensen T. *Lancet Healthy Longev.* 2026 Oct 6:100895. doi: 10.1016/j.lanhl.2026.100895. Online ahead of print. PMID: 42838078

[Immunogenicity and post-challenge virological outcomes of a multivalent subunit vaccine in sheep challenged with cytopathic BVDV-1a.](#)

Shao Z, Yuan J, Li Y, Xiao L, Ni R, Li Y, Gao Y, Wang Z, Zhang Y, Wu A, Gu M, Li J, Fu Z, Zhang T, Sheng J, Yi J, Wang Y. *Vet Microbiol.* 2026 Oct;321:111174. doi: 10.1016/j.vetmic.2026.111174. Epub 2026 Aug 3. PMID: 42561832

['Once Bitten': A Case of Tetanus Following Snakebite in Australia.](#)

Doherty AAS, Clarke NNE, Fletcher S, Huffam S, Awburn CV, Athan E. *Med J Aust.* 2026 Oct;224(10):e70308. doi: 10.5694/mja2.70308. PMID: 42810737

[\[Infectious bronchitis is ubiquitous - insights from 10 years of diagnostics in a poultry practice\].](#)

Heckmann L, Röring N, Dünghoef K. *Tierarztl Prax Ausg G Grosstiere Nutztiere.* 2026 Oct;54(5):334-340. doi: 10.1055/a-2901-4964. Epub 2026 Sep 9. PMID: 42716083

[Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study.](#)

Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Abu-Raddad LJ. *Open Forum Infect Dis.* 2026 Sep 22;13(10):ofag602. doi: 10.1093/ofid/ofag602. eCollection 2026 Oct. PMID: 42831111

[Effects of mRNA Vaccination on the Progression of Chronic Kidney Disease.](#)

Emre T, Mete F. *Clin Lab.* 2026 Oct 1;72(10):2293-2299. doi: 10.7754/Clin.Lab.2026.260204. PMID: 42847950

[An overview of current technologies in the development of drugs and vaccines against dengue virus.](#)

Pourzangiabadi M, Barkam M, Najafi H, Pouladi I. *Infect Genet Evol.* 2026 Oct 9:106041. doi: 10.1016/j.meegid.2026.106041. Online ahead of print. PMID: 42854934

[An E2 glycoprotein-based recombinant subunit vaccine confers protective immunity against classical swine fever virus in piglets.](#)

Li Z, Fang P, Dong Y, Xu R, Li J, Huang J. *Microb Pathog.* 2026 Oct;219:108743. doi: 10.1016/j.micpath.2026.108743. Epub 2026 Jul 31. PMID: 42537723

[SmartVax-Bp: An Immunoinformatic guided Multi-Epitope Vaccine Blueprint Against Burkholderia pseudomallei.](#)

Aljasir MA, Alammari DM, Helmi N, Saira, Ahmad S, Wei DQ. Probiotics Antimicrob Proteins. 2026 Oct 6. doi: 10.1007/s12602-026-11241-1. Online ahead of print. PMID: 42836932

[Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations.](#)

Roldan GA, Fletcher J, Davie T, Leventhal TM, Lake JR, Udombap P. JAMA Intern Med. 2026 Oct 1;186(10):1213-1223. doi: 10.1001/jamainternmed.2026.3831. PMID: 42606884

[Functional divergence of regulatory and conventional bovine neutrophils following Mycobacterium bovis infection.](#)

Saint-Vanne M, Bounab B, Eymieux S, Perdriau E, Cunha P, Carreras F, Roullier R, Le Vern Y, Pichon J, Doz-Deblauwe E, Germon P, Winter N, Remot A. J Innate Immun. 2026 Oct 9;1. doi: 10.1159/jin/adhag002. Online ahead of print. PMID: 42853732

[Knowledge, attitudes and practices of vaccination among older adults in Brunei Darussalam: a convergent mixed-method study.](#)

Matsamri SAM, Teo SP, Suryono S, Sharbini S, Abdul-Mumin KH, Chaw L. BMJ Open. 2026 Oct 9;16(10):e120792. doi: 10.1136/bmjopen-2026-120792. PMID: 42855239

[Oncogenic hub genes ANLN and CTHRC1: Implications for cancer prognosis and vaccine-based therapeutics.](#)

Roy SK, Hasan R, Biswas MS, Podder MK, Moin AT, Patil RB. Comput Biol Chem. 2026 Oct;124(Pt 1):109060. doi: 10.1016/j.compbiolchem.2026.109060. Epub 2026 Apr 19. PMID: 42025263

[Pre-clinical immunogenicity and safety evaluation of H2 strain Hepatitis A Inactivated Vaccine in rhesus macaques.](#)

Ping L, Chu H, Li Z, Liang J, Cai L, Yang J, Jiang Q, Wang X, Li J, Hu W, Ma Y, Gu Q, Gao N, Ji Q, Wen J, Liao H, Ji G, Jiang H, Hou D, Fu Y, Fu Y, Kong W, Qin X, Zheng H, Zhao T, Fan S, Yang J. Antiviral Res. 2026 Oct;254:106498. doi: 10.1016/j.antiviral.2026.106498. Epub 2026 Aug 11. PMID: 42580485

[Immunization timeliness and its determinants among young children in Baghdad, Iraq: A cross-sectional study using documented vaccination cards.](#)

Shah SSAM, Al-Ani HAM, Alwardi MAW, Zehra A, Kanwal U, Ansari T. PLoS One. 2026 Oct 1;21(10):e0359962. doi: 10.1371/journal.pone.0359962. eCollection 2026. PMID: 42821556

[Can Moderna's mRNA cancer vaccine for cutaneous melanoma be applicable to melanomas of the eye and ocular adnexa?](#)

Liu S, Leung HYE, Singh AD, Jager MJ, Fan X, Lam DSC. Asia Pac J Ophthalmol (Phila). 2026 Oct 3;100380. doi: 10.1016/j.apjo.2026.100380. Online ahead of print. PMID: 42829042

[An adenovirus-based multiantigen vaccine protects against tuberculosis by coordinating adaptive immunity and curbing immunosuppressive mechanisms.](#)

Wei L, Wang P, Li Y, Li X, Shen X, He F, Guo Y, Xing M, Zhou D. *Microbiol Spectr*. 2026 Oct 6;14(10):e0090726. doi: 10.1128/spectrum.00907-26. Epub 2026 Aug 28. PMID: 42663486

[An immunoinformatics-based multi-epitope vaccine candidate confers cross-protection against two *Actinobacillus pleuropneumoniae* serovars.](#)

Tan L, Fang Y, Liu P, Su M, Zhao X, Xu B, Li C, Li X, Wang Y, Zhang W. *Vaccine*. 2026 Oct 3;91:129104. doi: 10.1016/j.vaccine.2026.129104. Epub 2026 Aug 31. PMID: 42673711

[Mpox knowledge, anxiety, and preventive behaviours in Jordan: a socio-ecological perspective on vaccination and preparedness.](#)

Al Meslamani AZ, Abu-Naser D, Ali Mohammed EM. *Int J Environ Health Res*. 2026 Oct;36(10):2770-2782. doi: 10.1080/09603123.2026.2657446. Epub 2026 Apr 13. PMID: 41972874

[Wastewater Surveillance to Track Resurgent Measles Outbreak, Ontario, Canada, 2025.](#)

Corchis-Scott R, Mercier É, Mejia EM, Geng Q, Harrop E, Podadera A, Fong J, Lewoc N, Ng KKS, Santiago N, Knox N, Goodridge L, Mangat CS, Landgraft C, Riddell KB, Aloosh M, Delatolla R, McKay RM. *Emerg Infect Dis*. 2026 Oct;32(10):1667-1676. doi: 10.3201/eid3210.260092. PMID: 42811349

[An inactivated human adenovirus type 55 vaccine attenuates pulmonary pathology in a non-human primate challenge model.](#)

Lee JY, Choi JA, Jung DI, Park Y, Yang E, Kim C, Ko M, Baek SH, Hong JJ, Kwon SH, Kim WT, Song M, Seo SH. *Virus Res*. 2026 Oct;372:199793. doi: 10.1016/j.virusres.2026.199793. Epub 2026 Aug 21. PMID: 42624376

[Using the misinformation exposure-trust framework for audience segmentation: Predicting COVID-19 vaccine hesitancy among U.S. College Students.](#)

Zeng J, Li J, Yu N, Cui X, Xiao A. *J Health Psychol*. 2026 Oct;31(12):4899-4919. doi: 10.1177/13591053261419968. Epub 2026 Feb 27. PMID: 41755712

[Vaccination accelerates the race of influenza virus against collective immunity.](#)

Rouzine IM. *PLoS Pathog*. 2026 Oct 12;22(10):e1014311. doi: 10.1371/journal.ppat.1014311. Online ahead of print. PMID: 42862853

[Human Papillomavirus Vaccine Communication Skills for Pediatric Primary Care Clinicians: Evaluation of a Randomized Clinical Trial of the C-LEAR Training on Clinicians' Behavior.](#)

Bylund CL, Thompson LA, Hansen MD, DeGruccio K, Sanchez G, Lin T, Wang P, Staras SAS. *J Pediatr Clin Pract*. 2026 Jun 11;21:200221. doi: 10.1016/j.jpdc.2026.200221. eCollection 2026 Oct. PMID: 42473561

[Trends in sociodemographic factors associated with human papillomavirus vaccine hesitancy in the United States: 2010-2022.](#)

Aboueilla DK, Nair M, Gerend MA, Aspiras O, Osazuwa-Peters N, Adjei Boakye E. *Cancer*. 2026 Oct 1;132(19):e70636. doi: 10.1002/cncr.70636. PMID: 42804607

[Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.](#)

Heiman SL, Geiger N. *Vaccine*. 2026 Oct 3;91:129046. doi: 10.1016/j.vaccine.2026.129046. Epub 2026 Aug 17. PMID: 42607628

[Immunoinformatics-based design and in silico evaluation of a multi-epitope vaccine candidate against *Naegleria fowleri*.](#)

Velumani K, Umapathi S, Malla A, Shanmugaraj B. *Hum Immunol*. 2026 Oct 12;87(12):112108. doi: 10.1016/j.humimm.2026.112108. Online ahead of print. PMID: 42863409

[Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa.](#)

Dutta S, Ngemera D, Jaillard P, Juneja S. *Vaccine*. 2026 Oct 3;91:128994. doi: 10.1016/j.vaccine.2026.128994. Epub 2026 Aug 18. PMID: 42612463

[A major capsid protein subunit vaccine can block vertical transmission of LMBV in largemouth bass broodstock.](#)

Chen Y, Zhang X, Yang S, Cao J, Luo J, Xu T, Liang J, Zhu L, Li Y, Qin Q, Zhou S. *Dev Comp Immunol*. 2026 Oct;183:105726. doi: 10.1016/j.dci.2026.105726. Epub 2026 Sep 1. PMID: 42680006

[Health care providers' perspectives on county-level barriers and facilitators to HPV vaccination: A socio-ecological approach \(2022-2023\).](#)

Khatri RA, Zimet GD, Kasting ML, Head KJ. *Hum Vaccin Immunother*. 2026 Dec;22(1):2734052. doi: 10.1080/21645515.2026.2734052. Epub 2026 Oct 5. PMID: 42832184

[Real-time monitoring of aluminum phosphate sedimentation and resuspension using electrical resistance tomography.](#)

Pellicari R, Alberini F, Paglianti A, Luckham SLJ, Pergola C, Albano A. *Int J Pharm*. 2026 Oct 3;127503. doi: 10.1016/j.ijpharm.2026.127503. Online ahead of print. PMID: 42829012

[Recognizing a Few of the Vaccine-Preventable Diseases: Part 2.](#)

Williams A, Dehority W. *Pediatr Rev*. 2026 Oct 1;47(10):547-556. doi: 10.1542/pir.2026-007211. PMID: 42815941

[Improving Human Papillomavirus \(HPV\) Vaccine Uptake in Canada: A Call for Equity and Inclusivity.](#)

Doucette N, Steenbeek A. *Community Health Equity Res Policy*. 2026 Oct;47(1):77-82. doi: 10.1177/2752535X251368427. Epub 2025 Aug 14. PMID: 40808520

[Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk.](#)

Wang WW, Tan YT, Bellua Sam N, Li L, Chang YW, Asena Musonye H, Wang P, Pan HF. *Hum Vaccin Immunother*. 2026 Dec;22(1):2741765. doi: 10.1080/21645515.2026.2741765. Epub 2026 Oct 8. PMID: 42849061

[Meningitis B vaccine: Only a quarter of year 13 school leavers in England get jab.](#)

Baraniuk C. *BMJ*. 2026 Oct 5;395:e101035. doi: 10.1136/bmj-2026-101035. PMID: 42833676

[The next frontier in advanced practice nursing: Infectious diseases nurse practitioner certification.](#)

Rogers S, De Guzman S, Riley V, Kim S, Manning ML. *J Am Assoc Nurse Pract*. 2026 Oct 5. doi: 10.1097/JXX.0000000000001378. Online ahead of print. PMID: 42841815

[Experimental validation of a computationally designed mosquito midgut SGU protein-based epitope vaccine against malaria.](#)

Singh H, Dahiya N, Kirar M, Yadav M, Janjoter S, Sehrawat N. *Dev Comp Immunol*. 2026 Oct;183:105712. doi: 10.1016/j.dci.2026.105712. Epub 2026 Aug 15. PMID: 42603668

[Development of a combined GMMA and glycoconjugate iNTS-TCV trivalent vaccine against invasive salmonellosis.](#)

Citiulo F, Necchi F, Cappelletti E, Ferhati X, Aruta MG, Liverani I, Muzzi C, Benincasa M, Giannelli C, Mancini F, Rossi O, Micoli F, Vitali CG, Martin LB, Scorza FB, Colucci AM, Canals R. *Res Sq [Preprint]*. 2026 Oct 4;rs.3.rs-10957216. doi: 10.21203/rs.3.rs-10957216/v1. PMID: 42856723

[Maternal respiratory syncytial virus vaccination for infant protection: updated systematic review and meta-analysis of efficacy, effectiveness, and safety.](#)

Saif-Ur-Rahman KM, King C, Whelan S, Blair M, Donohue S, Madden C, Kothari K, Sommer I, Harder T, Dauby N, Ruta SM, Frère J, Schönfeld V, Poukka E, Olsson K, Melidou A, Dwan K, Devane D. *New Microbes New Infect*. 2026 Aug 24;73:101831. doi: 10.1016/j.nmni.2026.101831. eCollection 2026 Oct. PMID: 42699312

[Postpandemic COVID-19 Vaccination Willingness Among Physicians and Medical Trainees in China: Cross-Sectional Study.](#)

Mu Y, Wang Y, Gu X, Shang L, Che W, Xuan W, Cao X, Zhang C, Zhou X, Sun S, Zhao R, Liu A, Kuang J, Guo Y, Mo J, Cao B. *JMIR Public Health Surveill*. 2026 Oct 6;12:e88931. doi: 10.2196/88931. PMID: 42837522

[Vaccination of neonatal calves with a modified-live Mycoplasma \(Mycoplasma\) bovis vaccine confers protection and enhances immunity.](#)

Dreesen L, Asper DJ, Sobecki B, Mahan SM, Meinert T, Genteman K, Ketteler D, Martinon N, Bénéré E, Peterson D, Anderson K, Brueck B, Anto L, Gurjar A, Moulin V. *Am J Vet Res*. 2026 Jul 8;87(10):ajvr.26.03.0090. doi: 10.2460/ajvr.26.03.0090. Print 2026 Oct 1. PMID: 42419370

[A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.](#)

Liu L, Yan M, Liang R, Wu Q, Qu C, Wu H, Liao Z, Chen H, Zou J, Sun Z, Niu D, Wu L, Zhao L, Dai J, Shen J, Zhang L, Zhang W, Peng W. *EMBO Mol Med*. 2026 Oct;18(10):3979-4000. doi: 10.1038/s44321-026-00511-8. Epub 2026 Aug 29. PMID: 42668284

[Vaccination With *Trichuris muris* Poly-Cysteine and Histidine-Tailed Protein p43 Protects Against Chronic Infection.](#)

Bancroft AJ, Hayes KS, Campbell L, Thompson S, Dold C, Blackwell L, Rollier CS, Thornton DJ, Grencis RK. *Parasite Immunol.* 2026 Oct;48(10):e70107. doi: 10.1111/pim.70107.PMID: 42815557

[Safety of Messenger RNA COVID-19 Vaccination During Pregnancy: Findings from Post-Vaccination Follow-Up Data from the Canadian National Vaccine Safety Network.](#)

Soe P, Muller MP, Isenor JE, Valiquette L, Vanderkooi OG, Kellner JD, Top KA, De Serres G, McGeer A, Kiely M, Shulha HP, Irvine MA, Marty K, Sadarangani M, Bettinger JA; Canadian Immunization Research Network. *J Obstet Gynaecol Can.* 2026 Oct;48(10):103471. doi: 10.1016/j.jogc.2026.103471. Epub 2026 Jul 22.PMID: 42486365

[Fusion-loop-engineered Zika mRNA vaccine elicits convergent B cell immunodominance to uncouple protection from ADE in macaques.](#)

Yang C, Guo S, Lu Y, Duan M, Yang H, He W, Cheng Y, Wan F, Han Y, Wan S, Ma H, Wang J, Tang C, Wen J, Xu K, Liu S, Shu B, Zhang S, Huang N, Lu S, Gao GF, Dai L. *Cell Rep Med.* 2026 Oct 7:103091. doi: 10.1016/j.xcrm.2026.103091. Online ahead of print.PMID: 42843342

[Psychometric validity evidence for a measure of trust in U.S. public health actors for vaccine information.](#)

Gutierrez AM, Do MH, Motta M. *Vaccine.* 2026 Oct 3;91:129026. doi: 10.1016/j.vaccine.2026.129026. Epub 2026 Aug 25.PMID: 42641256

[From eradicating wild poliovirus to eradicating vaccine-derived polioviruses: why oral polio vaccine use must now be ended.](#)

Durrheim DN, Steinglass R, Hirschhorn N, Dharmapalan D, Tomori O, John TJ. *Int Health.* 2026 Oct 7:iha097. doi: 10.1093/inthealth/ihag097. Online ahead of print.PMID: 42841208

[Bayesian Hierarchical Modeling Approaches for Combining Information From Multiple Data Sources to Produce Annual Estimates of National Immunization Coverage.](#)

Utazi CE, Jochem WC, Danovaro-Holliday MC, Murphy P, Sahu SK, Gacic-Dobo M, Tatem AJ. *Biom J.* 2026 Oct;68(5):e70189. doi: 10.1002/bimj.70189.PMID: 42839684

[Adjuvanted *Edwardsiella anguillarum* vaccine confers protection and cross-protection against *E. piscicida* in Japanese eel \(*Anguilla japonica*\).](#)

Kim HG, Kim JY, Kim WS, Jung SJ. *Fish Shellfish Immunol.* 2026 Oct;177:111536. doi: 10.1016/j.fsi.2026.111536. Epub 2026 Jun 25.PMID: 42349703

[Investigation of trends in the research on ferritin-based drug delivery systems via a bibliometric and thematic analysis.](#)

Ma J, Tai Z, Li Y, Shen M, Shen C, Xin R, Zhu Q, Chen Z. *J Mater Chem B.* 2026 Oct 2. doi: 10.1039/d6tb00466k. Online ahead of print.PMID: 42825541

[Broad IBV protection induced by a live IBV-NDV vaccine containing a Mass and Q1 strain.](#)

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

Bataille H, Boerhout E, Stooker L, Zuanaze M, de Wit S. Avian Pathol. 2026 Oct;55(5):642-647. doi: 10.1080/03079457.2026.2680998. Epub 2026 Jul 13. PMID: 42438936

[Growth performance and immune responses of pigs from nursery to grower-finisher phase following different PRRSV-2 vaccination strategies: Evidence supporting a prime-boost regimen under field conditions in Korea.](#)

Lee W, Ham S, Na H, Chae C. Can J Vet Res. 2026 Oct 1;90(4):135-144. eCollection 2026 Oct. PMID: 42774789

[Accounting for serotypic heterogeneity improves the interpretation of pneumococcal vaccine response using serotype-specific ELISA IgG concentrations.](#)

Durand G, Belhoul C, Bensalah M, Jeljeli M, Toullec L, Gil M, Lachiche E, Baron C, Goulvestre C, Drouet C, Batteux F, Chevrier L. Microbiol Spectr. 2026 Oct 6;14(10):e0066126. doi: 10.1128/spectrum.00661-26. Epub 2026 Sep 11. PMID: 42725745

[SARS-CoV-2-Streptococcus pneumoniae Coinfection: A Narrative Review of Pathogenesis, Synergy, and Clinical Impact.](#)

Chatwitchanon W, Kongutsa K, Supharattanasitthi W, Audshasai T. Int J Microbiol. 2026 Oct 10;2026:3388334. doi: 10.1155/ijm/3388334. eCollection 2026. PMID: 42859595

[A Nitric Oxide-Based STING Agonist Nanoadjuvant With ICD-Derived Membrane Antigens Unleashes Robust Antitumor Immunity.](#)

Xu S, Song Y, Zhang T, Wang Y, Wang M, Xie X, Chen Q, Liang X. Exploration (Beijing). 2026 Oct 11:70238. doi: 10.1002/exp2.70238. Online ahead of print. PMID: 42861131

[Social Identities and Vaccine Exemptions in the United States: The Role of Religiosity, Partisanship, and Vaccine Hesitancy.](#)

Boyce MR, Blackburn CC, Duza SS. J Community Health. 2026 Oct;51(5):865-876. doi: 10.1007/s10900-026-01597-4. Epub 2026 Jul 23. PMID: 42493745

[Optimising pneumonia vaccine programmes: a strategic opportunity for child survival and lifelong lung health.](#)

Greenslade L; Secure PCV and Stop RSV Collaborators. Lancet Glob Health. 2026 Oct;14(10):104064. doi: 10.1016/j.langlo.2026.104064. Epub 2026 Aug 15. PMID: 42600626

[Rates of HPV Vaccination among Women and People with a Cervix Living with HIV in Canada.](#)

Nicolls S, Karlsen E, Martel-Laferrière V, Vachon ML, Yudin MH, Money D, McClymont E; NOVA-HIV Study Team. J Obstet Gynaecol Can. 2026 Oct 7:103542. doi: 10.1016/j.jogc.2026.103542. Online ahead of print. PMID: 42843520

[Caregivers' willingness and factors influencing uptake of the malaria vaccine among under-five children at Masaka Regional Referral Hospital, Uganda.](#)

Namusisi AM, Migisha R, Kizza D, Kwesiga B, Bulage L, Tusubira V, Nakayiza LM, Tageya S, Nsubuga F, Atugonza R, Baganizi M, Ario AR. *PLOS Glob Public Health*. 2026 Oct 6;6(10):e0005764. doi: 10.1371/journal.pgph.0005764. eCollection 2026. PMID: 42837393

[Bridging EIA and PCR testing results for the detection of rotavirus gastroenteritis in a US pediatric population, 2011-2016.](#)

Mattison CP, Mirza SA, Wikswo ME, Selvarangan R, Lee B, Moffatt ME, Harrison CJ, Weltmer K, Katz EM, Esona MD, Mijatovic-Rustempasic S, Bowen MD, Tate JE, Parashar U, Gautam R. *J Clin Virol*. 2026 Oct;186:105997. doi: 10.1016/j.jcv.2026.105997. Epub 2026 Aug 29. PMID: 42691790

[Expression of a conserved synthetic multiepitopic malaria protein CS712 in duckweed: immune response evaluation after oral delivery in BALB/c mice.](#)

Rad N, Zakeri S, Mehrizi AA, Baghini SS, Arezoumandi M, Taghipour E, Frootan F, Jafari M, Salmanian AH. *J Biotechnol*. 2026 Oct 7:S0168-1656(26)00268-3. doi: 10.1016/j.jbiotec.2026.10.003. Online ahead of print. PMID: 42843660

[Effect of Antiretroviral Therapy, Immune Dysregulation, and COVID-19 Vaccination on SARS-CoV-2 Outcomes in PLWHA in Kenya.](#)

Njue JK, Wekesa L, Maiyo A, Mwangi ZM, Kagendo D, Lwembe RM. *AIDS Res Treat*. 2026 Oct 5;2026:5621772. doi: 10.1155/arar/5621772. eCollection 2026. PMID: 42840250

[Influenza A and B Viral Shedding in Adults Immunized With Live Attenuated Influenza Vaccine.](#)

Tower BM, Liu CM, Diemert DJ, Nelson SG, Ware CE, Salazar JE, Pham T, Leventis RM, Rose KE, Roberts ALS, Weber NO, Sung EH, Aziz M, Troyer RM, Park DE. *Clin Infect Dis*. 2026 Oct 7;83(3):e611-e618. doi: 10.1093/cid/ciag294. PMID: 42097577

[Immunogenicity and Safety of Single-Dose MenACYW Conjugate Vaccine in Vietnamese Participants Aged 12 Months: A Phase III, Open-Label Study.](#)

Thiem VD, Janicot S, Syrkina O, Ha VH, Long PD, Nguyen DT, Zocchetti C. *Infect Dis Ther*. 2026 Oct 12. doi: 10.1007/s40121-026-01458-6. Online ahead of print. PMID: 42862517

[Early Action Review of Detection, Notification, and Response Timeliness during Cross-Border Bundibugyo Virus Disease Outbreak, Uganda, 2026.](#)

Kayiwa J, Bbuye M, Atuhaire R, Nyakato D, Tut M, Nozad B, Baryamujura J, Lubwama B, Okware S, Kajumba P, Akello G, Kintu B, Kahunde R, Aliddeki D, Guyassa M, Nakiire L, Ocom F, Mbaka P, Elyanu P, Muruta A, Kagirita A, Olaro C. *Emerg Infect Dis*. 2026 Oct;32(10):1543-1550. doi: 10.3201/eid3210.261411. PMID: 42810990

[Convalescent plasma in the pre-vaccine era-Lessons from PC-COVID and COV-PLAS.](#)

Díaz FJ, Atiénzar PJE, Cuello IG, Sánchez ED. *Enferm Infecc Microbiol Clin (Engl Ed)*. 2026 Oct;44(8):503261. doi: 10.1016/j.eimce.2026.503261. Epub 2026 Aug 13. PMID: 42595665

[Engineered VP2-NC antigen expressed in an NDV vector elicits enhanced protection against the challenge of the novel variant infectious bursal disease virus.](#)

Zhang Z, Liu C, Zhang Y, Dai J, Tan L, Sun Y, Song C, Qu Y, Tang N, Liao Y, Ding C, Qiu X. *Poult Sci.* 2026 Oct;105(10):107090. doi: 10.1016/j.psj.2026.107090. Epub 2026 May 8. PMID: 42341504

[Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates.](#)

Andrews JR, Hermans S, White RG, García-Basteiro AL, Croda J, Cobelens F. *Vaccine.* 2026 Oct 3;91:129097. doi: 10.1016/j.vaccine.2026.129097. Epub 2026 Aug 31. PMID: 42673713

[Understanding Mpox Knowledge, Communication, and Care Engagement Among Black and Latino Gay and Bisexual Men.](#)

Ebor MT, Karris MY, Barnes J, Parker KE, Kaur B, Glavee G, Blumenthal J, Campbell CK. *AIDS Patient Care STDS.* 2026 Oct;40(10):401-407. doi: 10.1177/10872914261471238. Epub 2026 Jul 23. PMID: 42488963

[RAD001-Adjuvanted Influenza Vaccine Synergizes With Anti-Programmed Cell Death Protein 1 Therapy to Enhance Antitumor Immunity in Programmed Cell Death Ligand 1-Low Murine Lung Cancer.](#)

Ou HL, Sun J, Wu SB. *World J Oncol.* 2026 Sep 4;17(5):751-764. doi: 10.14740/wjon2831. eCollection 2026 Oct. PMID: 42730473

[In silico designing of a novel multiple epitope vaccine against vancomycin resistant *Enterococcus faecalis*: An immunoinformatic-guided approach.](#)

Javaid MM, Nasir R, Rehman R, Abbasi R, Khalid M, Ibrahim A. *Comput Biol Chem.* 2026 Oct;124(Pt 1):109116. doi: 10.1016/j.compbiolchem.2026.109116. Epub 2026 May 10. PMID: 42119371

[Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates.](#)

Silva Marinho PE, Ghimire D, Tsai Silva J, Devlin J, Kwon S, Adams G, Jorquera P, Luban J, Lemieux JE. *J Virol.* 2026 Oct 5:e0122126. doi: 10.1128/jvi.01221-26. Online ahead of print. PMID: 42831627

[Positive emotions and credibility: Understanding how a community-engaged online campaign featuring clinician testimonials improved rural vaccine promotion.](#)

Tao R, Shen L, Bhattar M, Jones M, Garbacz A, Yang S, Passmore SR. *Soc Sci Med.* 2026 Oct 1;409:119898. doi: 10.1016/j.socscimed.2026.119898. Online ahead of print. PMID: 42833101

[RNA and lipid composition analyses reveal distinct profiles between HEK293-derived extracellular vesicles and HIV-1 Gag virus-like particles.](#)

García-Trujillo M, Lavado-García J, Pérez-Rubio P, Gòdia F, Cervera L. *Biomed Pharmacother.* 2026 Oct;203:119860. doi: 10.1016/j.biopha.2026.119860. Epub 2026 Aug 24. PMID: 42636636

[Respiratory Syncytial Virus Vaccination Strongly Induces RSVpreF-specific IgG and Neutralizing Activity in Immunocompromised Individuals.](#)

Bronder S, Gruell H, Urschel R, Lennartz S, Tschauowsky D, Abu-Omar A, Radun R, Fliser D, Wilkens H, Schmit D, Sester M. *Transplant Direct*. 2026 Sep 16;12(10):e2001. doi: 10.1097/TXD.0000000000002001. eCollection 2026 Oct. PMID: 42770140

[Protective efficacy of a squalene adjuvanted oral inactivated vaccine against *Streptococcus agalactiae* in Nile tilapia.](#)

Ev J, Akshay TR, Guha R, Elumalai P. *Vet Immunol Immunopathol*. 2026 Oct;300:111169. doi: 10.1016/j.vetimm.2026.111169. Epub 2026 Jul 15. PMID: 42468244

[Antibodies targeting a conserved cryptic epitope at the influenza hemagglutinin head-stem interface via distinct binding modes.](#)

Stroh GL, Lv H, Chen C, Sun Y, Pholcharee T, Zhu C, Teo ST, Mitchell DA, Mok CKP, Wu NC. *bioRxiv* [Preprint]. 2026 Oct 3:2026.09.24.754278. doi: 10.64898/2026.09.24.754278. PMID: 42856120

[Post-infectious Basal Ganglia Encephalitis Caused by Mumps: A Case Series.](#)

Kamate M, Pawar G, Hattiholi V. *J Child Neurol*. 2026 Oct;41(9):1353-1357. doi: 10.1177/08830738261422782. Epub 2026 Mar 10. PMID: 41804778

[Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.](#)

Monoi A, Endo A, Kriznar M, Suzuki M, Flasche S. *Vaccine*. 2026 Oct 3;91:129079. doi: 10.1016/j.vaccine.2026.129079. Epub 2026 Aug 26. PMID: 42648051

[Informing an mpox stockpile investment case: epidemiological modelling and cost-benefit analysis.](#)

Mitcham D, Bruns R, Goodtree H, Campbell E, Kelly A, Oyefolu O, Wellham H, Ameaka FN, Gillani S, Schneider-Firestone S, Hart A, Rivers C, Saksena N, Esteban I, Kaboré L, Allan S, Russell AL, Luquero FJ, Saad Duque NJ, Watson CR. *Lancet Glob Health*. 2026 Oct 9:104069. doi: 10.1016/j.langlo.2026.104069. Online ahead of print. PMID: 42854705

[Epitope Generation Gateway \(EGG\): A biological context-dependent approach to cancer vaccine development.](#)

Mannino L, Fratello M, Chiaro J, D'Alessio F, Lieto ED, Niittykoski M, Serra A, Ylä-Herttuala S, Cerullo V, Federico A, Greco D. *Gigascience*. 2026 Oct 1:giag095. doi: 10.1093/gigascience/giag095. Online ahead of print. PMID: 42820749

[Structure-based design and immunogenicity of an H5 hemagglutinin stem nanoparticle vaccine candidate.](#)

Wang A, Liu Y, Yin Y, Su Z, Qi W, Huang L, Yan R, Liao M. *Int J Biol Macromol*. 2026 Oct 8:154799. doi: 10.1016/j.ijbiomac.2026.154799. Online ahead of print. PMID: 42849673

[Recombinant Marek's disease virus expressing the VP2 gene provides effective protection against novel variant infectious bursal disease virus.](#)

Zhang Z, Chen Y, Fan W, Qi X, Zhang Y, Liu C, Wu L, Li Y, Liu Y, Wang S, Cui H, Duan Y, Gao Y. *Vaccine*. 2026 Oct 3;91:129028. doi: 10.1016/j.vaccine.2026.129028. Epub 2026 Aug 19. PMID: 42617354

[A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2.](#)

Feng Z, Day T, Glasser JW. J Theor Biol. 2026 Oct 7;633:112531. doi: 10.1016/j.jtbi.2026.112531. Epub 2026 Jul 11. PMID: 42435934

[Experimental evaluation of a novel bivalent vaccine against porcine circovirus type 2d and Mycoplasma hyopneumoniae.](#)

Suh J, Na H, Ham S, Kang I, Chae C. Vet Microbiol. 2026 Oct;321:111190. doi: 10.1016/j.vetmic.2026.111190. Epub 2026 Aug 9. PMID: 42585698

[Clinical Characterization of Invasive Meningococcal Disease Epidemic, Uzbekistan, 2026.](#)

Rakhimov BB, Tuychiev LN, Khamzayeva NT, Tadiyeva NU, Saidkasimova NS, Otamuratova NX, Norboev XN. Emerg Infect Dis. 2026 Oct;32(10):1712-1715. doi: 10.3201/eid3210.261144. PMID: 42811451

[Payers should cover COVID-19 vaccines for all ages and risk groups with no patient cost sharing.](#)

Hatton RC, Happe LE. J Manag Care Spec Pharm. 2026 Oct;32(10):1319-1328. doi: 10.18553/jmcp.2026.32.10.1319. PMID: 42808541

[Measles resurgence in Indonesia: the intersection of immunity gaps, subnational heterogeneity, and vaccine confidence.](#)

Hariyanto TI. Vaccine. 2026 Oct 3;91:129085. doi: 10.1016/j.vaccine.2026.129085. Epub 2026 Aug 27. PMID: 42659916

[Bioinformatics and immunoinformatic approaches for structural modeling and vaccine design of the CCHFV whole genome to develop a novel broad-spectrum multi-epitope vaccine candidate.](#)

Hashempour A, Hassanzadeh F, Hassanzadeh Z, Karbalaee-Alinazari MM, Honari Jahromi A, Ghasemi H. Comput Biol Chem. 2026 Oct;124(Pt 1):109019. doi: 10.1016/j.compbiolchem.2026.109019. Epub 2026 Mar 19. PMID: 42102528

[Inpatient Outcomes in a SARS-CoV-2 Naïve Population Achieving High Vaccination Coverage Preceding Planned Virus Entry: A Prospective, Natural Experiment, Pandemic Response Cohort Study.](#)

Raith EP, Wong HZ, Ross JV, Ziesing S, Asser I, Maclean M, Sundararajan K, Fielke L, Bihari S, Miller C, Spurrier N, Plummer M. Health Secur. 2026 Oct 7;23265094261480546. doi: 10.1177/23265094261480546. Online ahead of print. PMID: 42844724

[Live anticoccidial vaccines in the poultry industry: current knowledge, global strategies, technical foundations and future directions.](#)

Pagès M, Dardi M. Avian Pathol. 2026 Oct;55(5):571-596. doi: 10.1080/03079457.2026.2678272. Epub 2026 Jun 24. PMID: 42159705

[The World Expected More of Canada: Canada and the Pandemic Agreement.](#)

Lexchin J. *Int J Soc Determinants Health Health Serv.* 2026 Oct;56(4):442-450. doi: 10.1177/27551938261458695. Epub 2026 Jun 18. PMID: 42312458

[Protective near-germline antibodies to malaria elicited by RTS,S/AS01_E vaccination in African infants.](#)

Bloch E, Devys F, Cannac F, Jain M, Broadbent K, Sánchez C, Lee WH, Jairoce C, Aide P, Campo JJ, Macià D, Carolis C, Wilson IA, Ward AB, Amino R, Moncunill G, Dobaño C, Molinos-Albert LM. *bioRxiv [Preprint]*. 2026 Oct 4;2026.10.01.755937. doi: 10.64898/2026.10.01.755937. PMID: 42856535

[ORF2 of hepatitis E virus: genetic and antigenic variation across genotypes and implications for immunity, diagnostics and vaccine development.](#)

El-Kafrawy SA, Putra SS, Abbas AT, Abdel-Dayem UA, Alandijany TA, Altayb HN, Azhar EI. *J Gen Virol.* 2026 Oct;107(10):002342. doi: 10.1099/jgv.0.002342. PMID: 42848442

[GPTMS-chitosan-modified dendritic mesoporous silica nanoadjuvants synergistically enhance humoral and cellular immune responses.](#)

Hu X, Tang E, Li F, Wang R, Cao S, Wang C, Wu H. *Colloids Surf B Biointerfaces.* 2026 Oct;266:115789. doi: 10.1016/j.colsurfb.2026.115789. Epub 2026 May 7. PMID: 42127778

[A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults.](#)

Cosgrove CA, Avanesov A, Rust D, Osibajo S, Kang K, Leav B; ODYSSEY Study Group. *Clin Infect Dis.* 2026 Oct 7;83(3):e598-e610. doi: 10.1093/cid/ciag278. PMID: 42033146

[Assessing the Willingness of Future Health Care Providers to Participate in Vaccine Trials: Cross-Sectional VACCELERATE European Study.](#)

Yiallouris A, Filippou C, Merakou C, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Sarantopoulos A, Shaikh AR, Noura E, Nearchou A, Johnson EO, Papaconstantinou-Leontidou M, Arneftis C, Astras G, Stewart FA, Albus K, Salmanton-García J, Leckler J, Azzini AM, Davis RJ, Součková L, Askling HH, Battle TL, Álvarez-Barco E, Mozeryte A, Poulimeneas D, Kopsidas I, Prellezo JB, Valdenmaier O, Jakobsen SF, Cox RJ, Hellemans M, Hendrickx G, van Damme P, Ochando J, Zaoutis TE, Jancoriene L, Mallon P, Naclér P, Husa P, Tacconelli E, Cornely OA, Pana ZD. *JMIR Public Health Surveill.* 2026 Oct 9;12:e84952. doi: 10.2196/84952. PMID: 42854231

[Immunohistochemical evaluation of lymphocyte subpopulations in sheep pneumonia caused by RSV, PIV3, and their coinfections.](#)

Eser G, Tebrizi B, Özkara M, Timurkan MÖ. *Vet Immunol Immunopathol.* 2026 Oct;300:111178. doi: 10.1016/j.vetimm.2026.111178. Epub 2026 Jul 31. PMID: 42551330

[Expression of the SARS-CoV-2 nucleocapsid \(N\) gene in *Chlorella vulgaris* via electroporation-mediated transformation.](#)

Robben DM, Budiman C, Amin Z, Kumar VS. *Arch Microbiol.* 2026 Oct 10;209(1):9. doi: 10.1007/s00203-026-05249-y. PMID: 42859201

[Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study \(2023-2024\).](#)

Schrarstzhaupt IN, Diaz-Quijano FA. *Vaccine*. 2026 Oct 3;91:129096. doi: 10.1016/j.vaccine.2026.129096. Epub 2026 Aug 28. PMID: 42664527

[A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge.](#)

Del Rosario JMM, van Diemen PM, Frost SDW, Vishwanath S, Sujit SB, Ashokan SK, Mollett BC, Ramsay AM, Simpson BS, Asbach B, Huang CQ, Carnell GW, Chan A, Tonks P, Temperton NJ, Davies MN, McCauley JW, Kinsley R, Wagner R, Everett HE, Heeney JL. *J Virol*. 2026 Oct 6:e0107326. doi: 10.1128/jvi.01073-26. Online ahead of print. PMID: 42836655

[Role of *Toxoplasma gondii* calcium-binding protein \(TgpCaBP\) and its implications for the development of attenuated live vaccines.](#)

Zhang Y, Li H, Jing Y, Sun W, Wei B, Wei Z, Jiang N. *Microbiol Spectr*. 2026 Oct 6;14(10):e0182726. doi: 10.1128/spectrum.01827-26. Epub 2026 Sep 17. PMID: 42752185

[Development and fit-for-purpose validation of a qPCR assay for biodistribution assessment of plasmid DNA following electrode-needle device-assisted intramuscular electroporation.](#)

Wu WL, Huang WC, Chai KM, Chen IH, Chang JR, Tzeng TT, Chiu FF, Liao HC, Huang MS, Shen KY, Tsai YJ, Wu CR, Jou S, Shen ZQ, Hsieh MS, Chen HW, Liu SJ. *Int J Pharm*. 2026 Oct 5;703:127324. doi: 10.1016/j.ijpharm.2026.127324. Epub 2026 Aug 19. PMID: 42617896

[One-year reproductive effects of anti-GnRH and rabies vaccination in female pet cats.](#)

Novak S, Yakobson B, King R, Jaebker L, Eckery DC, Raz T. *Reprod Fertil*. 2026 Oct 5:RAF-26-0102. doi: 10.1530/RAF-26-0102. Online ahead of print. PMID: 42832253

[Parental Vaccine Refusal in Children With Developmental Risks or Difficulties.](#)

Akpınar F, Yılmaz B, Turmus GH, Yesiloglu D, Emiral GO, Kara A, Celik P. *Acta Paediatr*. 2026 Oct 11. doi: 10.1111/apa.70798. Online ahead of print. PMID: 42860626

[Aptamer-based *Salmonella enteritidis*-inactivated vaccine injected intradermally elicits local leukocyte recruitment and mucosal immunity in broiler chickens.](#)

Uribe-Diaz S, Omolewu AI, Santamaria JM, Beck CN, Stein A, Marcon R, Vuong CN, Erf GF, Hargis BM, Kwon YM. *Poult Sci*. 2026 Oct;105(10):107311. doi: 10.1016/j.psj.2026.107311. Epub 2026 Jun 17. PMID: 42330764

[The safety evaluation of the pVAX-ROP27 DNA vaccine against *Eimeria tenella*.](#)

Lv X, Li B, Chang X, Zhao W, Li M, Zhao J, Dou K, Niu Z, Bai R, Zhang L, Cui X. *Vet Immunol Immunopathol*. 2026 Oct;300:111182. doi: 10.1016/j.vetimm.2026.111182. Epub 2026 Jul 30. PMID: 42541964

[Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands.](#)

Langedijk AC, van den Dungen F, Franssen FME, Goeijenbier M, Averin A, Quinn E, Atwood M, Mendes D. *Infect Dis Ther.* 2026 Oct;15(10):2609-2625. doi: 10.1007/s40121-026-01400-w. Epub 2026 Jul 24. PMID: 42496785

[An immunoinformatics-driven multiepitope subunit vaccine targeting Oropouche virus: Molecular docking, immune and dynamics simulation approaches.](#)

Sharma J, Mahdeen AA. *PLoS One.* 2026 Oct 9;21(10):e0360186. doi: 10.1371/journal.pone.0360186. eCollection 2026. PMID: 42853813

[Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged 60 Years: A Randomized, Non-inferiority Trial.](#)

Leroux-Roels I, Lins M, Surowitz R, Pragalos A, Jua PKTG, Wauters D, Jayadev A, Akite JE, Jastorff AM, Cárdenas V, Van der Wielen M; RSV-019 study group. *Clin Infect Dis.* 2026 Oct 7;83(3):e589-e597. doi: 10.1093/cid/ciag250. PMID: 41994955

[Safety of 20-Valent Pneumococcal Conjugate Vaccine \(PCV20\) in Children in the Vaccine Adverse Event Reporting System.](#)

Moro PL, Zauche LH, Zhang B, Dooley C, Oliveira M, Stroud E. *J Pediatr.* 2026 Oct;297:115213. doi: 10.1016/j.jpeds.2026.115213. Epub 2026 Jul 1. PMID: 42386124

[Immunoinformatics-Based Design of a Multi-Epitope Vaccine Targeting a Conserved Copper-Associated Protein in *Neisseria gonorrhoeae*.](#)

Yakobi SH, Nwodo UU. *Biotechnol Appl Biochem.* 2026 Oct;73(5):2373-2387. doi: 10.1002/bab.70179. Epub 2026 May 8. PMID: 42101130

[Long-term immunogenicity and efficacy of the quadrivalent human papillomavirus vaccine in women with HIV: a longitudinal cohort study.](#)

McClymont E, Blitz S, Nicolls S, Lee M, Coutlée F, Walmsley S, Trottier S, Smaill F, Loutfy M, Yudin MH, Klein MB, Harris M, Stone S, Martinez-Cajas JL, Money D; CTN 236 HPV in HIV Study Team. *Lancet HIV.* 2026 Oct 5:S2352-3018(26)00204-3. doi: 10.1016/S2352-3018(26)00204-3. Online ahead of print. PMID: 42833230

[Response Letter to the Editor Regarding "Adult RSV Vaccination: What Is the Role of RSV Subgroup in Disease Prevention?".](#)

Williams SE, Lisi GC, Luisi K, Ilangoan K, Hall-Murray C, Hayford K, Begier E. *Infect Dis Ther.* 2026 Oct;15(10):2831-2833. doi: 10.1007/s40121-026-01417-1. Epub 2026 Aug 12. PMID: 42587243

[Streptococcus pneumoniae haemolytic uraemic syndrome in Aotearoa New Zealand across changing pneumococcal conjugate vaccine eras.](#)

Humphrey AB, Prestidge C, Dickens A, Haszard J, Morgan J, Ren X, Sinclair O, Anglemyer A, Best E. *Arch Dis Child.* 2026 Oct 6:archdischild-2026-330946. doi: 10.1136/archdischild-2026-330946. Online ahead of print. PMID: 42838725

[From Sequence to Structure: AlphaFold and the AI Revolution in Aquaculture Drug Discovery and Vaccine Design.](#)

Üstüner E, Öz M. *Biotechnol Bioeng.* 2026 Oct 12. doi: 10.1002/bit.70398. Online ahead of print. PMID: 42861495

[An integrated strategy of multiplex qPCR and BclA gene length polymorphism analysis for differentiating Bacillus anthracis wild-type and vaccine strains.](#)

Yang J, Liang Y, Liang B, Li Y, Zhu L, Qu Y. *Microbiol Spectr.* 2026 Oct 6;14(10):e0019226. doi: 10.1128/spectrum.00192-26. Epub 2026 Sep 1. PMID: 42678165

[Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025.](#)

Sumner KM, Noble EK, Grant LB, Meeker JR, Murugan V, Nordstrom L, House SL, Presti RM, Walter EB, Williams OL, Saade EA, Canaday DH, Williams KV, Zimmerman RK, Gross FL, Valencia S, Gurbaxani B, Lewis NM, Li ZN, Mishin V, Gubareva L, Zhou B, Levine MZ, Flannery B, Ellington S. *medRxiv [Preprint]*. 2026 Oct 2:2026.10.01.26364413. doi: 10.64898/2026.10.01.26364413. PMID: 42856744

[Evolutionary dynamics of porcine parvovirus type 1 reveal antigenic divergence with implications for vaccine coverage.](#)

de Sá PAF, Luvison NA, Flores RS, Lunge VR, Silva SAE, Streck AF. *Res Vet Sci.* 2026 Oct;210:106269. doi: 10.1016/j.rvsc.2026.106269. Epub 2026 May 30. PMID: 42242133

[Structural and biochemical insights into HCV envelope proteins for germline-targeting vaccines.](#)

Yechezkel I, Maimon HE, Tennenhouse A, Chen F, Tarabih H, Weisz J, Fraenkel R, Fleishman SJ, Law M, Tzarum N. *PLoS Pathog.* 2026 Oct 12;22(10):e1014651. doi: 10.1371/journal.ppat.1014651. Online ahead of print. PMID: 42862868

[Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 in RSV Seronegative Children.](#)

Cunningham CK, Karron RA, McFarland EJ, Giganti MJ, Ketchum R, Perlowski C, Libous J, Brozik H, Oliva J, Yin DE, Jean-Philippe P, Moye J, Schappell E, Barr EA, Rexroad V, Johnston B, Malonga G, Aziz M, Rutherford T, Sallee H, Jao J, Freck RW, Deville JG, Walter EB, Day JC, Spector SA, Camacho-Gonzalez A, Dobroszycki J, Nachman S, Paul ME, Campbell J, Liu X, Yang L, Luongo C, Collins PL, Buchholz UJ; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2021 Study Team. *J Infect Dis.* 2026 Oct 3:jiag489. doi: 10.1093/infdis/jiag489. Online ahead of print. PMID: 42828774

[Langerhans cell-targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity.](#)

Klein K, Johnson L, Rîca R, Sarcevic M, Carta G, Seiser S, Elbe-Bürger A, Langer F, Rahhal N, Rademacher C, Wawrzinek R, Quattrone F, Sparber F. *J Invest Dermatol.* 2026 Oct;146(10):2793-2801.e6. doi: 10.1016/j.jid.2026.03.026. Epub 2026 Apr 7. PMID: 41956398

[Booster dose of COVID-19 vaccine and its effectiveness against post COVID-19 condition in individuals with pre-existing immunity: a sequential propensity score-matched cohort study.](#)

Copyright © 2020. Todos los derechos reservados | [INSTITUTO FINLAY DE VACUNAS](#)

Morris L, Bülow E, Li H, Xu Y, Gisslén M, Nyberg F, Bygdell M. *EClinicalMedicine*. 2026 Sep 23;100:104215. doi: 10.1016/j.eclinm.2026.104215. eCollection 2026 Oct. PMID: 42830827

[\[Fever and rash after international travel: two cases of vaccine failure\].](#)

Schnell AP, Berckenhagen L, Schmiedel S. *Inn Med (Heidelb)*. 2026 Oct;67(10):1127-1130. doi: 10.1007/s00108-026-02182-6. Epub 2026 Sep 8. PMID: 42709141

[Enhancing Disease Surveillance and Pharmacovigilance Practices for RTS,S/AS01\(E\) Malaria Vaccine Rollout in Ghana, Kenya, and Malawi: Strategies, Impact, Challenges, and Lessons Learned.](#)

Haine V, Essoh TA, Franck CP, Savic M. *Drug Saf*. 2026 Oct;49(10):1199-1210. doi: 10.1007/s40264-026-01685-3. Epub 2026 Jul 14. PMID: 42446783

[Serological and transcriptomic response of African fruit bats to immune challenge with recombinant vaccines expressing Ebola or Nipah virus antigens.](#)

Jax E, Garnier R, Tsagkogeorga G, Buczkowski H, Gibson L, Benia P, Suu-Ire R, Warmuth VM, Languon S, Quaye O, Yan L, Broder CC, Rossiter SJ, Wright E, Gilbert SC, Lambe T, Wood JLN, Cunningham AA, Restif O. *R Soc Open Sci*. 2026 Oct 7;13(10):252189. doi: 10.1098/rsos.252189. eCollection 2026 Oct 7. PMID: 42841161

[Measles outbreak risk in Afghanistan: provincial immunity gaps and epidemic potential following immunisation system disruption.](#)

Ranjan R, Anwari P, Colson A, van der Meer R. *Vaccine*. 2026 Oct 3;91:129078. doi: 10.1016/j.vaccine.2026.129078. Epub 2026 Aug 25. PMID: 42641255

[Construction of a suckling mouse model based on an EV-C96 clinical isolate and its application in drug screening and vaccine development.](#)

Wang J, Qu Y, He Y, Yang Q, Zhu H, Chen Y, Duan X, Zheng H, Xiao S, Liu Q, Liu H. *Antiviral Res*. 2026 Oct;254:106511. doi: 10.1016/j.antiviral.2026.106511. Epub 2026 Aug 13. PMID: 42595093

[Residual DNA in COVID-19 mRNA vaccines: Regulatory context and misinformation.](#)

Nitta T, Kashiwayama T, Matsumoto Y, Toyoda T, Miyazawa T, Kamijima Y, Takeya H. *Vaccine*. 2026 Oct 3;91:129080. doi: 10.1016/j.vaccine.2026.129080. Epub 2026 Aug 26. PMID: 42648052

[Influenza Vaccination Preferences Among Adults Aged 60 Years and Older in Beijing, China.](#)

Jia M, Liu Y, Zheng J, Su F, Zhang J, Jiang M, Wang T, Wang X, Wang T, Dai W, Feng L. *JAMA Netw Open*. 2026 Oct 1;9(10):e2638674. doi: 10.1001/jamanetworkopen.2026.38674. PMID: 42862555

[A multi-antigen chimeric PvCSP-MSP1\(19\) vaccine induces robust humoral responses against distinct stages of Plasmodium vivax.](#)

Diniz LLCL, Santos DO, Maffetano CV, Taguchi NT, Marques RF, Camargo TM, Oliveira TR, Bouillet LEM, Silva GAS, Abreu KES, Gaitán XA, Bargieri DY, Boscardin SB, Silveira ELV, Gimenez AM, Soares

IS.Vaccine. 2026 Oct 2;93:129197. doi: 10.1016/j.vaccine.2026.129197. Online ahead of print.PMID: 42826687

[Augmented innate and humoral immune responses enhance early and durable rabies protection by a CD40L-overexpressing rabies vaccine.](#)

Xing X, Wang Y, Xiong Z, Liu D, Wang Y, Hu Y, Liu Y, Li Y.Vet Microbiol. 2026 Oct;321:111162. doi: 10.1016/j.vetmic.2026.111162. Epub 2026 Aug 1.PMID: 42546450

[Letter to the Editor Regarding "Adult RSV Vaccination: What is the Role of RSV Subgroup in Disease Prevention?".](#)

Madhava H, Velthove K.Infect Dis Ther. 2026 Oct;15(10):2827-2829. doi: 10.1007/s40121-026-01418-0. Epub 2026 Aug 12.PMID: 42587246

[cGAMP-liposome: A versatile and scalable STING agonist adjuvant for enhanced anti-infective and antitumor immunity.](#)

Xie M, Wu Q, Sheng Y, Wu W, Lu Y.Int J Pharm. 2026 Oct 5;703:127377. doi: 10.1016/j.ijpharm.2026.127377. Epub 2026 Sep 3.PMID: 42692376

[The human gut microbiome primes fever after vaccination.](#)

Huus KE; µHEAT Study Group‡; Abo H, Tan YH, Atay E, Rytter H, Keller R, Dauser S, Vu DL, Azad MB, Knight R, Ke A, Lotoski L, Langlois MA, Liu R, Tyakht AV, Youngblut N, Kang SM, Parsonnet J, Maier L, Chassaing B, Kremsner PG, Gewirtz AT, Esen M, Ley RE, Gabor JJ, Gaile JM, Fleischmann WA, Siebner AS, Smeenk G, Flügge J, De Moraes RA, Jakob D, Prokipchuk A, Wilhelm C.Science. 2026 Oct 8;394(6820):eaea7733. doi: 10.1126/science.aea7733. Epub 2026 Oct 8.PMID: 42848888

[Development and evaluation of a virus like particle based vaccine candidate against Indian Isolate of porcine circovirus 2d in pig.](#)

Deb R, Maity HK, Samanta K, Madhanmohan M, Sengar GS, Pegu SR, Kar I, Parthiban S, Khulape SA, Das PJ, Rajkhowa S, Gupta VK.Microb Pathog. 2026 Oct;219:108748. doi: 10.1016/j.micpath.2026.108748. Epub 2026 Aug 3.PMID: 42546908

[Investigating the weak antibody response to vaccination with inactivated polio virus serotype 3 when delivered by microneedle patch.](#)

Gomaa Y, Kolluru C, Lee JW, Prausnitz MR.J Control Release. 2026 Oct 10;398:115251. doi: 10.1016/j.jconrel.2026.115251. Epub 2026 Aug 10.PMID: 42575211

[Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.](#)

Fitz-Patrick D, Sahgal O, Fouché LF, Mitha E, Malahleha M, Gayed J, Keep G, Zhang Y, Modjarrad K, Belanger T, Xu X, Cooper D, Mensa FJ, Sahin U, Türeci Ö, Swanson KA, Anderson AS, Gurtman A, Kitchin N.Infect Dis Ther. 2026 Oct;15(10):2645-2667. doi: 10.1007/s40121-026-01409-1. Epub 2026 Jul 25.PMID: 42501282

[Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.](#)

Schmidt H, Hewel C, Büscher N, Linke M, Plachter B. Microbiol Resour Announc. 2026 Oct 8;15(10):e0039726. doi: 10.1128/mra.00397-26. Epub 2026 Sep 10. PMID: 42720293

[A pathogen-mimicking nanovaccine orchestrating danger recognition and immune activation for potent cellular immunity.](#)

Bai S, Luo T, Xiong K, Li Y, Tang Y, Wang Y, Xue Y, Zhu Y, Ke B, Sun X. J Control Release. 2026 Oct 10;398:115287. doi: 10.1016/j.jconrel.2026.115287. Epub 2026 Aug 20. PMID: 42624432

[Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022-2023 and 2023-2024 seasons.](#)

Imran M, Chastek B, Bancroft T, Webb N, Pelton SI, Haag MDM, McGovern I. Int J Infect Dis. 2026 Oct;171:109025. doi: 10.1016/j.ijid.2026.109025. Epub 2026 Aug 3. PMID: 42546898

[Endolysosomal routing combined with immune stimulation enhances anti-tumor efficacy of an HPV16 mRNA therapeutic vaccine.](#)

Song W, Ying B, Gao P, Zhang Z, Ma X, Ma J, Yang S, Wu Y, Wu D, Wu J, Du T. Mater Today Bio. 2026 Aug 20;40:103587. doi: 10.1016/j.mtbio.2026.103587. eCollection 2026 Oct. PMID: 42699170

[Serotypic and Genomic Diversity of Vibrio anguillarum in Rainbow Trout Farms in Turkey: Implications for Vibriosis Control and Vaccine Candidate Selection.](#)

Altun S, Duman M, Romalde JL, Ajmi N, Tasci G, Ozakin C, Tuzemen NU, Akça B, Ergün S, Yılmaz S, Saticioglu IB. J Fish Dis. 2026 Oct;49(10):e70203. doi: 10.1111/jfd.70203. Epub 2026 May 15. PMID: 42141499

[Can we rule out that COVID-19-vaccination did not increase all-cause mortality?](#)

Aarstad J. Eur J Epidemiol. 2026 Oct 12. doi: 10.1007/s10654-026-01443-w. Online ahead of print. PMID: 42862266

[Longitudinal dynamics of serum IL-33 and sST2 across age and sex in a healthy Finnish cohort before and after Tdap booster vaccinations.](#)

Anabe D, Teräsjarvi JT, Barkoff AM, Mertsola J, He Q. Cytokine. 2026 Oct;206:157197. doi: 10.1016/j.cyto.2026.157197. Epub 2026 Aug 13. PMID: 42594457

[Validation of the behavioural and social drivers of influenza vaccine survey in Australia: Cognitive interviews and psychometric evaluation.](#)

Sabahelzain MM, Christou-Ergos M, Leask J. Hum Vaccin Immunother. 2026 Dec;22(1):2739738. doi: 10.1080/21645515.2026.2739738. Epub 2026 Oct 4. PMID: 42829802

[Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA vaccine in mice.](#)

Shichinohe S, Li Q, Tanaka H, Anindita J, Yoshimoto S, Kaewaroon N, Shimooka M, Anzai I, Akita H, Watanabe T. *Vaccine*. 2026 Oct 2;93:129215. doi: 10.1016/j.vaccine.2026.129215. Online ahead of print. PMID: 42826690

[A modified-live PRRSV vaccine administered at weaning confers partial protection against a highly virulent PRRSV-1 strain throughout the grower-finisher period.](#)

Pey A, Curto P, Gurri E, Aulinas E, Ramirez G, Molín J, Fraile L, Stoian AMM. *Res Vet Sci*. 2026 Oct;210:106346. doi: 10.1016/j.rvsc.2026.106346. Epub 2026 Jul 27. PMID: 42556097

[A cohort study to assess the safety and coverage of COVID-19, influenza, and pertussis vaccine in Australian pregnant women.](#)

Mohammed H, Andraweera P, Marshall HS. *Vaccine*. 2026 Oct 3;91:129081. doi: 10.1016/j.vaccine.2026.129081. Epub 2026 Aug 29. PMID: 42667899

[Design and preclinical evaluation of a multi-epitope circular RNA vaccine targeting the spike protein of canine coronavirus genotype II.](#)

Zhang X, Wang L, He W, Ren Z, Zhang C, Zhou M, Wan J, Zhao J, Zhao L. *Vet Microbiol*. 2026 Oct;321:111188. doi: 10.1016/j.vetmic.2026.111188. Epub 2026 Aug 9. PMID: 42579946

[Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations.](#)

Ginet V, Garapon C, Coiffier C, Salvi JP, Ayad C, Djebali S, Paul S, Sohier J, Vidalain PO, Verrier B. *J Control Release*. 2026 Oct 10;398:115271. doi: 10.1016/j.jconrel.2026.115271. Epub 2026 Aug 18. PMID: 42612875

[Intranasal BCG cell wall polysaccharide-based subunit vaccine confers protection against Mycobacterium bovis challenge in mice.](#)

Li N, Zhou M, Song Y, Tang L, Ma H, Xu J, Cao J, Li N, Chu Y. *Vet Microbiol*. 2026 Oct;321:111208. doi: 10.1016/j.vetmic.2026.111208. Epub 2026 Aug 30. PMID: 42685465

[Protective efficacy and DIVA potential of a rfbG and galE double-deleted Salmonella Enteritidis attenuated live vaccine in chickens.](#)

Ruan Y, Kang X, Lin Z, Sun T, Pan Z, Wang X, Pan T, Zhao Y, Song H. *Poult Sci*. 2026 Oct;105(10):107373. doi: 10.1016/j.psj.2026.107373. Epub 2026 Jul 2. PMID: 42456323

[Sustainable Hydrogel-Forming Microneedle-Reservoir Patches for Transdermal Delivery of Hydrophilic Macromolecules: Biopolymers, Green Manufacturing and Translation.](#)

Mohanty S, Aydogdu MO, Kang S, Li X, Edirisinghe M. *Adv Sci (Weinh)*. 2026 Oct 11:e78195. doi: 10.1002/advs.78195. Online ahead of print. PMID: 42860601

[Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.](#)

Faust SN, Céspedes J, Avila L, Ivankovich-Escoto G, Marshall HS, Richmond P, Nolan T, Bernatoniene J, Bandi S, Shenoy A, Rayner S, Weissfeld L, Lang W, Samal V, Goldstein P, Rubin K, Loch C, Noviello S; SUPER Trial Investigators. *Lancet Infect Dis.* 2026 Oct 1:S1473-3099(26)00470-6. doi: 10.1016/S1473-3099(26)00470-6. Online ahead of print.PMID: 42822488

[Efficacy, safety, and immunogenicity of a nine-valent vaccine \(ExPEC9V\) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial \(E.mbrace\).](#)

Bonten M, Butler CC, Edwards A, Gravenstein S, Ikeda H, Johansen IS, Lambregts MMC, Matsumoto T, Patterson DL, Rodriguez-Baño J, Saade E, Zingman BS, Day T, Geurtsen J, Hardt K, McLean C, Scheys I, Shukarev G, Guiñazú JR, Sarnecki M, Spiessens B, Peeters M, Pau MG, Poolman J, Cohen KA; E.mbrace Study Team. *Lancet Infect Dis.* 2026 Oct 12:S1473-3099(26)00469-X. doi: 10.1016/S1473-3099(26)00469-X. Online ahead of print.PMID: 42863477

[Protective efficacy of bacterial sialidase-based intranasal inactivated avian influenza vaccine against H5N1 infection in poultry.](#)

Kurnia RS, Nugroho CMH, Silaen OSM, Krisnamurti DGB, Soebandrio A, Putra MA, Indrawati A. *Avian Pathol.* 2026 Oct 2:1-13. doi: 10.1080/03079457.2026.2679211. Online ahead of print.PMID: 42825403

[A strain of high cell-adapted porcine deltacoronavirus: Isolation, genetic evolution, and pathogenicity analysis.](#)

Yang M, Ma Y, Liu M, Zhou H, Fan H, Lin H. *Microb Pathog.* 2026 Oct;219:108750. doi: 10.1016/j.micpath.2026.108750. Epub 2026 Aug 4.PMID: 42551610

[The smallpox ghost in Voltaire's life: inoculation and the origins of vaccine acceptance.](#)

Tuells J, Plotkin SA. *NPJ Vaccines.* 2026 Oct 1;11(1):183. doi: 10.1038/s41541-026-01596-5.PMID: 42823421

[Impact of High-Dose Influenza Vaccine on Cardiorespiratory Outcomes in Older Adults: An Updated Systematic Review and Meta-Analysis.](#)

Araújo de Lucena L, Hakkeem B, Schettino Samad N, Erzinger G, Mendes Gaia GS, Giorgi J, Stabile F, Martins Prizão V, de Coelho Castro P, Batista da Hora DA, Hespanhol LC, Dandamudi M, Saraiva da Silva Maia FG, Pipolo Milan E, Gulati M. *Am J Prev Med.* 2026 Oct 8:108598. doi: 10.1016/j.amepre.2026.108598. Online ahead of print.PMID: 42849859

[Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the Post-COVID Era".](#)

Gould S, Rohde CM, Destexhe E, Tiesjema B, Segal L. *Vaccine.* 2026 Oct 1;93:129180. doi: 10.1016/j.vaccine.2026.129180. Online ahead of print.PMID: 42822179

[Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial.](#)

Pley C, Jeffries DJ, Kanteh E, Strandmark J, Baldeh AK, Leigh MN, Ndow P, Clarke E, Kampmann B. *Lancet Infect Dis.* 2026 Oct;26(10):1070-1078. doi: 10.1016/S1473-3099(26)00193-3. Epub 2026 Jun 11.PMID: 42276083

[Evaluation of alum-adjuvanted *Fasciola gigantica* recombinant pro-cathepsin L1H as a potential vaccine for goats.](#)

Sangfuang M, Sungsuwan P, Khumgra G, Kueakhai P, Changklungmoa N, Suphamungmee W, Roytrakul S, Preyavichyapugdee M, Sobhon P, Meemon K, Preyavichyapugdee N. *Vet Parasitol.* 2026 Oct;347:110885. doi: 10.1016/j.vetpar.2026.110885. Epub 2026 Aug 12. PMID: 42607420

[A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa.](#)

Bavdekar A, Chansinghakul D, Dhati RM, Zambrano B, Madhi SA, Riekert G, Dhingra MS, Peter J, Wang C, Mohapatra S, Delgado A, Palkar S, Kosolsak C, Pretorius A, Lyabis O, Das C, Rehm C. *Vaccine.* 2026 Oct 5;93:129186. doi: 10.1016/j.vaccine.2026.129186. Online ahead of print. PMID: 42832931

[A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine \(Vero cells\), inactivated, Sabin strains administered with or without routine infant vaccines.](#)

Islam MA, Zehra SM, Kazi Z, Ather S, Ahmed S, Timu RT, Hotwani A, Hossain MS, Tahir A, Xin Q, Han W, Khan WA, Saleem AF. *Vaccine.* 2026 Oct 3;91:129095. doi: 10.1016/j.vaccine.2026.129095. Epub 2026 Aug 27. PMID: 42659917

[Molecular and computational analysis of conserved outer membranes \(oprI and oprL\) in MDR clinical isolates of *Pseudomonas aeruginosa* as potential vaccine targets from Lahore, Pakistan.](#)

Ulfat R, Bashir R, Abubakar K, Murtaza I. *Int Microbiol.* 2026 Oct;29(7):1421-1432. doi: 10.1007/s10123-026-00822-3. Epub 2026 Jul 1. PMID: 42380383

[Vaccine recipient and volunteer experiences from COVID-19 mass vaccine clinics at a university campus: drive-through and walk-through approaches.](#)

Tome J, Schwind JS, Richmond HL, Deloach B, Harvey D, Robinson R, Riner McJ SE, Robinson S. *Vaccine.* 2026 Oct 10;94:129229. doi: 10.1016/j.vaccine.2026.129229. Online ahead of print. PMID: 42858680

[Vaccination for girls and women across the life course: Evidence-based recommendations for clinical practice and policy.](#)

Divakar H, McAuliffe FM, Goba G, Benedetto C, Bhuienneáin MN, Khadilkar S, Labovsky M, Abou-Dakn M, Barnea ER, da Silva-Filho AL, Argale E, Genazzani A, Ramos D, Pasupathy D. *Int J Gynaecol Obstet.* 2026 Oct 12. doi: 10.1002/ijgo.71330. Online ahead of print. PMID: 42861791

[Balancing Act: Dual targeting of PhoPQ and QseBC two-component systems in *Edwardsiella tarda* enhances attenuation but diminishes protective immunity.](#)

Rehman MNU, Lin Y, Feng W, Wang M, Khan I, Fan L, Li X, Yang N, Guo G, Zheng J. *Microb Pathog.* 2026 Oct;219:108764. doi: 10.1016/j.micpath.2026.108764. Epub 2026 Aug 12. PMID: 42586514

[Voices from the classroom: Exploring COVID-19 vaccine perceptions among teachers and adolescent learners in the Western Cape, South Africa.](#)

Coetzee B, Haine P, Kagee A. *J Health Psychol.* 2026 Oct 7;13591053261493242. doi: 10.1177/13591053261493242. Online ahead of print. PMID: 42844922

[Effect of a comic book-based educational intervention on human papillomavirus vaccine knowledge and safety perception among girls aged 9-14 in Nigeria.](#)

Dickerson JC, Adeyemo P, Kim N, Ighodaro E, Ibeka P, Fasawe O, Chege MW, Warshaw KG, Aliyu L, Craycroft J, Huang FW, Giwa O, Bhatt AS. *Vaccine.* 2026 Oct 5;93:129194. doi: 10.1016/j.vaccine.2026.129194. Online ahead of print. PMID: 42832933

[A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus.](#)

Zhang Y, Duan Y, Shi L, Zhu X, Mao W, Li L, Yuan C, Sun M, Zhang J, Cao L, Kong X, Zheng H, Wang Q. *J Virol.* 2026 Oct 5:e0119326. doi: 10.1128/jvi.01193-26. Online ahead of print. PMID: 42831625

[Assessment of the Fasciola hepatica saposin-like protein 2 \(rFhSAP2\) vaccine candidate in sheep: Immunogenicity without protective efficacy.](#)

Balderas Loaeza AV, Espinoza Gutiérrez BJ, Cruz Mendoza I, Villa Mancera AE, Robles Robles JM, Quiroz Romero H, Sahagún Ruiz A, Ortega Vargas S. *Vaccine.* 2026 Oct 6;93:129223. doi: 10.1016/j.vaccine.2026.129223. Online ahead of print. PMID: 42837893

[A qualitative study on addressing COVID-19 vaccine hesitancy in marginalised communities in the UK - Professional and public perspectives.](#)

Hussain B, Marson-Smith H, Duke B, Gbadesire M, Khurshid S, Timmons S. *J Health Serv Res Policy.* 2026 Oct;31(4):245-254. doi: 10.1177/13558196251409115. Epub 2025 Dec 22. PMID: 41424253

[Development and immune evaluation of a LAMP-targeted TolC II DNA vaccine delivered by mannosylated chitosan against Aeromonas veronii in crucian carp \(Carassius auratus\).](#)

Hu S, Cheng J, Ma L, Li Y, Wu Z. *Fish Shellfish Immunol.* 2026 Oct;177:111551. doi: 10.1016/j.fsi.2026.111551. Epub 2026 Jun 29. PMID: 42372929

[Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults 50 Years of Age.](#)

Roussy JF, Dennis P, Gupta AK, Wallace G, Abitbol A, Aggarwal N, Surber JG, Lee T, Smith BA, Gérard C, Hailemariam HA, David MP, Jastorff AM, Van der Wielen M; RSV-020 Study Group. *Clin Infect Dis.* 2026 Oct 7;83(3):e578-e588. doi: 10.1093/cid/ciag208. PMID: 42054374

[Evaluation of the efficacy of avian pathogenic Escherichia coli bivalent live vaccine \(serogroups O 1 &2\) against Escherichia coli infection in broilers.](#)

Wu J, Jiang L, Wang B, Wang H, Gao Q, Huan C, Gao S. *Vet Microbiol.* 2026 Oct;321:111144. doi: 10.1016/j.vetmic.2026.111144. Epub 2026 Jul 24. PMID: 42520699

[Effects of attenuated influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial.](#)

Metz J, Qian G, Morales-Aza B, Oliver J, Oliver E, Rice H, Duale K, Heath P, Faust S, Snape M, Hughes S, Hole L, Mann R, Shackley F, Rudd P, Ludman S, Gessner B, Danon L, Finn A. *Lancet Microbe*. 2026 Oct;7(10):101422. doi: 10.1016/j.lanmic.2026.101422. Epub 2026 Aug 18. PMID: 42612652

[Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca.](#)

Nasraa MH, Abd-Elshafy DN, Nadeem R, Shalaby S, Amer K, Hassan WA, Bader AH, Elshehaby HA, Bahgat MM. *Viral Immunol*. 2026 Oct;39(8):293-304. doi: 10.1177/08828245261474281. Epub 2026 Aug 7. PMID: 42565654

[Small quantity lipid-based nutritional supplementation and measles vaccination coverage in children aged 6-23 months: a pragmatic cluster-randomized trial.](#)

Cazes C, Goni BW, Gabillard D, Owolabi O, Yapi B, Nabunje J, Atanga I, Akinyi AM, Danho S, Balestre E, Badje A, Idriss F, Kasim M, Audu Bukarti MM, Emeka CU, Chouinard M, Mushenvula JP, Bahonan S, Plazy M, Abdoulaye O, Chiroma U, Adam HM, Montfort C, Muhammad NS, Becquet R, Phelan KPQ. *Nat Med*. 2026 Oct 2. doi: 10.1038/s41591-026-04675-1. Online ahead of print. PMID: 42827131

[Rapid Motility Arrest of the Lyme Disease Spirochete, *Borrelia burgdorferi*, by Vaccine-Induced OspA Antibodies.](#)

Bhattacharyya A, Yau R, Bartlett TM, Mantis NJ. *Mol Microbiol*. 2026 Oct 6. doi: 10.1111/mmi.70122. Online ahead of print. PMID: 42839382

[Perception of COVID-19 vaccine effectiveness perception in older racialized communities: role of major racial discrimination and health literacy.](#)

Beogo I, Xu Y, Kibret TC, Muray M, Cénat JM. *Vaccine*. 2026 Oct 5;93:129214. doi: 10.1016/j.vaccine.2026.129214. Online ahead of print. PMID: 42832932

[Meningococcal B vaccination and gonorrhea: Communicating evolving evidence to young adults and sexual and gender minorities.](#)

Broker P. *Int J STD AIDS*. 2026 Oct;37(11-12):1162-1165. doi: 10.1177/09564624261475940. Epub 2026 Jul 31. PMID: 42535352

[Impact of digital health interventions in improving pediatric immunization coverage and timeliness in low- and middle-income countries: a systematic review and meta-analysis.](#)

Samante FLD, Tiu VJU, Cansino EJF, Jose RIL, Capistrano MPR, Aliño PAL, Samante FID, Vidal MS Jr. *Vaccine*. 2026 Oct 2;93:129176. doi: 10.1016/j.vaccine.2026.129176. Online ahead of print. PMID: 42826688

[Can We Compare Adverse Events' Attributable Risk Using a Self-Controlled Case Series Design for Vaccine Safety? A Guillain-Barre Syndrome Use Case.](#)

Liang C, Chilson EL, Wu J, Kelly SP, Liu Q, Dooling KL, Lino MM, Lewnard JA, Gessner BD, Begier E. *Infect Dis Ther.* 2026 Oct;15(10):2737-2750. doi: 10.1007/s40121-026-01365-w. Epub 2026 Aug 6. PMID: 42562995

[Routine early childhood vaccination uptake before and during the COVID-19 pandemic in Scotland: A population-based cohort study of administrative data.](#)

Smith CD, Hardie I, Auyeung B. *Public Health.* 2026 Oct;259:106460. doi: 10.1016/j.puhe.2026.106460. Epub 2026 Aug 13. PMID: 42594547

[Design and in silico evaluation of PV-GNProtecta: an mRNA multi-epitope vaccine candidate against Puumala virus using immunoinformatics and structural analysis.](#)

Hossain T, Al Mahmud A, Afrin M, Rahman S, Tahia SS, Mahdeen AA, Masum MHU. *Genomics Inform.* 2026 Oct 12;24(1):19. doi: 10.1186/s44342-026-00081-8. PMID: 42864648

[Ethical Challenges Posed by HIV-Vaccine Induced Seropositivity for the Informed Consent Process and HIV Testing Practices in Maputo City, Mozambique.](#)

Fumane E, Munguambe K, Salome G, Moon TD, Heitman E, Sevene E. *J Empir Res Hum Res Ethics.* 2026 Oct;21(4):284-298. doi: 10.1177/15562646261448776. Epub 2026 May 15. PMID: 42138353

[When Polymerase Chain Reaction Positivity Is Not Disease: Implications for Clostridioides difficile Vaccine Trial Endpoints.](#)

Foster CB. *Clin Infect Dis.* 2026 Oct 7;83(3):e669-e670. doi: 10.1093/cid/ciag238. PMID: 42053262

[Immune responses in the olfactory organ and brain of Atlantic cod \(Gadus morhua\) following nasal vaccination against Francisella noatunensis.](#)

Cordero CP, Brenne H, Ytteborg E, Hansen M, Johansen LH, Vanrompay D, Winther-Larsen HC, Lazado CC. *Fish Shellfish Immunol.* 2026 Oct 8:111767. doi: 10.1016/j.fsi.2026.111767. Online ahead of print. PMID: 42849585

[Influence of COVID-19 and COVID-19 rumours on trust and uptake of single-dose male HPV vaccination in the Add-Vacc cluster-randomised trial, northwest Tanzania.](#)

Malibwa D, Lees S, Ewing V, Deogratias D, Hashim R, Mkungu G, Kapiga S, Hayes R, Baisley K, Chantalucha J, Watson-Jones D, Kelly S. *Vaccine.* 2026 Oct 9;94:129231. doi: 10.1016/j.vaccine.2026.129231. Online ahead of print. PMID: 42854550

[Validation of Health Belief Model and Theory of Planned Behaviour Constructs for Predicting Malaria Vaccine Acceptance in Ghana: A Partial Least Squares Structural Equation Modelling Approach.](#)

Sarfo M, Snowden M, Halsall JP. *Trop Med Int Health.* 2026 Oct;31(10):1443-1452. doi: 10.1111/tmi.70193. Epub 2026 Jun 30. PMID: 42376904

[Real-world influenza surveillance and vaccine effectiveness in children: a multicentre study of the Italian Federation of Primary Care Paediatricians.](#)

Barretta M, Ricci S, Compagnone A, Indaco R, Napoleone E, Rossi PG, Leoni F, Nieddu F, Ferraro E, Moriondo M, Azzari C, D'Avino A; FIMP vaccination study group. Clin Microbiol Infect. 2026 Oct;32(10):1645-1653. doi: 10.1016/j.cmi.2026.07.001. Epub 2026 Jul 11. PMID: 42435855

[Response to the comment on "Distinct differences between COVID-19 vaccine refusers and vaccine hesitant in the United States: Results from a population-based survey and latent class analysis".](#)

Huang K, Pollack HA, Schneider JA. Ann Epidemiol. 2026 Oct;122:110192. doi: 10.1016/j.annepidem.2026.110192. Epub 2026 Jul 9. PMID: 42425415

[\[Interventions to mitigate hesitation related to vaccines of childhood and adolescence, 2012-2023: an integrative review\].](#)

Rocha FMD, Silva PSD, Bordin R. Cien Saude Colet. 2026 Oct 5;31(9):e20992024. doi: 10.1590/1413-81232026319.20992024. eCollection 2026. PMID: 42848635

[Estimation of the relative effectiveness and waning of the monovalent third dose of COVID-19 vaccine against hospital admission in France: a novel self-controlled case series analysis.](#)

Botton J, Ghebremichael-Weldeslassie Y, Hocine MN, Farrington P. Am J Epidemiol. 2026 Oct 5; kwag250. doi: 10.1093/aje/kwag250. Online ahead of print. PMID: 42831256

[Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F \(RSVpreF\) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.](#)

Thakkar K, Shajarizadeh A, Gaiind N, Ivkovic L, Balasubramanian G, Kefalogianni R, Zhang J, See KC, Kwa AL, Mendes D. Expert Rev Pharmacoecon Outcomes Res. 2026 Oct 2;1-13. doi: 10.1080/14737167.2026.2737558. Online ahead of print. PMID: 42811754

[Immunoinformatics-driven design of a multiepitope vaccine against the EGFR extracellular domain for head and neck squamous cell carcinoma.](#)

Shah FH, Cho JS, Moon WW, Jo YR, Huh SJ, Chung HJ, Jung J, Jeong NY. Hum Immunol. 2026 Oct;87(10):112042. doi: 10.1016/j.humimm.2026.112042. Epub 2026 Aug 14. PMID: 42600189

[Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis: The COVER Randomized Clinical Trial.](#)

Curtis JR, Mudano AS, Cutter G, Mikuls TR, George MD, Thiele GM, Law M, Chun KY, Bastidas M, Zikry M, Sodhi SK, Sinha J, Tesser J, Alvarez N, Winthrop KL. JAMA Intern Med. 2026 Oct 5;e264894. doi: 10.1001/jamainternmed.2026.4894. Online ahead of print. PMID: 42832241

[An immunoinformatics-derived multi-epitope DNA vaccine targeting the Micropterus salmoides rhabdovirus G protein elicits protective immunity in largemouth bass.](#)

Yu Z, Gu B, Gui Q, Sun C, Lu J, Chen J. Fish Shellfish Immunol. 2026 Oct;177:111572. doi: 10.1016/j.fsi.2026.111572. Epub 2026 Jul 3. PMID: 42398741

[Effectiveness of a trivalent inactivated split-virion influenza vaccine \(Tri Fluvac\) in Thailand: a phase IV test-negative case-control study.](#)

Arunothong W, Ngamprasertchai T, Thaipadungpanit J, Phetkub N, Thongbai A, Saengsawang K, Wirachwong P, Techatanawat I, Surichan S, Narakorn P, Boonya-Anan K, Khamsiriwatchara A, Kaewkungwal J, Lawpoolsri S. *Lancet Reg Health Southeast Asia*. 2026 Sep 8;53:100857. doi: 10.1016/j.lansea.2026.100857. eCollection 2026 Oct. PMID: 42751285

[Elevating immunization as a political and economic priority in Africa: Reflections from the continental consensus on Africa's continental immunization strategy in november 2025 in Kigali, Rwanda.](#)

Ba AE, Ngabo F, Wiysonge CS, Akonwi CN, Ekoe T, Njai M, Mekuria E, Ismail A, Kuuzagr RN, Diawara M, Joseph-Amayo F, Ellas M, Olayinka F, Tsague L. *Vaccine*. 2026 Oct 3;91:129042. doi: 10.1016/j.vaccine.2026.129042. Epub 2026 Aug 22. PMID: 42632372

[Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation.](#)

Dézsi L, Kökény G, Szénási G, Révész C, Mészáros T, Barta BA, Facsko R, Szilasi A, Bakos T, Kozma GT, Dobos AB, Merkely B, Radovits T, Szebeni J. *Br J Pharmacol*. 2026 Oct;183(20):6225-6239. doi: 10.1111/bph.70563. Epub 2026 Jul 26. PMID: 42503016

[Vaccination for girls and women across the life course: Evidence-based recommendations for clinical practice and policy.](#)

Divakar H, McAuliffe FM, Goba G, Benedetto C, Bhuienneáin MN, Khadilkar S, Labovsky M, Abou-Dakn M, Barnea ER, da Silva-Filho AL, Argale E, Genazzani A, Ramos D, Pasupathy D. *Int J Gynaecol Obstet*. 2026 Oct 12. doi: 10.1002/ijgo.71330. Online ahead of print. PMID: 42861791

[An LNP-encapsulated mRNA vaccine targeting the major capsid protein of largemouth bass virus confers protective immunity and reduces RIG-I pathway activation in *Micropterus salmoides*.](#)

Liu Y, Zhang G, Qu H, Hu Z, He M, Ling F, Wang G, Liu T. *Fish Shellfish Immunol*. 2026 Oct;177:111560. doi: 10.1016/j.fsi.2026.111560. Epub 2026 Jun 30. PMID: 42379032

[Diversity and population genetic analysis of the *Babesia bovis* merozoite surface Antigen 1 \(MSA-1\) gene in South African cattle isolates from field and clinical samples.](#)

Bambeni T, Schnittger L, Bhoora RV. *Vet Parasitol*. 2026 Oct;347:110862. doi: 10.1016/j.vetpar.2026.110862. Epub 2026 Jul 19. PMID: 42480497

[A targeted metabolic intervention via exercise applied after vaccination shapes kinetics and durability of serum antibody accompanied by a distinct immunometabolic signature: pilot study.](#)

Kothadiya S, Holden KG, Cutshaw GP, Jones TC, de Almeida CB, Sirotiak Z, Meyer JD, Bardhan R, Kohut ML. *Brain Behav Immun Health*. 2026 Jul 15;56:101310. doi: 10.1016/j.bbih.2026.101310. eCollection 2026 Oct. PMID: 42502427

[Efficacy Assessment of Montanide GEL 02 PR and Liposome-Based Encapsulation as Adjuvants for an FrpA Subunit Vaccine Against Photobacteriosis in *Solea senegalensis*.](#)

Lages MA, Balado M, Forero AM, Ageitos L, Rodríguez J, Jiménez C, Lemos ML, Magariños B. *J Fish Dis*. 2026 Oct;49(10):e70187. doi: 10.1111/jfd.70187. Epub 2026 Apr 15. PMID: 41983377

[Efficacy of intraperitoneal and oral administration of a lectin-adjuvanted microencapsulated scaffold vaccine on immune response in Nile tilapia \(*Oreochromis niloticus*\) infected with *Streptococcus iniae*.](#)

Nandhakumar, Jimsha E 5th, Wangkahart E, Elumalai P. *Vet Immunol Immunopathol*. 2026 Oct;300:111184. doi: 10.1016/j.vetimm.2026.111184. Epub 2026 Jul 30. PMID: 42546425

[Engineered invasive *Lactococcus lactis* as an oral vaccine delivery platform is associated with compartmentalized immune modulation and enhances control of *Leishmania infantum* infection.](#)

Rihs JB, Duval IB, Amorim CCO, Pinto JC, Grossi de Oliveira AL, Lemos GGM, Cirilo TM, Cardozo ME, Oliveira IDS, Porto ARA, do Amaral LVB, Mota GC, de Oliveira-Silva A, Mendanha SB, de Sousa ACS, Dos Santos Brant MLT, Ramos KKS, Souza JLN, Barroso FLA, Santos RCV, Américo MF, De Jesus LCL, Salvi M, Akamatsu MA, Ho PL, Cassali GD, Bueno LL, Magalhães LMD, Santos JSCD, Azevedo VAC, Fujiwara RT. *Vaccine*. 2026 Oct 2;93:129218. doi: 10.1016/j.vaccine.2026.129218. Online ahead of print. PMID: 42826691

[Cholesterol 25-Hydroxylase Deficiency Provides an Optimal and Durable Protective T Helper 1 Immunity via Interleukin-12-Interleukin-2 Axis in BCG-Vaccinated Mice.](#)

Kim H, Choi E, Kwon KW, Choi HH, Kim K, Jung W, Shin SJ. *MedComm* (2020). 2026 Sep 30;7(10):e70989. doi: 10.1002/mco2.70989. eCollection 2026 Oct. PMID: 42819388

[Longitudinal SARS-CoV-2 mRNA vaccine immunogenicity in inflammatory bowel disease in relation to anti-TNF therapy and age: a prospective cohort study.](#)

Mayr W, Knell AI, Boehm AK, Jäger M, Ennemoser L, Griesmacher A, Bellmann-Weiler R, Koch R, Tilg H, Posch W, Weiss G. *Vaccine*. 2026 Oct 8;94:129224. doi: 10.1016/j.vaccine.2026.129224. Online ahead of print. PMID: 42849224

[Impact of pneumococcal conjugate vaccines on *S. pneumoniae* carriage in infant and toddlers with acute otitis media in Morocco.](#)

Katfy K, Benlahcène D, Loudghiri A, Katfy M, Raji F, Abdallaoui MS. *Infect Dis Now*. 2026 Oct;56(7):105349. doi: 10.1016/j.idnow.2026.105349. Epub 2026 Sep 12. PMID: 42731756

[Evaluation of immune responses in cattle immunized with an experimentally developed inactivated aluminum potassium sulfate-adjuvanted *Brucella abortus* biovar 3 vaccine.](#)

Rahman MZ, Nahiduzzaman F, Parvin R, Khatun MM, Haque MA, Islam MA. *J Dairy Sci*. 2026 Oct;109(10):10828-10840. doi: 10.3168/jds.2025-27577. Epub 2026 Jun 23. PMID: 42336047

[Protective efficacy of a recombinant pseudorabies virus expressing three copies of PCV2 Cap protein and its ability to decrease PCV2 loads in pigs.](#)

Yu C, Ma Z, Ye K, Tian M, Zhang F, Sun Y, Wang H, Gao Y, Sun H, Bai J, Jiang P. *J Virol*. 2026 Oct 6:e0038426. doi: 10.1128/jvi.00384-26. Online ahead of print. PMID: 42836640

[Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.](#)

Campbell Statler M, Bishop-Royse J, Sampson AT, Martin M. *Vaccine*. 2026 Oct 3;91:129024. doi: 10.1016/j.vaccine.2026.129024. Epub 2026 Aug 19. PMID: 42617355

[Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.](#)

Nunes JPDS, Daher IP, Pires ADS, Yamamoto MM, Sulczewski FB, Lima BFDC, Rodrigues BM, Marques RF, Janini LMR, Maricato JT, Cunha-Neto E, Kalil J, Boscardin SB, Rosa DS. *Vaccine*. 2026 Oct 3;91:129073. doi: 10.1016/j.vaccine.2026.129073. Epub 2026 Aug 22. PMID: 42632374

[Buffaloed in Brandenburg: Germany's first brush with foot-and-mouth disease after four decades of freedom.](#)

Eschbaumer M, Staubach C, Pfaff F, Gethmann J, Schulz K, Rogoll L, Bock S, Bock WI, Schulze C, Marquart R, Reinhardt N, Nickisch S, Kakerow N, Freter S, Rudovsky A, Albrecht K, Leo S, Haarmann C, Lenz S, Hoffmann B, Calvelage S, Höper D, Zitzow P, Breithaupt A, Çokçalışkan C, Parlak Ü, Karniely S, Abdulrasool LMS, Knowles N, Girault G, Romey A, Kassimi LB, King DP, Kühn C, Sauter-Louis C, Beer M. *Sci Adv*. 2026 Oct 9;12(41):eae6459. doi: 10.1126/sciadv.aeh6459. Epub 2026 Oct 9. PMID: 42853942

[COVID-19 outcomes among vaccinated and unvaccinated patients receiving disease-modifying antirheumatic drugs and biologic therapies: a retrospective multihospital cohort study.](#)

Le D, Wert Y. *Clin Rheumatol*. 2026 Oct;45(10):5989-5997. doi: 10.1007/s10067-026-08371-w. Epub 2026 Aug 21. PMID: 42627611

[A multivalent mRNA-lipid nanoparticle vaccine containing eight hemagglutinin antigens elicited broad neutralizing antibody responses and protected against influenza A virus challenge in swine.](#)

Ciacchi Zanella G, Vincent ML, Flores L, Aljets EK, Paiva RC, Markin A, Inderski B, Dwivedi G, Weissman D, Wymore Brand M, Santos JJS, Hensley SE, Anderson TK, Gauger PC, Baker AL. *J Virol*. 2026 Oct 9:e0084826. doi: 10.1128/jvi.00848-26. Online ahead of print. PMID: 42852895

[Household and Community Clustering of Concurrent Vaccine Hesitancy in China: Multicenter Survey.](#)

Zhang Y, Bhuyan SS, Wang S, Guo X, Cao T, Zhu D, Miao Y, Hu J, Wang W, Li Q, Wu J. *JMIR Public Health Surveill*. 2026 Oct 7;12:e104263. doi: 10.2196/104263. PMID: 42842944

[Temperature during vaccination shapes antibody responses and protection against infectious salmon anemia in Atlantic salmon under different prime-boost vaccine strategies.](#)

Soto-Dávila M, Whyte SK, Quispe RL, Chen YR, Wheatley T, Semple SL, Ghanei-Motlagh R, Fajei E, Glahn E, von Rönge F, Swanson A, Fast MD. *Fish Shellfish Immunol*. 2026 Oct;177:111562. doi: 10.1016/j.fsi.2026.111562. Epub 2026 Jul 3. PMID: 42398742

[Erratum to "Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026" \[Vaccine 88 \(2026\) 128882\].](#)

McConeghy KW, Wilker EH, DeVone F, Skov B, Sun T, Patry E, Newbern EC, Araujo AB, Ghaswalla P, Clarke C, Tufts JR, Abul Y, Gravenstein S. *Vaccine*. 2026 Oct 3;91:129072. doi: 10.1016/j.vaccine.2026.129072. Epub 2026 Aug 29. PMID: 42668252

[Vaccination with a PRRSV-1 modified live vaccine provides protection against a highly virulent PRRSV-1.1 Spanish strain challenge in piglets.](#)

Pla H, Simon-Grifé M, Cros S, Del Mar Fenech M. *Virology*. 2026 Oct;623:110979. doi: 10.1016/j.virol.2026.110979. Epub 2026 Jun 5. PMID: 42259180

[Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis.](#)

Chen WG, Li L, Dai GD, Wu YD, Zhu CG, Zhang H, Li XR, Li L, Zhang NZ, Wang LQ, Li GC, Ma WL, Pan JT, Tan ML, Da FL, Yin H, Fu BQ, Luo XN, Yan HB, Jia WZ. *PLoS Pathog*. 2026 Oct 9;22(10):e1014659. doi: 10.1371/journal.ppat.1014659. Online ahead of print. PMID: 42853894

[An intervention study to compare the outcome of administering a live intranasal Bovine Respiratory Syncytial Virus and Parainfluenza-3 vaccine to maternally derived antibody positive calves on the day of birth with calves vaccinated at one week of age.](#)

Baxter-Smith K, Baird G, Cooper R, Roberts J, Denholm KS. *Res Vet Sci*. 2026 Oct;210:106339. doi: 10.1016/j.rvsc.2026.106339. Epub 2026 Jul 22. PMID: 42497673

[Ethiopia missed opportunities for vaccination study: Cluster-randomized evaluation of 5-dose measles vaccine vials and a flexible open-vial policy, 2021-2022.](#)

Wallace AS, Sugerman C, Getachew B, Matanock A, Admassu M, Kassahun T, Wubie HT, Alemu MN, Tefera YL, Kokebie MA. *Vaccine*. 2026 Oct 3;91:129065. doi: 10.1016/j.vaccine.2026.129065. Epub 2026 Aug 20. PMID: 42623714

[Quantifying the counter-intuitive effects of vaccination by coupling the transmission dynamics of COVID-19 and the evolution of human behaviors.](#)

Li Q, Tang B, Xiao Y. *J Theor Biol*. 2026 Oct 7;633:112548. doi: 10.1016/j.jtbi.2026.112548. Epub 2026 Jul 1. PMID: 42385992

[Reduced humoral response to recombinant zoster vaccine in patients with SLE: a prospective cohort study across immune-mediated inflammatory diseases.](#)

Goulenok T, Ferré VM, Bouzid D, Letang G, Antoine B, Alexandra JF, Chauveheid MP, Chezel J, Dossier A, Pizzuto A, Rouzaud D, Papo T, Mageau A, Sacre K. *Lupus Sci Med*. 2026 Oct 1;13(2):e002305. doi: 10.1136/lupus-2026-002305. PMID: 42823098

[Ethnic disparities in COVID-19 vaccine uptake among among 55+ year-old Canadians: Exploring the role of racial discrimination, chronic disease comorbidities, and conspiracy beliefs.](#)

Beogo I, Kibret TC, Zhang Q, Muray M, Xu Y, Cénat JM. *Vaccine*. 2026 Oct 6;93:129213. doi: 10.1016/j.vaccine.2026.129213. Online ahead of print. PMID: 42837895

[Safety Monitoring of COVID-19 Vaccines in the Vaccine Adverse Event Reporting System \(VAERS\): United States, August 22, 2024-July 4, 2025.](#)

Romanson B, Moro PL, Strid P, Hause A, Stroud E, Marquez PL, Zhang B, Ennulat C, Brown H, Su JR. *Drug Saf*. 2026 Oct 3. doi: 10.1007/s40264-026-01709-y. Online ahead of print. PMID: 42828645

[Oral administration of a live-attenuated Bordetella bronchiseptica vaccine \(Vanguard B Oral\) induces protective immunity against challenge 7 days after vaccination in dogs.](#)

Wappel S, Velineni S, King V, Abma E, Hoevers J, Martorell S, Houser C, Tague A, Wilmes L, Millership J. *Am J Vet Res.* 2026 Jun 30;87(10):ajvr.26.03.0100. doi: 10.2460/ajvr.26.03.0100. Print 2026 Oct 1. PMID: 42379217

[An integrated immunoinformatics and experimental pipeline identifies an LCL-scaffolded OmpA loop 3 construct as a protective vaccine candidate against Acinetobacter baumannii.](#)

Banisaeed SR, Rasooli I, Ghazanfari T, Ajdary S, Nikbin VS. *Vaccine.* 2026 Oct 1;93:129205. doi: 10.1016/j.vaccine.2026.129205. Online ahead of print. PMID: 42822178

[Molecular cloning, mRNA expression analysis of immune-related genes and innate immune response of freshwater African catfish \(Clarias gariepinus\) vaccinated with heat-killed Aeromonas hydrophila.](#)

Adibe AC, Elsheshtawy A, Crumlish M, Payne C, MacKenzie S. *Dev Comp Immunol.* 2026 Oct;183:105706. doi: 10.1016/j.dci.2026.105706. Epub 2026 Aug 12. PMID: 42586284

[Psychometric validity evidence for a measure of trust in U.S. public health actors for vaccine information.](#)

Gutierrez AM, Do MH, Motta M. *Vaccine.* 2026 Oct 3;91:129026. doi: 10.1016/j.vaccine.2026.129026. Epub 2026 Aug 25. PMID: 42641256

[Optimization, physicochemical characterization, and immunoprotective efficacy of an oral inactivated largemouth bass ranavirus vaccine encapsulated in N,O-Carboxymethyl chitosan-chitosan nanoparticles.](#)

He T, Chen S, Jiang J, Lan H, Zhao S, Xu S, Fan S, Zhang Q, Wei W, Geng Y, Huang X, Chen D, Ouyang P. *Fish Shellfish Immunol.* 2026 Oct 6;179:111760. doi: 10.1016/j.fsi.2026.111760. Online ahead of print. PMID: 42838354

[Engineered Bacillus subtilis Spores Surface-Displaying a PRRSV GP3/GP4/GP5 Fusion Antigen: A Preliminary Immunogenicity Evaluation in Mice and Piglets.](#)

Tang Y, Wang Y, Wang Z, Fang P, Fei L, Li J, Yang Y, Ma C, Zhang D, Jing B, Ni X, Yang J, Zeng Y, Pan K. *Probiotics Antimicrob Proteins.* 2026 Oct 3. doi: 10.1007/s12602-026-11221-5. Online ahead of print. PMID: 42828674

[Computational systems immunology and multi-scale modeling for the design of a Multi-Epitope Vaccine \(MEV\) against emerging multidrug-resistant Klebsiella michiganensis.](#)

Assiri RA, Saleh FM, Muhammad S, Fenibo EO, Matambo T. *Int Microbiol.* 2026 Oct 3. doi: 10.1007/s10123-026-00903-3. Online ahead of print. PMID: 42827211

[A versatile reversed-phase liquid chromatography charged aerosol detection method for streamlined monitoring of QS-21 content and stability in liposomal adjuvant formulations.](#)

Kinsey C, Barrientos RC, Bhavsar M, Wang H, Mukherjee M, Appiah-Amponsah E, Regalado EL. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2026 Oct 1;1282:125220. doi: 10.1016/j.jchromb.2026.125220. Epub 2026 Jul 21. PMID: 42520362

[Human papillomavirus \(HPV\) Vaccination programmes across European countries: time-harmonized coverage among adolescent females, socioeconomic predictors, and impact on public interest.](#)

Pavia G, Quirino A, Marascio N, Licata F, Matera G, Bianco A, Di Gennaro G. *Vaccine*. 2026 Oct 3;91:129058. doi: 10.1016/j.vaccine.2026.129058. Epub 2026 Aug 20. PMID: 42623713

[Correction to "Impairment of Innate Immunity and Depletion of Vaccine-Induced Memory B and T Cells in the Absence of the Spleen".](#)

[No authors listed] *Am J Hematol*. 2026 Oct;101(10):2706. doi: 10.1002/ajh.70461. Epub 2026 Jul 30. PMID: 42533545

[Optimization of Fermentation Conditions Using Design of Experiment \(DoE\) to Enhance the Production of Antigenic Capsular Polysaccharides From *Streptococcus pneumoniae* Serotype 18C for Pneumococcal Vaccine Development.](#)

Mahajan AD, Jadhav PM, Memane AR, Jha GK, Jana SK, Dandekar PD, Pathak PD. *Biotechnol Appl Biochem*. 2026 Oct;73(5):2123-2134. doi: 10.1002/bab.70158. Epub 2026 Mar 23. PMID: 41873143

[Evaluation of Protective Efficacy of Formalin-Killed and Auxotrophic-Live *Vibrio anguillarum* Against Homologous and Heterologous Strains in Rainbow Trout \(*Oncorhynchus mykiss*\).](#)

Lee KM, Lee JM, Kim KH. *J Fish Dis*. 2026 Oct;49(10):e70210. doi: 10.1111/jfd.70210. Epub 2026 May 13. PMID: 42130044

[Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide.](#)

Aikawa NE, Medeiros JB, Pasoto SG, Medeiros-Ribeiro AC, Seguro LPC, Luppino-Assad AP, Yuki EFN, Guedes LKN, Silva CA, Bonfa E. *Vaccine*. 2026 Oct 7;93:129227. doi: 10.1016/j.vaccine.2026.129227. Online ahead of print. PMID: 42843284

[Erratum for the Research Article "Multifunctional antibody responses from a primate *Shigella* outbreak inform vaccine design".](#)

[No authors listed] *Sci Transl Med*. 2026 Oct 7;18(870):eaem3393. doi: 10.1126/scitranslmed.aem3393. Epub 2026 Oct 7. PMID: 42842726

[Regional distribution of serological evidence of vaccine-induced immunity to hepatitis B among cancer patients in a city in southeastern Brazil.](#)

Paula VG, Pinto MRC, Ferreira GM, Battaglia DBR, Oliveira R, Manchiero C, Dantas BP, Tengan FM, Abdala E, Magri MC. *Rev Inst Med Trop Sao Paulo*. 2026 Oct 2;68:e66. doi: 10.1590/S1678-9946202668066. eCollection 2026. PMID: 42848617

[Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged 45 years in Spain.](#)

Simuzingili M, Fernández-Soberón S, Yi Z, Cossrow N, Johnson KD, Owusu-Edusei K. *Vaccine*. 2026 Oct 3;91:129077. doi: 10.1016/j.vaccine.2026.129077. Epub 2026 Aug 30. PMID: 42669238

[Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway.](#)

Dzus TE, Sarrage J, Samdal H, Montastruc F, Rocca E.Br J Clin Pharmacol. 2026 Oct;92(10):3559-3575. doi: 10.1002/bcp.70648. Epub 2026 Jun 29.PMID: 42366848

[beta-glucan particles as oral carriers for a dual-antigen hepatitis B vaccine: Liver targeting and immune potentiation following subcutaneous priming.](#)

Panão-Costa J, Colaço M, Félix P, Melo AA, Gomes CMF, Borges O.Eur J Pharm Biopharm. 2026 Oct;227:115209. doi: 10.1016/j.ejpb.2026.115209. Epub 2026 Aug 6.PMID: 42562079

[Barriers and solutions to implementing pediatric-focused immunization training at United States schools and colleges of pharmacy.](#)

Yett ES, Miller ML, Phan H, Woodyard JL.Curr Pharm Teach Learn. 2026 Oct 8;19(1):102826. doi: 10.1016/j.cptl.2026.102826. Online ahead of print.PMID: 42849389

[Mi3 nanoparticles displaying the knob domains of Fiber1 and Fiber2 from fowl adenovirus serotype 4 induce robust humoral and cellular immune responses in chickens.](#)

Dong X, Ji J, Liu S, Zhu Z, Lu C, Zhang W, Lei B, Zhang Y, Yuan W, Li L, Lu Y, Zhao K.Vet Microbiol. 2026 Oct;321:111182. doi: 10.1016/j.vetmic.2026.111182. Epub 2026 Aug 4.PMID: 42561831

[Health and Economic Impact of Seasonal Maternal Vaccination With Bivalent Respiratory Syncytial Virus Prefusion F Vaccine in Belgium.](#)

De Bock M, Marbaix S, Goovaerts H, Debiève F, Proesmans M, Raes M.Pediatr Infect Dis J. 2026 Oct 1;45(10):905-910. doi: 10.1097/INF.0000000000005226. Epub 2026 Mar 25.PMID: 41876434

[Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study.](#)

Anand A, Jepkosgei D, Mwachari C, Jalang'o R, Kitwan L, Kagecha C, Leboo I, Hussein A, Kitungulu B, Kigen H, Mutuku P, Tobolowsky FA, Jafri B, Lang'at D, Mainou BA, Wiesen E, Wafula S, An Q, Ahmed J, Herman-Roloff A, Koech E.Vaccine. 2026 Oct 3;91:128969. doi: 10.1016/j.vaccine.2026.128969. Epub 2026 Aug 28.PMID: 42664529

[Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk.](#)

Wang WW, Tan YT, Bellua Sam N, Li L, Chang YW, Asena Musonye H, Wang P, Pan HF.Hum Vaccin Immunother. 2026 Dec;22(1):2741765. doi: 10.1080/21645515.2026.2741765. Epub 2026 Oct 8.PMID: 42849061

[Corrigendum to "Construction of a suckling mouse model based on an EV-C96 clinical isolate and its application in drug screening and vaccine development" \[Antivir. Res. 254 \(2026\) 106511\].](#)

Wang J, Qu Y, He Y, Yang Q, Zhu H, Chen Y, Duan X, Zheng H, Xiao S, Liu Q, Liu H.Antiviral Res. 2026 Oct 1:106543. doi: 10.1016/j.antiviral.2026.106543. Online ahead of print.PMID: 42823249

[Herpes zoster recurrence in primary care: Unmeasured residual confounding, the recombinant vaccine era, and external validity for Latin America.](#)

Therán-León JS, Hernández-Cañas MC, Quintero-Arévalo BY. *Enferm Infecc Microbiol Clin (Engl Ed)*. 2026 Oct;44(8):503246. doi: 10.1016/j.eimce.2026.503246. Epub 2026 Jul 24. PMID: 42498597

[Retraction notice to "Uptake pathways of cell-penetrating peptides in the context of drug delivery, gene therapy, and vaccine development" \[Cellular Signalling 117 \(2024\) 111116\].](#)

Dowaidar M. *Cell Signal*. 2026 Oct;146:112611. doi: 10.1016/j.cellsig.2026.112611. Epub 2026 Jun 11. PMID: 42276875

[Maternal vaccination with gamete-related antigens of *Cystoisospora suis* reduces clinical effects and oocyst excretion in an experimental model of suckling piglet coccidiosis.](#)

Joachim A, Cruz-Bustos T, Feix AS, Rutkowski B, Schwarz L. *Int J Parasitol*. 2026 Oct;56(10):104868. doi: 10.1016/j.ijpara.2026.104868. Epub 2026 May 5. PMID: 42097526

[Evaluation of the immunobiological properties of the attenuated strain CP-65 K for the development of a cowpox vaccine.](#)

Muzarap D, Dzhaldybayeva A, Mambetaliyev M, Ostapchuk Y, Tuyskanova M, Tabys S, Sarsenkulova N, Valieva A, Kenzhebayeva M, Abdolla N, Kilibayev S, Azanbekova M, Aldayarov N, Myrzakhmetova B, Kutumbetov L, Rsaliev A, Abduraimov Y, Zhugunissov K. *Vaccine*. 2026 Oct 10;94:129239. doi: 10.1016/j.vaccine.2026.129239. Online ahead of print. PMID: 42858679

[Recombinant *Toxoplasma gondii* expressing FIPV spike protein S1 subunit: A proof-of-concept approach against toxoplasmosis and feline infectious peritonitis.](#)

Xie F, Jiang X, Yang Y, Xie Y, Zhao C, Suo J, Zhang Z, Wang C, Tang X, Suo X, Liu X. *Acta Trop*. 2026 Oct;282:108297. doi: 10.1016/j.actatropica.2026.108297. Epub 2026 Aug 30. PMID: 42669354

[Multi-copy expression of classical swine fever virus E2 in a recombinant pseudorabies virus enhances immunogenicity and supports its potential as a PRV-CSFV bivalent vaccine candidate.](#)

Shang X, Zhao H, He Y, Rong Z, Ke X, Gao J, Zhang K, Luo J, Zhang M, Chen H, Li X, Qian P. *Vet Microbiol*. 2026 Oct;321:111158. doi: 10.1016/j.vetmic.2026.111158. Epub 2026 Jul 22. PMID: 42501659

[A novel TK/gE-deleted pseudorabies virus vaccine expressing CCL3L1 enhances humoral immunity by stimulating the dendritic cell-T follicular helper-germinal center axis.](#)

Yao L, Hao S, Zhang C, Jin M, Hu Q, Luo Q, Wen G, Wu H. *Vet Microbiol*. 2026 Oct;321:111204. doi: 10.1016/j.vetmic.2026.111204. Epub 2026 Aug 24. PMID: 42659736

[Postpandemic COVID-19 Vaccination Willingness Among Physicians and Medical Trainees in China: Cross-Sectional Study.](#)

Mu Y, Wang Y, Gu X, Shang L, Che W, Xuan W, Cao X, Zhang C, Zhou X, Sun S, Zhao R, Liu A, Kuang J, Guo Y, Mo J, Cao B. *JMIR Public Health Surveill*. 2026 Oct 6;12:e88931. doi: 10.2196/88931. PMID: 42837522

[Saponin derivative and MPLA-adjuvanted intranasal protein nanoparticle vaccines induce potent mucosal immunity and durable heterologous influenza protection in mice.](#)

Wei L, Zhu W, Dong C, Kim JK, Arsana A, Omotara P, Ferrante A, Morris WR, Kim H, Denning TL, Kang SM, Wang P, Wang BZ. *Nanomedicine*. 2026 Oct;77:103008. doi: 10.1016/j.nano.2026.103008. Epub 2026 Aug 19. PMID: 42617671

[Establishing a human co-infection challenge study of Streptococcus pneumoniae \(Spn\) and live attenuated influenza vaccine \(LAIV\) in older healthy adults: Exploring Co-infection with Live Attenuated Influenza Vaccine and Pneumococcus in healthy older adults \(ECLIPSE\), a UK-based single-centre, single-blind randomised controlled trial.](#)

Jackson RI, Hennigan O, Kelleher K, Solórzano C, Mitsi E, Morey E, Madupuri T, Singh N, Baughan H, Patel B, Verleur N, Codreanu T, Elterish F, Comma E, Mujadidi YF, Plested E, Robinson H, Brito-Mutunayagam S, Liu X, Didierlaurent AM, Urban BC, Pollock KM, Ferreira DM. *BMJ Open*. 2026 Oct 12;16(10):e118632. doi: 10.1136/bmjopen-2026-118632. PMID: 42864130

[The use of the enzyme chitosanase to enable vaccine potency determination in a formulation containing the adjuvant chitosan.](#)

Fox N, Trausch JJ, Yarovoi H, Stiving AQ, Bowman A, Smith ML, Liu Y, Eddins MJ, Loughney JW, Mayhood T, Paduraru C, Grau B. *J Pharm Sci*. 2026 Oct;115(10):104461. doi: 10.1016/j.xphs.2026.104461. Epub 2026 Aug 15. PMID: 42603690

[Adaptation of suspension Vero cells to commercially available cell culture media and enhanced production of vaccine-strain mumps virus.](#)

Hong R, Blanda TR, Bednar M, Olson J, Baron EKB, Spatafore D 3rd, Oruc DE, Wagner JM. *Biotechnol Prog*. 2026 Oct 11:e88561. doi: 10.1002/btpr.88561. Online ahead of print. PMID: 42860675

[Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026.](#)

Fortunato F, Campanozzi A, Acquafredda A, Mariano M, Delli Carri V, Rollo T, Micelli L, Tedeschi D, Prato R, Martinelli D. *Infection*. 2026 Oct 9. doi: 10.1007/s15010-026-02995-5. Online ahead of print. PMID: 42853491

[Enhanced passive safety surveillance \(EPSS\) of a seasonal intranasal influenza vaccine \(Fluenz Tetra\) in children in England: methodology, results and lessons learned from eight influenza seasons \(2015/2016 to 2022/2023\).](#)

Dhanda S, Morris DE, Morton K, Hazell L, Härmark L. *Vaccine*. 2026 Oct 3;91:129007. doi: 10.1016/j.vaccine.2026.129007. Epub 2026 Aug 17. PMID: 42607627

[Balancing individual risks and collective benefits: Effects of vaccine price, message framing, and value orientations on influenza vaccination in China.](#)

Chu Y, Jiang Y, Cheng Q, Zha X, Wang Y, Liang W, Chen L. *Hum Vaccin Immunother*. 2026 Dec 31;22(1):2743369. doi: 10.1080/21645515.2026.2743369. Epub 2026 Oct 8. PMID: 42850200

[Cognitive and behavioral determinants of HPV vaccination willingness and Behavior among female university students in Karnataka, India.](#)

Thomas Gil M, Gopal S, Oduro Owusu S. Hum Vaccin Immunother. 2026 Dec;22(1):2738253. doi: 10.1080/21645515.2026.2738253. Epub 2026 Oct 8. PMID: 42847160

[Corrigendum to "Efficacy of the 4CMenB vaccine against gonorrhoea among men who have sex with men in Hong Kong: A double-blind randomised placebo-controlled trial" \[International Journal of Infectious Diseases 170 \(2026\) 108926\].](#)

Kwan TH, Chan DPC, Lai CKC, Lam TT, Kwan CK, Shan Lee S. Int J Infect Dis. 2026 Oct;171:109112. doi: 10.1016/j.ijid.2026.109112. Epub 2026 Sep 9. PMID: 42715824

[Assessing the Willingness of Future Health Care Providers to Participate in Vaccine Trials: Cross-Sectional VACCELERATE European Study.](#)

Yiallouris A, Filippou C, Merakou C, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Sarantopoulos A, Shaikh AR, Noura E, Nearchou A, Johnson EO, Papaconstantinou-Leontidou M, Armeftis C, Astras G, Stewart FA, Albus K, Salmanton-García J, Leckler J, Azzini AM, Davis RJ, Součková L, Askling HH, Battle TL, Álvarez-Barco E, Mozeryte A, Poulimeneas D, Kopsidas I, Prellezo JB, Valdenmaier O, Jakobsen SF, Cox RJ, Hellemans M, Hendrickx G, van Damme P, Ochando J, Zaoutis TE, Jancoriene L, Mallon P, Naucler P, Husa P, Tacconelli E, Cornely OA, Pana ZD. JMIR Public Health Surveill. 2026 Oct 9;12:e84952. doi: 10.2196/84952. PMID: 42854231

[Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.](#)

Inam M, Jamshed M, Osman A. Hum Vaccin Immunother. 2026 Dec;22(1):2737475. doi: 10.1080/21645515.2026.2737475. Epub 2026 Oct 2. PMID: 42826091

[Global, regional, and national burden of tetanus in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.](#)

GBD 2023 Tetanus Collaborators. EClinicalMedicine. 2026 Sep 28;100:104202. doi: 10.1016/j.eclinm.2026.104202. eCollection 2026 Oct. PMID: 42840379

[Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.](#)

Ferraro D, Abbadessa G, Azzolini F, Bianco A, Carta S, Dinoto A, Di Sante G, Maniscalco GT, Mariotto S, Constantin G, Di Filippo M, Iorio R, Magliozzi R, Mechelli R, Procaccini C, Signoriello E, Centonze D. Neurol Ther. 2026 Oct 9. doi: 10.1007/s40120-026-01048-1. Online ahead of print. PMID: 42853527

[A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.](#)

Fahfouhi Y, Fiévez S, Cohen R, Levy C, Nunes MC, Chillotti L, Moreau R, Greenwood W, Blanc E, Law A. Vaccine. 2026 Oct 3;91:129036. doi: 10.1016/j.vaccine.2026.129036. Epub 2026 Aug 22. PMID: 42628195

[Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy.](#)

Michler T, Kosinska A, Merdan O, Hagen P, Bunse T, Öz EA, Su J, Busch DH, Mogler C, Protzer U. JHEP Rep. 2026 Oct;8(10):101943. doi: 10.1016/j.jhepr.2026.101943. Epub 2026 Jun 30. PMID: 42379305

[Two divergent BoHV-1 isolates from yaks show distinct biological properties and neutralization profiles.](#)

Yu C, Liu J, Ake A, He C, Zeng J, Chu J, Zhang B. Res Vet Sci. 2026 Oct;210:106347. doi: 10.1016/j.rvsc.2026.106347. Epub 2026 Jul 27. PMID: 42537337

[Building equitable epidemic response: the Interdisciplinary Consortium for Epidemics Research \(ICER\) position on Bundibugyo ebolavirus and regional preparedness in sub-Saharan Africa.](#)

Wayengera M, Katoto PDMC, Sabiiti W, Muttamba W, Adegbite BR, Makali SL, Nyanda EN, Mbala PK, Chanda D, Ssengooba W, Muwonge H, Sendagire H, Mtafya B, Niyomwungere D, Hugor S, Nsawotebba A, Bbuye M, Musabyimana JP, Bakamutumaho B, Bosa HK, Kiiza D, Anzala O, Mwenebitu DL, Birindwa AM, Rogers C, Mparanyi GJ, Nakazibwe B, Fallah MP, Byakika-Kibwika P, Njenga K, Kirenga B; Interdisciplinary Consortium for Epidemics Research. Int J Infect Dis. 2026 Oct 12:109163. doi: 10.1016/j.ijid.2026.109163. Online ahead of print. PMID: 42863700

[Species breadth is a preparedness metric: lessons from the 2026 Bundibugyo virus disease outbreak.](#)

Hassan AM, Yusuf AA, Hirsi AM, Khalif IA, Maxamed AA, Abdi DA. Emerg Microbes Infect. 2026 Dec;15(1):2744490. doi: 10.1080/22221751.2026.2744490. Epub 2026 Oct 12. PMID: 42831485

[VirPLM: antigenic prediction of influenza A/H3N2 viruses with a fine-tuned protein language model.](#)

Li X, Xiao K, Zhou C, Jia X, Zhao D, Xu J, Zeng X, Shi J, Shang X, Zhu J, Kong H. Bioinformatics. 2026 Oct 2;42(10):btag692. doi: 10.1093/bioinformatics/btag692. PMID: 42758138

[Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.](#)

Fagniez I, Tsumura M, Guérin A, Abolhassani H, Sharafian S, Mesdaghi M, Nishimura T, Lashkari HP, Rao S, Richards S, Han JE, Delmonte OM, Kergaravat C, Markle JG, Ogishi M, Han J, Peel J, Vellutini J, Feng Y, Soudée C, Migaud M, Palterer B, Jackson KJL, Nishimura S, Sakata S, Kinoshita K, Yamamoto A, Moritake H, Alzahrani M, Vallejos F, Cole T, Smart JM, Choo S, Chavoshzadeh Z, Armin S, Toubert A, Zhang P, Rosain J, Notarangelo LD, Pan-Hammarström Q, Tangye SG, Casanova JL, Ma CS, Puel A, Bustamante J, Okada S, Boisson-Dupuis S, Yang R. J Exp Med. 2026 Oct 5;223(10):e20252038. doi: 10.1084/jem.20252038. Epub 2026 Sep 4. PMID: 42695969

[A high-throughput screen to identify potential inhibitors of HSV-2.](#)

Hao H, Roy A, Johnson DK, Davido DJ. Antiviral Res. 2026 Oct;254:106494. doi: 10.1016/j.antiviral.2026.106494. Epub 2026 Jul 30. PMID: 42532196

[Utilization of Similar Epitopes to Develop Viral Vaccines that Produce Lifelong Immunity.](#)

Yang XY, Fu YF, Xie LB, Zhang ZW, Yuan S. *Viral Immunol.* 2026 Oct;39(8):313-317. doi: 10.1177/08828245261474283. Epub 2026 Jul 30. PMID: 42529933

[Vaccination recommendations and adherence in inflammatory bowel disease: A physician-patient discordance study.](#)

Ferreiro-Iglesias R, Hernández-Camba A, Valdivia A, Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M; GETECCU Youth Group and ACCU Spain. *Gastroenterol Hepatol.* 2026 Oct;49(8):502714. doi: 10.1016/j.gastrohep.2026.502714. Epub 2026 Mar 2. PMID: 41780635

[A chicken microRNA expressing LaSota targets Newcastle disease virus phosphoprotein and impacts interferon expression.](#)

Bakre A, Satterlee TR, Mears MC. *Poult Sci.* 2026 Oct 5;105(12):107893. doi: 10.1016/j.psj.2026.107893. Online ahead of print. PMID: 42863174

[Interventions to mitigate post-infection morbidity: Management insights from simple models.](#)

Jaiswal P, Coombs D, Wagner CE, Day T, Saad-Roy CM. *Proc Natl Acad Sci U S A.* 2026 Oct 13;123(41):e2609982123. doi: 10.1073/pnas.2609982123. Epub 2026 Oct 9. PMID: 42853666

[The grammar of the pangenome: terms, concepts, methods, and emerging patterns-a general framework for comparative genomics and genome biology.](#)

Chasapi A, Michailidis A, Schriml LM, Donati C, Kyrpides NC, Ouzounis CA. *Microbiol Mol Biol Rev.* 2026 Oct 5:e0040325. doi: 10.1128/mmbr.00403-25. Online ahead of print. PMID: 42831618

[Engineering tolerogenic mRNA-LNPs for allergen-specific immune reprogramming in pollen allergy.](#)

Yao Z, Wang D, Zhang Y, Xin P, Li Y, Cerav EN, Tang D, Zhao Z, Wang Z, Wang H, Liu H, Liang Z, Xue C, Xiao H, Cheng G, Fan X, Deng S, Xia T, Sun B. *Mater Today Bio.* 2026 Aug 31;40:103611. doi: 10.1016/j.mtbio.2026.103611. eCollection 2026 Oct. PMID: 42729701

[Elucidate the structural role of helper lipids in modulating hepatic expression following repeated intravenous administration of mRNA-LNPs.](#)

Ge J, Bo X, Zhu X, Long M, Zhang Y, Qiu M, Yuan Q, Ott M, Liu Y, Zhao Z, Huang L, Xia Q, Yang T, Tang S. *Mater Today Bio.* 2026 Aug 28;40:103621. doi: 10.1016/j.mtbio.2026.103621. eCollection 2026 Oct. PMID: 42718620

[Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine.](#)

Jafari A, Manzari-Tavakoli A, Manzari Tavakoli M, Hashemian SM, Jamaati H, Akhtari M, Tabarsi P, Omrani M. *Expert Rev Mol Diagn.* 2026 Oct;26(10):805-828. doi: 10.1080/14737159.2026.2714060. Epub 2026 Aug 11. PMID: 42549821

[\[Comprehensive cardiovascular prevention: the role of vaccination in older adults with cardiovascular disease. Expert consensus document\].](#)

Bonanad C, Alfaro R, Morán Bayón Á, Cainzos-Achirica M, García-Lledó A, Raposeiras-Roubín S, Vivas D, Freixa-Pamias R, Mora J, Martín-Toro MA, Fernández-Olmo R, Maidana D, Barreres-Martín G, Barrios V, Redondo E. *Semergen*. 2026 Oct;52(7):102819. doi: 10.1016/j.semern.2026.102819. Epub 2026 Jul 27. PMID: 42508371

[Evaluation of a thermostable Newcastle disease virus D58 strain by in ovo vaccination and challenge study.](#)

Ranjini R, Govindaraj E, Karuppannan A, Rajalakshmi S, Shoba K, Porteen K, Raja P. *Virus Genes*. 2026 Oct;62(5):624-638. doi: 10.1007/s11262-026-02252-9. Epub 2026 Jun 24. PMID: 42340557

[Phage display in veterinary infectious diseases: From molecular recognition to diagnostic validation and protective efficacy.](#)

Villa-Mancera A, Robles-Robles JM, Olivares-Pérez J, Olmedo-Juárez A, González-Garduño R, Ortega-Vargas S. *Microb Pathog*. 2026 Oct 6;221:108867. doi: 10.1016/j.micpath.2026.108867. Online ahead of print. PMID: 42838392

[Self-Assembly of Antigenic Peptide Nanofibrils Templates the Growth of Silica Nanoparticles for Nanovaccines.](#)

Yang X, Li M, Yao Z, Hu Y, Wang Z, Shi W, Sun B. *Adv Sci (Weinh)*. 2026 Oct;13(56):e76636. doi: 10.1002/advs.76636. Epub 2026 Jul 14. PMID: 42444591

[Clinical efficacy, immunogenicity and safety of RTS,S/AS01, R21/Matrix-M and candidate malaria vaccines in children: A systematic review and meta-analysis.](#)

Bashlakova K, Zarro M, Villari P, De Vito C, Rosso A. *J Infect Public Health*. 2026 Oct;19(10):103356. doi: 10.1016/j.jiph.2026.103356. Epub 2026 Sep 6. PMID: 42715783

[Biomarker-guided immunotherapies for primary CNS tumors.](#)

Bunse L, Bunse T, Poschke I, Prins RM, Lim M, Platten M. *Neuro Oncol*. 2026 Oct 10:noag116. doi: 10.1093/neuonc/noag116. Online ahead of print. PMID: 42858163

[Intramuscular Non-replicating Tiantan Vaccinia Drives Superior Antibody Maturation and Sterilizing Protection Against Lethal Orthopoxvirus Challenge in Mice.](#)

Wang Y, Wu C, Huang B, Huo S, Huang J, Ma J, Jiang Y, Jin L, Liu S, Wang W, Deng Y, Tan W. *Mol Ther*. 2026 Oct 9:S1525-0016(26)00866-X. doi: 10.1016/j.ymthe.2026.10.008. Online ahead of print. PMID: 42855885

[Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany.](#)

Simuzingili M, Mueller PP, Oexle LM, de Lepper M, Yi Z, Owusu-Edusei K. *Expert Rev Vaccines*. 2026 Dec;25(1):2739087. doi: 10.1080/14760584.2026.2739087. Epub 2026 Oct 5. PMID: 42834615

[Counterfactual evaluation of COVID-19 control policies in South Korea: A scenario-based modeling study.](#)

Jo S, Min KD, Cho SI. *Int J Infect Dis*. 2026 Oct;171:108997. doi: 10.1016/j.ijid.2026.108997. Epub 2026 Jul 22. PMID: 42486221

[Molecular adaptation and clinical progression of Cryptococcus neoformans infection from the lungs to systemic dissemination.](#)

Yu SR, Jang YB, Choi JT, Bahn YS. Curr Opin Microbiol. 2026 Oct;93:102802. doi: 10.1016/j.mib.2026.102802. Epub 2026 Jul 22. PMID: 42485747

[Varicella-zoster virus reactivation and cardiovascular risk: implications for patients receiving JAK inhibitors.](#)

Cacciapaglia F, Gadina M, Spinelli FR. Ann Rheum Dis. 2026 Oct;85(10):1899-1903. doi: 10.1016/j.ard.2026.06.027. Epub 2026 Jul 20. PMID: 42476902

[Advances in the Application of Additive Manufacturing in Respiratory Inhalation Therapy.](#)

Zhang C, Zhang X, Zhang J, Huo C. J Aerosol Med Pulm Drug Deliv. 2026 Oct;39(5):236-248. doi: 10.1177/19412711261442505. Epub 2026 Apr 15. PMID: 41984640

[Meningococcal meningitis in patients under prolonged eculizumab therapy: Clinical and immunological observations from a case series.](#)

Varela-Fernández R, Ortega-Valín L, Sáez-Villafañe M, Lucas-Álvarez C, Ortiz-de-Urbina-González JJ. Nefrologia (Engl Ed). 2026 Oct;46(8):501554. doi: 10.1016/j.nefro.2026.501554. PMID: 42829229

[Engineered probiotic-propelled micro-robot as biological truck for deep tumor penetration and treatment.](#)

Huang K, Lin Y, Zheng W, Fan X, Ji Y, Feng S. Mater Today Bio. 2026 Aug 14;40:103549. doi: 10.1016/j.mtbio.2026.103549. eCollection 2026 Oct. PMID: 42662118

[Human papillomavirus research in Gulf Cooperation Council \(GCC\) countries - current evidence, genotypes, and priority gaps: A scoping review.](#)

AlMeslamani AZ, Ahmad M, Nauman J, Ahmad LA, Al-Rifai RH. J Infect Public Health. 2026 Oct;19(10):103335. doi: 10.1016/j.jiph.2026.103335. Epub 2026 Aug 13. PMID: 42641534

[Integrated molecular, epidemiological, and bioinformatics perspectives on the Mpox virus: Implications for surveillance and Global Health preparedness.](#)

Detroja R, Chandra M. J Microbiol Methods. 2026 Oct;249:107656. doi: 10.1016/j.mimet.2026.107656. Epub 2026 Aug 6. PMID: 42562267

[The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation.](#)

Ahmed MM, Joerger T, Wang Z, Li Y, Gerber JS. Clin Infect Dis. 2026 Oct 7;83(3):e487-e494. doi: 10.1093/cid/ciag406. PMID: 42560328

[Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunization.](#)

Froehlich G, Scognamiglio A, Totaro S, Nocchi L, Pellino E, Campanile A, Infante L, Miano G, Centore A, Molfetta F, Napolano A, D'Alise AM, Parisi S, Nicosia A, Sasso E, Zambrano N. Mol Ther. 2026 Oct 7;34(10):6028-6038. doi: 10.1016/j.ymthe.2026.07.050. Epub 2026 Jul 29. PMID: 42528135

[Circadian immunometabolic states impart a temporal response to SARS-CoV-2 spike proteins in mammalian macrophages.](#)

Buel SM, Balaraman J, Jankowski MS, Hixson K, Gao Y, Kim YM, Muñoz N, Kyle JE, Lipton MS, Nicora CD, Piehowski PD, Baker SE, Hurley JM. *Microb Pathog.* 2026 Oct;219:108716. doi: 10.1016/j.micpath.2026.108716. Epub 2026 Jul 19. PMID: 42472597

[The Q653R substitution in the spike protein is associated with attenuation of a GVI-1 infectious bronchitis virus strain.](#)

Tian Y, Lu Y, Zeng Y, Song X, Dai Z, Qiao B, Hu X, Zhao N, Xia J, Su J, Ping J. *Avian Pathol.* 2026 Oct;55(5):707-721. doi: 10.1080/03079457.2026.2695132. Epub 2026 Sep 14. PMID: 42734165

[Assessment of interferon- \$\gamma\$ response profiles after vaccination against bovine viral diarrhea virus \(BVDV\) as correlates of protection.](#)

Falkenberg S, Dassanayake RP, Putz EJ, Silvis S, Crawford LS, Boggiatto PM. *Vet Immunol Immunopathol.* 2026 Oct;300:111166. doi: 10.1016/j.vetimm.2026.111166. Epub 2026 Jul 9. PMID: 42431124

[Marek's disease virus: mechanistic insights into host immune responses and multilayered immune evasion strategies.](#)

Gao K, Yu Q, Guo R, Sun H, Duan Y, Zhang Y, Gao Y, Liu Y. *J Virol.* 2026 Oct 12:e0073626. doi: 10.1128/jvi.00736-26. Online ahead of print. PMID: 42861981

[ParaEM: Antigen-aware sequence-based paratope prediction with Expectation-Maximization.](#)

Kim T, Cho C, Jung I, Kim S. *Bioinformatics.* 2026 Oct 5:btag739. doi: 10.1093/bioinformatics/btag739. Online ahead of print. PMID: 42834434

[Algorithm-assisted personalized risk communication to encourage flu vaccination in the USA: three randomized field trials.](#)

Rosenbaum GM, Goren A, Shermohammed M, Wolk DM, Tice AM, Doyle JJ Jr, Meyer MN, Chabris CF. *Nat Hum Behav.* 2026 Oct 5:10.1038/s41562-026-02603-4. doi: 10.1038/s41562-026-02603-4. Online ahead of print. PMID: 42834081

[Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.](#)

Gupta MK, Vadde R, Nagaraju GP. *MedComm (2020).* 2026 Sep 25;7(10):e71009. doi: 10.1002/mco2.71009. eCollection 2026 Oct. PMID: 42798783

[Recurring Temporal Association Between Influenza A Epidemics and Subsequent Influenza B Dominance in Post-Pandemic Korea, 2022-2026.](#)

Lee Y, Yoon Y, Park JE, Kim WK, Choi YY, Kim YK, Kang C, Yoo Y, Choe YJ. *J Med Virol.* 2026 Oct;98(10):e71169. doi: 10.1002/jmv.71169. PMID: 42781893

[Higher Human Papillomavirus Vaccination Coverage Among American Indian and Alaska Native Adolescents and Rural Adolescents in Alaska.](#)

Pletnikoff PP, Aho S, Ohlsen EC, McLaughlin J.J Community Health. 2026 Oct;51(5):805-812. doi: 10.1007/s10900-026-01586-7. Epub 2026 Jul 1. PMID: 42384135

[The spatial proteome of Eimeria tenella provides a high-resolution view of proteins localised to key invasion organelles.](#)

Attree E, Barylyuk K, Noonan C, Einarsson E, Marugan-Hernandez V, Gundogdu O, Blake D, Tomley F, Waller RF, Xia D. Int J Parasitol. 2026 Oct;56(10):104878. doi: 10.1016/j.ijpara.2026.104878. Epub 2026 May 6. PMID: 42102995

[Risk Factors Associated With Secondary Measles Transmission in Index Cases.](#)

Takahashi Y, Tanaka H, Shibata T, Tanikake C, Moriwaki T, Miyazono M, Matsumoto S, Kinoshita M, Nagai H, Shirai C, Takayama Y, Okada M, Tsuda Y, Hazama A, Ohara T, Yoshida H, Kurata T, Kanbayashi D, Taniguchi C, Motomura K. J Epidemiol. 2026 Oct 5;36(10):307-312. doi: 10.2188/jea.JE20250293. Epub 2026 Aug 31. PMID: 41656081

[Prior COVID-19 vaccination and cognitive outcomes after SARS-CoV-2 infection: a mini-review.](#)

da Silva LG, Oliveira JCM, Fini BCD, Porto AA, Costa DS, de Miranda DM, Romano-Silva MA, de Paula JJ. Dement Neuropsychol. 2026 Oct 2;20:e20260494. doi: 10.1590/1980-5764-DN-2026-0494. eCollection 2026. PMID: 42841133

[A multimeric S1-nucleocapsid fusion antigen elicits cellular and humoral immune responses against porcine epidemic diarrhea virus in mice.](#)

Fragoso-Saavedra M, Thivierge B, Liu Q. Microb Pathog. 2026 Oct;219:108745. doi: 10.1016/j.micpath.2026.108745. Epub 2026 Aug 4. PMID: 42551608

[Human metapneumovirus: an underestimated cause of severe respiratory infection.](#)

Cilloniz C, Ho A, Rhee C. Ann Am Thorac Soc. 2026 Oct 1;23(10):1414-1426. doi: 10.1093/annalsats/aaag172. PMID: 42323864

["I'll Never Get that Time Back": Public Health's Impact on Prolonged Incarceration in Los Angeles County.](#)

Buchbinder L, Nguyen K, Samra S, Shoptaw S. J Correct Health Care. 2026 Oct;32(5):312-319. doi: 10.1177/10783458261455723. Epub 2026 Jun 12. PMID: 42283393

[Efficient Cell Removal and Impurity Reduction for Poxvirus Purification in a Single Step Alluvial Filtration.](#)

Weber LG, Stephan C, Makris G, John L, Jordan I, Wolff MW. Biotechnol Bioeng. 2026 Oct 12. doi: 10.1002/bit.70413. Online ahead of print. PMID: 42864826

[Principal component analysis-based three-dimensional quantitative characterization of cracks on perforated embryo eggs.](#)

Zhao M, Chen H, He C, Zhu X, Wei Y, Fu D, Chen D. Poult Sci. 2026 Oct;105(10):107086. doi: 10.1016/j.psj.2026.107086. Epub 2026 May 7. PMID: 42335768

[BTV-3 vaccination decisions among German livestock farmers: a KAP survey.](#)

Rogoll L, Schulz K, Gerdes U, Sauter-Louis C, Gethmann J. *Vaccine*. 2026 Oct 11;94:129228. doi: 10.1016/j.vaccine.2026.129228. Online ahead of print. PMID: 42860064

[Self-destructing attenuated adjuvant *Salmonella* strains: design, construction, characterization, and evaluation of safety and efficacy following *in ovo* inoculation of chicken embryos.](#)

Lima V, Natoce D Jr, Wanda S-Y, Wang S, Swain B, Curtiss R 3rd. *Infect Immun*. 2026 Oct 8:e0031826. doi: 10.1128/iai.00318-26. Online ahead of print. PMID: 42847965

[Improved Predictive Capacity of SARS-CoV-2 Seroconversion Using a Model Based on Torque Teno Virus Viral Load.](#)

Hermida E, Reyes NS, Jara R, Boccia N, Schiavone M, Poletta FA, Laham G, Echavarria M. *Clin Transplant*. 2026 Oct;40(10):e70690. doi: 10.1111/ctr.70690. PMID: 42829947

[Self-Assembling Peptide-Adjuvant Conjugate \(SaPAC\) Platform for Precision Cancer Immunotherapy.](#)

Wu YF, Hu JC, Hu YF, Li WJ, Rong L, Li RH, Yao Y, Hu L, Wang XL, Zhang BZ, Lu Y, Chow SF, Su C, Yau T, Chung CY, Huang JD. *Adv Sci (Weinh)*. 2026 Oct 2:e77632. doi: 10.1002/adv.77632. Online ahead of print. PMID: 42827008

[Spatiotemporal clustering, socioeconomic drivers and policy evaluation of mumps in Hunan Province, China, 2015-2024.](#)

Liang L, Liu X, Liu F, Liu L. *Prev Med Rep*. 2026 Aug 17;70:103601. doi: 10.1016/j.pmedr.2026.103601. eCollection 2026 Oct. PMID: 42662080

[Age-specific hospitalization dynamics during a measles outbreak in Nyanza District, Southern Province, Rwanda, 2026: A survival analysis with implications for clinical management.](#)

Ntirenganya F, Itanga I, Uwamahoro S, Rwagitinywa B, Benimana JL, Mucunguzi HV, Ruseesa E, Igihozo EH, Rwagasore E. *Int J Infect Dis*. 2026 Oct;171:108999. doi: 10.1016/j.ijid.2026.108999. Epub 2026 Jul 21. PMID: 42480767

[Pediatric Measles Resurgence: Implications for Acute and Critical Care Nursing Practice.](#)

Rameswaran J, Farber JS, Atlas K, Shields K. *Crit Care Nurse*. 2026 Oct 1;46(5):10-20. doi: 10.4037/ccn2026877. PMID: 42463154

[Interventional radiology in bone metastases: Current concepts and perspectives.](#)

Stacoffe N, Mesny E, Proriot M, Fontana A, Chalamet B, BenRejeb MI, Bonnelye E, Pialat JB, Confavreux C, Massy E. *Joint Bone Spine*. 2026 Oct;93(5):106076. doi: 10.1016/j.jbspin.2026.106076. Epub 2026 May 12. PMID: 42128267

[Family health and willingness to Receive Self-paid vaccines: the role of Self-efficacy and health literacy.](#)

Chen Y, Li R, Liu Y, Guo R, He M, Li W, Gao X, Zhang W, Wei Y, Chen Z, Liu H, Zhang X. *Psychol Health Med*. 2026 Oct;31(9):2443-2464. doi: 10.1080/13548506.2025.2512158. Epub 2025 May 27. PMID: 40420692

[Humoral and Cellular Immune Responses Following Bivalent SARS-CoV-2 mRNA Vaccines in Patients Undergoing Hemodialysis: A Prospective Cohort Study.](#)

Ling TC, Chen PL, Wang JR, Ko WC, Chao CH, Shieh CC, Wu JL, Sun CY, Lin WR, Huang CH, Chang YT. *Kidney Med.* 2026 Jul 23;8(10):101480. doi: 10.1016/j.xkme.2026.101480. eCollection 2026 Oct. PMID: 42819460

[Immunoglobulin Use, Availability, and Administration Considerations in Measles Prevention.](#)

Le D, Ahmed A, Raschka M, Stinchfield P, Goad J. *Am J Health Syst Pharm.* 2026 Oct 8;zxag315. doi: 10.1093/ajhp/zxag315. Online ahead of print. PMID: 42847317

[Integrated computational approaches for identifying and evaluating phytochemical inhibitors against HCV NS3/4A protease.](#)

Pradhan S, Dansana J, Gadtya A, Mallik V, Meher BR. *J Biol Phys.* 2026 Oct 5;52(1):32. doi: 10.1007/s10867-026-09728-7. PMID: 42830361

[Structural integrity of surface antigens determines complement-dependent protective immunity against *Philasterides dicentrarchi* in turbot.](#)

Gulías P, Sueiro RA, Lamas J, Leiro JM. *Fish Shellfish Immunol.* 2026 Oct;177:111561. doi: 10.1016/j.fsi.2026.111561. Epub 2026 Jul 1. PMID: 42386035

[Symptomatic injection granuloma of buttock and management with ultrasound-guided barbotage procedure.](#)

Dede BT, Oğuz M, Alyanak B, Bağcier F. *Pain Manag.* 2026 Oct;16(10):1093-1097. doi: 10.1080/17581869.2026.2688378. Epub 2026 Jun 16. PMID: 42299468

[Immunocastration and testosterone supplementation alter testicular development and muscle collagen gene expression in male chickens.](#)

Zhang X, Hoshina K, Uemori M, Egawa S, Nishimura S, Hosaka YZ. *Poult Sci.* 2026 Oct 9;105(12):107932. doi: 10.1016/j.psj.2026.107932. Online ahead of print. PMID: 42863179

[Design and scale-up of a mixed-substrate fed-batch strategy for enhanced HPV VLP production in *Komagataella phaffii*.](#)

Rani AK, Khan N, Rathore AS. *Biotechnol Prog.* 2026 Oct 9:e88559. doi: 10.1002/btpr.88559. Online ahead of print. PMID: 42855890

[Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies.](#)

Baydaş T, Ökten İN. *J Gastrointest Cancer.* 2026 Oct 3;57(1):233. doi: 10.1007/s12029-026-01610-y. PMID: 42828719

[Dual susceptibility to hepatitis A and B among people newly diagnosed with HIV in Taiwan during the vaccination era: A multicenter study.](#)

Chiu PW, Tsai TY, Huang SH, Wu TY, Liu WD, Chen AP, Lin KY, Tsai CS, Hung CC. *Int J Infect Dis.* 2026 Oct;171:109016. doi: 10.1016/j.ijid.2026.109016. Epub 2026 Jul 31. PMID: 42537780

[Associations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore.](#)

Huang Z, Se Soh AM, Zeng K, Thein TL, Chavatte JM, Cui L, Lin R, Lim V, Chia YW, Tambyah PA, Luo N, Chen MI. *J Infect Public Health.* 2026 Oct;19(10):103359. doi: 10.1016/j.jiph.2026.103359. Epub 2026 Sep 9. PMID: 42748761

[Multiomics Dissection Reveals Natural Killer Cell-CD8+ T-cell Cooperation in Shaping an Immunostimulatory Tumor Microenvironment.](#)

Shimizu K, Sanpei A, Liu Y, Ishibashi T, Yanagawa M, Nakazato H, Shinga J, Ueda S, Yamasaki S, Fujii SI. *Cancer Res.* 2026 Oct 2;86(19):4873-4890. doi: 10.1158/0008-5472.CAN-25-4957. PMID: 42545372

[Broadly cross-reactive neutralizing and enhancing antibody responses to dengue, Japanese encephalitis and Zika viruses in sera from Vietnamese pediatric dengue cases.](#)

Raekiansyah M, Ngwe Tun MM, Balingit JC, Nguyen TTN, Nguyen TV, Kapandji M, Takamatsu Y, Urano T, Le TQM, Hasebe F, Morita K. *Int J Infect Dis.* 2026 Oct;171:109000. doi: 10.1016/j.ijid.2026.109000. Epub 2026 Jul 27. PMID: 42508521

[Reconstruction of native cellular microanatomy in a novel bioengineered full thickness human nasal mucosal construct.](#)

Bradbury S, Dickson B, Curtis N, Bunton D, Goncalves K, Przyborski S. *J Anat.* 2026 Oct;249(4):950-969. doi: 10.1111/joa.70130. Epub 2026 Mar 16. PMID: 41839648

[Assessing the incidence of retinal hemorrhage in pediatric patients following COVID-19 vaccination.](#)

Wong BM, Perkins JM, Zontag N, Levin AV. *J AAPOS.* 2026 Oct 12:105323. doi: 10.1016/j.jaapos.2026.105323. Online ahead of print. PMID: 42863653

[Early and sustained anti-Trypanosoma cruzi IgG reactivity in experimentally infected dogs detected with chimeric recombinant antigens.](#)

Moreira JVF, Serrano IM, Jesus FSS, Campos DAA, Celedon PAF, Zanchin NIT, Carneiro CM, Reis AB, Santos FLN. *Vet Parasitol.* 2026 Oct 9;348:110941. doi: 10.1016/j.vetpar.2026.110941. Online ahead of print. PMID: 42863257

[Identification of three novel overlapping epitopes within the immunodominant region of ASFV p30 protein facilitates development of a competitive ELISA for antibody detection.](#)

Li X, Niu Q, Wang J, Zou X, Sun H, Yin H, Dou S, Guan G, Yang J. *Virology.* 2026 Oct;623:111026. doi: 10.1016/j.virol.2026.111026. Epub 2026 Jul 8. PMID: 42430997

[From Selective Prophylaxis to Broad Infant RSV Protection: A Bibliometric Analysis and Evidence Gap Map, 1998-2025.](#)

[COVID-19 vaccination and immunoreactant deposition in non-autoimmune oral mucosal pathologies.](#)

Alawi F, Davila A, Carrasco-Labra A, Sollecito TP, Kulkarni R. Oral Surg Oral Med Oral Pathol Oral Radiol. 2026 Oct;142(4):616-623. doi: 10.1016/j.oooo.2026.04.005. Epub 2026 Apr 22. PMID: 42128785 **Free article.**

[Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.](#)

Yoo GS, Jeong JU, Lee JH, Ahn YC, Chang AR, Chie EK, Rim CH, Lim AR; Korean Cancer Association Oligometastasis Working Group. Cancer Res Treat. 2026 Oct 8. doi: 10.4143/crt.2026.0730. Online ahead of print. PMID: 42845030

[Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review.](#)

Verma KK. Crit Rev Oncol Hematol. 2026 Oct;226:105512. doi: 10.1016/j.critrevonc.2026.105512. Epub 2026 Aug 1. PMID: 42542196

[TBC1D14 positively regulates autophagy induced by Brucella melitensis vaccine strain BA0711 in Sheep Leydig Cells.](#)

Cheng Y, Niu S, Zhang Z, Qian H, Huang Z, Jing H, Liao L, Man C, Gao H, Chen Q, Du L, Chen S, Wang F. Microb Pathog. 2026 Oct;219:108664. doi: 10.1016/j.micpath.2026.108664. Epub 2026 Jul 16. PMID: 42463075

[Structure-guided design of ionizable lipids with distinct amine headgroups for muscle-selective mRNA delivery and enhanced antitumor immunotherapy.](#)

Lv H, Liu W, Zhang M, Gao X, Liu F, Yang C. Colloids Surf B Biointerfaces. 2026 Oct;266:115810. doi: 10.1016/j.colsurfb.2026.115810. Epub 2026 May 13. PMID: 42142472

[Global epidemiology of hepatitis B virus infection in dialysis patients: a systematic review and meta-analysis of prevalence, immunity, risk factors, and beyond.](#)

Pranto AH, Suez E, Uddin ME, Tonmoy HS, Meem MMRM, Montasir F, Nourin F, Ahmed F, Abir SN, Islam DZ, Ajmal M, Begum R, Khandker SS. Int Urol Nephrol. 2026 Oct;58(10):4253-4278. doi: 10.1007/s11255-026-05112-5. Epub 2026 Mar 25. PMID: 41880131

[Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.](#)

Hama MA, Madhat MA, Awlqadr FH, Mahmood AHA, Abdalla RA, Ali RK, Kareem SHT, Hama NE, Hamalaw SR, Al-Farga AM. Med Oncol. 2026 Oct 8;43(11):313. doi: 10.1007/s12032-026-03396-2. PMID: 42848277

[Multiomics reveals alterations in the gut microbiome, host proteins, and host metabolites correlating with SARS-CoV pathogenicity and the immune response in piglets.](#)

Tang X, Chao H, Li C, Sun J, Li W, Sun Y, Lan T, Ma J. Virol Sin. 2026 Oct 6:S1995-820X(26)00177-X. doi: 10.1016/j.virs.2026.10.001. Online ahead of print. PMID: 42838398

[Monophosphoryl lipid A, the Toll-like receptor 4 agonist, mitigates acute radiation syndrome via hematopoietic stem cells regeneration.](#)

Ji HJ, Kwon Y, Lee JH, Ahn KB, Park HR, Seo HS. *Biomed Pharmacother.* 2026 Oct;203:119931. doi: 10.1016/j.biopha.2026.119931. Epub 2026 Sep 12. PMID: 42731511

[Chicken viperin inhibits fowl adenovirus serotype 4 replication and affects related innate immune signaling pathways.](#)

Wan L, Wang S, Zeng T, Wang C, Ya H, Ren H, Chen Z, Fan Q, Li M, Xie Z, Luo S, Yan M, Xie L. *Poult Sci.* 2026 Oct;105(10):107374. doi: 10.1016/j.psj.2026.107374. Epub 2026 Jul 2. PMID: 42462452

[A double-antibody sandwich ELISA based on nanobody against the viral spike protein detects porcine epidemic diarrhea virus.](#)

Wang D, Yu R, Zhang L, Zhang Z, Zhou P, Guo H, Li X, Lan X, Song C, Ju J, Pan L, Wang Y, Liu X. *J Virol Methods.* 2026 Oct 7;347:115480. doi: 10.1016/j.jviromet.2026.115480. Online ahead of print. PMID: 42843568

[High prevalence of human papillomavirus at different steps of assisted reproductive procedures.](#)

Mery L, Ghazi M, Detoc M, Charaoui S, Pillet S, Labruyere C, Presles E, Gonzalo S, Jacquet J, Chansel-Debordeaux L, Garrigue I, Pozzetto B, Cottier M, Chauleur C, Aknin I, Klein JP, Bourlet T. *J Clin Virol.* 2026 Oct 3;187:106015. doi: 10.1016/j.jcv.2026.106015. Online ahead of print. PMID: 42843290

[Llama mRNA-LNP immunization enables rapid isolation of target specific nanobodies using cell-based panning.](#)

Bélanger K, Callaghan D, Renner T, Azizi H, Hu J, Raphael S, Goneau MF, Hussack G, McCluskie MJ, Akache B. *Antib Ther.* 2026 Jun 11;9(4):480-494. doi: 10.1093/abt/tbag033. eCollection 2026 Oct. PMID: 42824824

[Myth-busting influenza and fear of adverse reactions in healthcare workers: two experimental studies on vaccination intentions.](#)

Bott L, Liu J, Challenger A, Powell E, Sumner P. *Vaccine.* 2026 Oct 3;91:129086. doi: 10.1016/j.vaccine.2026.129086. Epub 2026 Aug 28. PMID: 42664528

[Trends in HIV/AIDS Knowledge and Self-Testing Preferences Among College Students: A Five-Year Repeated Cross-Sectional Survey in Shenzhen, China.](#)

Song A, Wang H, Fan R, Liu J, Liao Y, Yin D, Wu N, Ye W, Sun C, Yuan J. *AIDS Res Hum Retroviruses.* 2026 Oct-Nov;42(10-11):298-306. doi: 10.1177/08892229261479805. Epub 2026 Aug 20. PMID: 42619613

[Oral or nasal immunization of piglets with porcine epidemic diarrhea virus \(PEDV\) S1 protein bacterial-like particles induces robust intestinal mucosal immune responses and provides reliable protection.](#)

Su K, Ren J, Wang Y, Yuan C, Zhang Y, Fan T, Liu Z, Sun T, Yang L, Wang X, Song Q. *Vet Microbiol.* 2026 Oct;321:111173. doi: 10.1016/j.vetmic.2026.111173. Epub 2026 Aug 12. PMID: 42600389

[The use of subtractive proteomics and comparative genomics prioritizes novel therapeutic targets in *Salmonella* *Infantis*.](#)

Garrido-Palazuelos LI, Aguirre-Sánchez JR, Soto-Gamboa M, Guerra-Meza O. *Int J Environ Health Res.* 2026 Oct;36(10):2932-2947. doi: 10.1080/09603123.2026.2662518. Epub 2026 Apr 23. PMID: 42026984

[A single-cell profile of the porcine immune repertoire: concurrent profiling of T cell receptor and B cell receptor V\(D\)J sequences in health.](#)

Zhang H, Zhang Q, Zhang H, Wang P, Geng R, Pan R, Li C, Shi F, Liu J, Wu Y, Cao Y. *Adv Biotechnol (Singap).* 2026 Oct 9;4(4):38. doi: 10.1007/s44307-026-00139-2. PMID: 42850485

[Recombinant L1R protein induces cross-neutralizing antibodies against capripoxviruses despite a subdominant humoral response.](#)

Kumar A, Karki M, Kushwaha A, Kumar AP, Goulmei P, Kelwan AP, Goswami D, Venkatesan G, Dhar P. *Microb Pathog.* 2026 Oct;219:108715. doi: 10.1016/j.micpath.2026.108715. Epub 2026 Jul 17. PMID: 42468748

[Mild exogenous inflammation reduces dynamic small-world topology in resting-state brain networks of healthy males.](#)

Queirazza F, Krishnadas R. *Brain Behav Immun.* 2026 Oct;137:106880. doi: 10.1016/j.bbi.2026.106880. Epub 2026 Jun 20. PMID: 42323056

[Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.](#)

Bähner F, Faust SN, Davies LRL, Blokhina O, Brandon DM, Smith WB, Chatterjee VKK, Hassanin H, Babu TM, Zuiani A, Steinhauser S, Poran A, Brittain C, Mucker E, Hooper JW, van der Most RG, Alonso PL, Türeci Ö, Mensa FJ, Şahin U. *Lancet Infect Dis.* 2026 Oct;26(10):1045-1057. doi: 10.1016/S1473-3099(26)00177-5. Epub 2026 Jun 3. PMID: 42235570

[Protein secretion by the type IV pilus machinery in *Francisella tularensis*.](#)

DeRosa A, Benziger PT, Sampath V, Kopping EJ, Kim H, Thanassi DG. *J Bacteriol.* 2026 Oct 6:e0025326. doi: 10.1128/jb.00253-26. Online ahead of print. PMID: 42836839

[Resurgence and molecular epidemiology of dengue virus serotype 4 amid the COVID-19 pandemic in Thailand.](#)

Obaga LB, Boondouylan T, Nuwong W, Horthongkham N, Suwannakarn K, Ajawatanawong P, Athiprayoon P, Boonmee A, Tanlieng N, Sayasit K, Chaimayo C. *J Clin Virol.* 2026 Oct;186:106004. doi: 10.1016/j.jcv.2026.106004. Epub 2026 Sep 15. PMID: 42753459

[Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.](#)

Li E, Butkovich N, Tucker JA, Nelson EL, Wang SW. *Biomaterials.* 2026 Oct;333:124128. doi: 10.1016/j.biomaterials.2026.124128. Epub 2026 Mar 14. PMID: 41946315

[Gathering Insights About Sexual Health Promotion From Adolescents' Adoption of COVID-19-Protective Behaviors.](#)

Nelson KM, Bond JC, Dunsiger SI, Haiken S, Alcid C, Ranker LR, Ybarra ML. *Health Educ Behav.* 2026 Oct;53(5):541-550. doi: 10.1177/10901981261426309. Epub 2026 Mar 22. PMID: 41865297

[Sigma-1 Receptor-Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models.](#)

Zhang C, Dong X, Liu J, Chen M, Lin L, Song G, Xia X, Su G, Li X, Shang C. *J Med Virol.* 2026 Oct;98(10):e71123. doi: 10.1002/jmv.71123. PMID: 42856001

[Paediatric mpox during Sierra Leone's 2024 to 2025 clade IIb outbreak: A national surveillance and outbreak-investigation study of 415 children.](#)

Ikoona EN, Namulemo L, Sinnah MM, Vandi MA, Sahr F. *PLoS Negl Trop Dis.* 2026 Oct 7;20(10):e0014785. doi: 10.1371/journal.pntd.0014785. Online ahead of print. PMID: 42842633

[Evaluating the impact of a rheumatologist-led comorbidity review in patients with inflammatory arthritis.](#)

Kobza A, Bourgeois-Avella C, Fogel O, Dougados M, Moltó A. *Joint Bone Spine.* 2026 Oct;93(5):106089. doi: 10.1016/j.jbspin.2026.106089. Epub 2026 Jun 23. PMID: 42336196

[Identification of enteric viral pathogens in Tanzanian children under the age of five with diarrhea using nanopore-based metagenomic sequencing.](#)

Shayo MJ, Kuchaka D, Beti M, Kimu P, Wadugu B, Jensen EEB, Kumburu H, Kazyoba P, Ali M; SeqTZ Consortium; Clausen PTL, Muro F, Mmbaga BT, Kiwelu I, Alifrangis M, Aarestrup FM, Sonda T. *Virology.* 2026 Oct;623:111024. doi: 10.1016/j.virol.2026.111024. Epub 2026 Jul 10. PMID: 42442081

[Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route.](#)

Mandviwala AS, Liman K, Huckriede ALW, Mishra AC, Patil HP. *Virology.* 2026 Oct;623:111007. doi: 10.1016/j.virol.2026.111007. Epub 2026 Jun 13. PMID: 42314330

[\[Herpes Simplex Virus and Varicella-Zoster Virus Keratitis\].](#)

Szentmáry N, Della Volpe Waizel M, Élő Á, Rickmann A, Kahlert J, Fries FN, Saternus R, Seitz B. *Klin Monbl Augenheilkd.* 2026 Oct 2. doi: 10.1055/a-2857-9740. Online ahead of print. PMID: 42826726

[Extracorporeal membrane oxygenation for life-threatening measles in children: a case series.](#)

Watad S, Avniel Aran A, Mandel A, Langer Y, Weinblatt E, Manaster I, Barsoum N, Dorozko SE, Averbuch D, Gordon O, Pollak U. *Eur J Pediatr.* 2026 Oct 1;185(10):791. doi: 10.1007/s00431-026-07467-4. PMID: 42821145

[Application of mRNA vaccines in head and neck cancer immunotherapy: Current progress and challenges.](#)

Wu L, Liu H, Wang Z, Yan J, Xu K, Ye D, Zhu Z, Xiang Y, Zhang J. *Crit Rev Oncol Hematol.* 2026 Oct;226:105501. doi: 10.1016/j.critrevonc.2026.105501. Epub 2026 Jul 28. PMID: 42520865

[Association of COVID-19 vaccination with improved treatment adherence in patients with schizophrenia: A propensity score-matched cohort study.](#)

Jung S, Lee DH, Hong M, Kim MK, Shin W. *Schizophr Res.* 2026 Oct;296:111-120. doi: 10.1016/j.schres.2026.07.008. Epub 2026 Jul 15. PMID: 42456570

[Maternal and neonatal outcomes in The Gambia, 2022-2024: prospective pregnancy surveillance to strengthen maternal immunization safety monitoring.](#)

Okomo U, Longley AT, Nkereuwem O, Kochhar S, Nyassi MT, Bittaye M, Marena M, Fofana S, Jarju G, Shaum A, Gidudu J, Kampmann B. *Vaccine.* 2026 Oct 10;94:129235. doi: 10.1016/j.vaccine.2026.129235. Online ahead of print. PMID: 42858678

[Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.](#)

Aminu K, Amzat J, Nwebo RA, Nnannah PC, Ezeagu CN, Edukugho AA, Omobowale O, Shehu A, Jayasinghe YA, Amzat G, Kanmodi KK. *Health Sci Rep.* 2026 Sep 25;9(10):e73254. doi: 10.1002/hsr2.73254. eCollection 2026 Oct. PMID: 42799168

[Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.](#)

Choi SH, Huh JW, Hong SB, Sung H, Do KH, Lee SO, Lim CM, Koh Y. *Tuberc Respir Dis (Seoul).* 2026 Oct;89(4):553-563. doi: 10.4046/trd.2026.0003. Epub 2026 Aug 10. PMID: 42572802

[Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake, the Netherlands, 2016 to 2025.](#)

Pijpers J, Haverkate M, van Gaalen R, Hahné S, de Melker H, van den Hof S. *Euro Surveill.* 2026 Oct;31(40):2600159. doi: 10.2807/1560-7917.ES.2026.31.40.2600159. PMID: 42852520

[Cryo-EM Analysis of Adenovirus Vector Reveals Purification Conditions Leading to Loss of Viral Fiber Proteins and Reduced Infectivity.](#)

Widdicombe B, Barritt JD, Pipatpadungsinn N, Sanchez BC, Stibbs D, Cooper L, Rouse SL, Bracewell DG. *Biotechnol Bioeng.* 2026 Oct 6. doi: 10.1002/bit.70407. Online ahead of print. PMID: 42837313

[The effect of HPV vaccination on precancerous lesions and invasive cervical cancer in a low-vaccination-coverage setting in Germany: a retrospective cohort analysis.](#)

Baffour Awuah G, Fett S, Schauburger G, Osmani V, Tauscher M, Röbl-Mathieu M, Kiechle M, Klug SJ. *Lancet Reg Health Eur.* 2026 Aug 26;69:101830. doi: 10.1016/j.lanepe.2026.101830. eCollection 2026 Oct. PMID: 42699790

[Gallic acid-usnic acid complex alleviates necrotic enteritis in broilers by remodeling gut microbiota and strengthening intestinal barrier.](#)

Guo X, Zhao Z, He S, Lv Z, Guo Y, Nie W. *Poult Sci.* 2026 Oct;105(10):107412. doi: 10.1016/j.psj.2026.107412. Epub 2026 Jul 8. PMID: 42456322

[T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.](#)

Terada T, Suzuki T, Ohnuki K, Yoshikawa T, Shimomura M, Shoda K, Amaishi Y, Takeichi K, Kudo M, Sugimoto M, Kobayashi S, Takenouchi K, Tsukamoto N, Gotohda N, Okamoto S, Nakatsura T. *Cancer Lett.* 2026 Oct 1;657:218695. doi: 10.1016/j.canlet.2026.218695. Epub 2026 Jun 26. PMID: 42362103

[Invasive Pneumococcal Disease in Children: A Retrospective Three-Center Study in Zhejiang Province, China \(2010-2024\).](#)

Zhu YY, Zhou JS, Yang JH, Lu ZJ, Fang C, Zhou MM, Yao KH, Li XY, Sun AL, Catusse J, Dunne EM, Hua CZ. *Infect Dis Ther.* 2026 Oct 7. doi: 10.1007/s40121-026-01454-w. Online ahead of print. PMID: 42842080

[Trends of congenital rubella syndrome among infants \(0-11 months old\) in India: a multicentre hospital-based sentinel surveillance \(2016-2025\).](#)

Shanmugasundaram D, Verma S, Tripathi S, Dwibedi B, Singh K, Mahantesh S, Malik S, Singh H, Santhanam S, Mondal N, Sinha MK, Jain M, Chowdhary BK, Vishwanathan R, Pawar SD, Sapkal G, Som TK, Kumar A, Pati S, Datta S, Ramasamy S, Rajendran PP, Singh MP, Ratho RK, Shukla S, Mishra B, Gadepalli R, Nag VL, Munivenkatappa A, Biswas D, Devara SM, Vannavada SR, Abraham AM, Dhodapkar R, Ray R, Pati BK, Sreenivasan P, Geetha S, Bavdekar A, Prakash J, Ray J, Gupta M, Rohit MK, Sankhyan N, Gupta PC, Kumar P, Munjal SK, Naganur SH, Sharma A, Agarwal S, Verma V, Sahoo A, Gupta N, Priyanka P, Augustine AM, John D, Kumar M, Bethou A, Alexander A, Anantharaj A, Kasturi N, Gupta D, Chowdhoury SR, Mukherjee S, Basu S, Prasad A, Raj A, Bhavana K, Nalavade U, Rane SV, Murhekar M. *Lancet Reg Health Southeast Asia.* 2026 Aug 11;53:100839. doi: 10.1016/j.lansea.2026.100839. eCollection 2026 Oct. PMID: 42707121

[Phylogeography and molecular evolution of Newcastle disease virus across a century of global surveillance.](#)

Ul-Rahman A, Shabbir MZ, Munir M. *Virus Res.* 2026 Oct;372:199783. doi: 10.1016/j.virusres.2026.199783. Epub 2026 Aug 11. PMID: 42580484

[Hepatitis B Virus Infection Status in Japanese Children Prior to Universal Vaccination: Sustained Effectiveness of Mother-to-Child Transmission Prevention and Residual Infection Burden.](#)

Sakai A, Tanaka Y, Yotsuyanagi H, Sugiyama M, Morioka I, Kosugiyama K, Uetake K, Katsuta T, Imamura A, Takano T, Tajiri H, Ishida A, Ushijima K, Nakashima Y, Moriuchi H, Iwane S, Sawada K, Shimizu Y, Uemura Y, Tagawa M, Mizokami M, Sumazaki R. *Hepatol Res.* 2026 Oct;56(10):1457-1465. doi: 10.1111/hepr.70212. Epub 2026 Jul 1. PMID: 42383420

[Electrostatically assembled CaO₂@MPN-HA nanoreactors potentiate anti-PD-1 therapy in thyroid cancer via synergistic ferroptosis and calcium overload.](#)

Hu Y, Liu L, Li Z, Liu J, Yang C, Shao L. *Colloids Surf B Biointerfaces.* 2026 Oct;266:115767. doi: 10.1016/j.colsurfb.2026.115767. Epub 2026 May 3. PMID: 42140130

[iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy.](#)

Kumar A, Dwivedi D, Ghosh N, Gopalakrishnan K, Rahamathulla M, Ahmed MM, Nair C, Singh D, Singh R, Das U. *Mol Immunol.* 2026 Oct;198:98-120. doi: 10.1016/j.molimm.2026.08.008. Epub 2026 Aug 13. PMID: 42594762

[Bacillus Calmette-Guérin Vaccination and SARS-CoV-2 Infection among Healthcare Workers: A Case-Control Study in Cape Verde.](#)

Cortes J, Monteiro TJ, Monteiro K, Monteiro J, Monteiro O, Spencer JL, Vicente J, Nhamússua L, Ca E, Silva I, Nielsen S, Schaltz-Buchholzer F, Lima Mendonça ML, Ferrinho PLGM, Delgado AP, Stabell Benn C, Aide P, Monteiro de Pina Araújo II, Fronteira I. *Port J Public Health*. 2026 May 21;44(2):109-119. doi: 10.1159/000550531. eCollection 2026 Oct. PMID: 42294404

[\[Utilizing administrative data to enhance the Health Management Support Program for public assistance recipients aged <40 years: Lessons from Toyonaka City\].](#)

Takemoto S, Nishioka D. *Nihon Koshu Eisei Zasshi*. 2026 Oct 5;73(9):792-800. doi: 10.11236/jph.25-107. Epub 2026 Apr 22. PMID: 42021055

[Invasive Haemophilus Influenzae Infection in Children: Clinical Characteristics, Serotypes and Outcome: A Multicenter Study in Oman.](#)

AlRawahi A, Al Yazidi L, Al Rashdi A, Al Reesi M, Al Abdali K, Al Amri H, Altahir N, Al Habsi R, Al Nadhairi Z, Al Sidari H, Al Jardani A, Al-Sumri S, Al Bulushi N, Mahrami ZA, Al Mamari M, AlWaili B. *Pediatr Infect Dis J*. 2026 Oct 6. doi: 10.1097/INF.0000000000005431. Online ahead of print. PMID: 42837147

[Unmasking human T cell receptor germline diversity: 335 novel alleles identified in 47 Pangenome reference individuals using the gAIRR Suite.](#)

Yang YH, Yao CY, Lin MJ, Huang KT, Lin YH, Huang YH, Chiu IH, Lai SK, Chen CY, Yang YC, Hsu CL, Hsu JS, Chen CY, Chen PL. *J Adv Res*. 2026 Oct;88:437-452. doi: 10.1016/j.jare.2026.01.053. Epub 2026 Jan 30. PMID: 41621533

[African swine fever virus protein R298L opposes the NF-κB signaling pathway and interferon-mediated pathway.](#)

Yang ZY, Ding MY, Chen X, Ling XH, Fan S, Zhu ZX, Zhang YH, Han SC, He WR, Zheng HX, Zhang GP, Wan B. *Vet Microbiol*. 2026 Oct 8;322:111243. doi: 10.1016/j.vetmic.2026.111243. Online ahead of print. PMID: 42863326

[Increased risk of pulmonary embolism following SARS-CoV-2 activity in Ontario, Canada.](#)

Lee CE, Wilson NJ, Fisman DN. *Public Health*. 2026 Oct;259:106463. doi: 10.1016/j.puhe.2026.106463. Epub 2026 Aug 25. PMID: 42641300

[Eimeria in chickens: Recent advances in host-pathogen interactions, molecular insights, and control strategies.](#)

Zhen Z, Baihe M, Meiliang G, Shuhua L, Lianrui L. *Vet Parasitol*. 2026 Oct;347:110894. doi: 10.1016/j.vetpar.2026.110894. Epub 2026 Aug 22. PMID: 42641196

[Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.](#)

Bamberg S, Schulte-Frankenfeld PM, Kreye J. Brain Behav Immun Health. 2026 Jul 6;56:101301. doi: 10.1016/j.bbih.2026.101301. eCollection 2026 Oct. PMID: 42473682

[Discovery and biological characterization of 1-\[4-\(2-difluoromethoxyphenyl\)-5-methylthiazol-2-yl\]-3-\(naphthalen-1-yl\)urea \(DFMNTU\): A novel thiazolyl-urea chemotype targeting yellow fever virus and host casein kinase 2 \(CK2\).](#)

Demchenko A, Martynov A, Volynets G, Bdzhola V, Mahdysiuk M, Demchenko S, Yarmoluk S, Zaporozhets D, Sukhovieiev V, Usenko M, Gorbatiuk O, Antonenko SV, Zaitsev V. Eur J Pharm Sci. 2026 Oct 3;227:107679. doi: 10.1016/j.ejps.2026.107679. Online ahead of print. PMID: 42829118

[CodeMergeR: A Shiny-Based Application for Codelist Integration.](#)

Hoxhaj V, Riera-Arnau J, Mohammadi S, Sturkenboom MCJM, Andaur Navarro CL. Pharmacoepidemiol Drug Saf. 2026 Oct;35(10):e70491. doi: 10.1002/pds.70491. PMID: 42806513

[Characterisation of HIV-1 Gag Cytotoxic T-Lymphocyte Epitopes in the Southern African Region-A Systematic Review.](#)

Fortuin TL, Nkone P, Loubser S, Tiemessen CT, Mayaphi SH. Immunology. 2026 Oct;179(2):165-184. doi: 10.1111/imm.70156. Epub 2026 May 31. PMID: 42219374

[Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.](#)

Butfield R, Rai KK, Jennison T, Said J, Wright H, Sethi D, Watkins J, Geneidat A, Jimenez I, Wiseman D. Infect Dis Ther. 2026 Oct 6. doi: 10.1007/s40121-026-01447-9. Online ahead of print. PMID: 42836949

[A bireporter recombinant SARS-CoV-2 Omicron BA.5 for *in vitro* and *in vivo* studies.](#)

Castro EM, Barre RS, Ye C, Imbiakha B, Ezzatpour S, Cupic A, Walter MR, Kobie JJ, K Plemper R, García-Sastre A, Elsayed AM, Aguilar HC, Martinez-Sobrido L. Microbiol Spectr. 2026 Oct 6;14(10):e0021726. doi: 10.1128/spectrum.00217-26. Epub 2026 Sep 10. PMID: 42720299

[Probe-based metagenomic sentinel surveillance of viral respiratory infections in primary care: a prospective, national, pilot study.](#)

Mourik K, Sidorov I, Meijers E, van den Brink S, Bos S, Aarts L, Veetil NK, Boers SA, Eggink D, Meijer A, de Vries JJC. Lancet Microbe. 2026 Oct;7(10):101473. doi: 10.1016/j.lanmic.2026.101473. Epub 2026 Aug 6. PMID: 42561992

[Causes of mortality and severe morbidity in young children in Sierra Leone: a prospective cohort study.](#)

Owusu-Kyei K, Cussó M, Fombah AE, Quintó L, Bofill A, Morató A, Fumadó V, Samai M, Menéndez C; ICARIA Safety Team. Lancet Glob Health. 2026 Oct;14(10):104025. doi: 10.1016/j.langlo.2026.104025. Epub 2026 Aug 10. PMID: 42575116

[Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.](#)

Choi Y, Jacobs DR Jr, Kramer HJ, Coresh J, Cushman M, Reiner AP, Demmer RT, Tracy RP, Sun Y, Balte PP, Raffield LM, Min YI, Vasan RS, Xanthakis V, Regan EA, Kanaya AM, Lash JP, Umans JG, Oelsner

EC.Am J Kidney Dis. 2026 Oct;88(4):531-544.e1. doi: 10.1053/j.ajkd.2026.04.011. Epub 2026 Jun 26.PMID: 42362101

[Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study.](#)

Ren S, Cong B, Zou J, Guo L, Nair H, Sparrow E, Feikin DR, Li Y.EClinicalMedicine. 2026 Sep 23;100:104219. doi: 10.1016/j.eclinm.2026.104219. eCollection 2026 Oct.PMID: 42831028

Patentes registradas en Patentscope

Estrategia de búsqueda: (Vaccine) AND DP:([01.10.2026 TO 12.10.2026]) as the publication date 65 records.

1.WO/2026/206152UBIQUITIN VACCINE COMPONENTS

WO - 01.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/NL2026/050087Solicitante ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)Inventor/a VERDOES, Martijn

Provided herein is a vaccine component comprising a ubiquitin covalently bonded to an antigen, wherein the vaccine component does not comprise a cell permeability tag; as well as vaccines comprising such a vaccine component. The vaccine component may be useful in the activation of dendritic cells. Also provided are combinations comprising such a vaccine component or vaccine and a biologically active substance; and formulations comprising such a vaccine component, vaccine, or combination. The vaccine component, vaccine, combination, or formulation may be used as a medicament, for example in the treatment of a condition selected from a cancer and an autoimmune disease.

2.20260306605INHALED ADENOVIRUS VECTOR VACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF

US - 08.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19476109Solicitante CANSINO BIOLOGICS INC.Inventor/a Xiaolong ZHAO

The present invention relates to an inhaled aerosol vaccine, and in particular to a recombinant adenovirus vector inhaled aerosol vaccine, a preparation method therefor and a use thereof. The inhaled aerosol vaccine can simultaneously express one or more antigens. After inhaling and mucosal immunization are carried out on the body, a high-level specific antibody can be generated in the lung and the body at the same time, and a high cell immune response can be generated by means of stimulation. In addition, the vaccine is an inhaled preparation, which can effectively stimulate mucosal immunization and increase the third protection of the body. The recombinant adenovirus vector vaccine has good stability, is safe, efficient and painless, and can effectively cope with the recurrence of emerging infections and latent infections of bacteria and viruses.

3.20260306620TUMOR NEOANTIGEN VACCINE SYSTEM SPECIFICALLY MARKING HETEROLOGOUS PROTEIN, AND USE THEREOF

US - 08.10.2026

Clasificación Internacional A61K 39/29Nº de solicitud 19643770Solicitante CHINA PHARMACEUTICAL UNIVERSITYInventor/a Yong YANG

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

4. 20260306611DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYS

US - 08.10.2026

Clasificación Internacional A61K 39/145Nº de solicitud 19432665Solicitante Vaxxas Pty LimitedInventor/a Michael Carl JUNGER

The present invention relates to devices and methods for coating microprojection or microneedle arrays including arrays that contain vaccine formulations, more specifically to multivalent vaccine formulations where components of the multivalent vaccine might be incompatible. The present invention further relates to stable vaccine formulations for administration via a microprojection array in which the microprojections are densely packed and in which the vaccine formulations are sprayed on to the microprojections such that the formulations dry quickly.

5. 4817626VARICELLA-ZOSTER-IMPfstoffzusammensetzung und Verwendung davon

EP - 07.10.2026

Clasificación Internacional A61K 39/25Nº de solicitud 24896640Solicitante HUAPU SHIJIAZHONG PHARMACEUTICAL CO LTDInventor/a WANG XINZHONG

A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.

6. WO/2026/213490NOVEL BAT INFLUENZA A VIRUS-VECTORED MERS VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

WO - 08.10.2026

Clasificación Internacional A61K 39/215Nº de solicitud PCT/US2026/022203Solicitante THE CURATORS OF THE UNIVERSITY OF MISSOURIIInventor/a MA, Wenjun

Described herein is a novel bat influenza A virus-based **vaccine** vector modified by replacing the open reading frame of either bat influenza hemagglutinin or neuraminidase with that of hemagglutinin-esterase-fusion gene from influenza D virus that can infect multiple species including humans and camels. A temperature-sensitive, cold-adapted and attenuated MERS **vaccine** candidate expressing the clade A MERS-CoV spike S1 was then developed, referred to as Len_S1, using the developed bat influenza vector and demonstrated its safety and immunogenicity. A single-dose intranasal immunization with Len_S1 was able to protect hDPP4 transgenic mice from a lethal MERS-CoV challenge. Notably, two-dose immunization with Len_S1 completely blocked viral replication and lung damage of challenged mice. Len_S1 is a safe and effective MERS **vaccine** that can induce a comprehensive immune response and provide cross-protection against different clades of MERS-CoVs.

7.20260306625TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION

US - 08.10.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19709661Solicitante BIONTECH SEInventor/a Ugur SAHIN

The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding **vaccine** antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding **vaccine** antigen may provide (following expression of the RNA by appropriate target cells) **vaccine** antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against **vaccine** antigen (and disease-associated antigen) in the subject.

8.WO/2026/208866ARF-BASED VACCINES FOR ENHANCING LIFESPAN AND REDUCING AGE-RELATED PATHOLOGIES IN AGING INDIVIDUALS

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2026/087476Solicitante THE UNIVERSITY OF HONG KONGInventor/a HUANG, Jiandong

Provided herein is a **vaccine** composition for inducing a T-cell-mediated immune response against senescent cells expressing Arf protein. The **vaccine** comprises one or more T-cell epitopes derived from an Arf protein or a fragment thereof, optionally formulated with an adjuvant such as Poly (I: C). The **vaccine** composition can be used to treat age-related conditions by eliminating Arf-positive senescent cells, reducing inflammation, oxidative stress, and bone degeneration, and extending lifespan. Administration of the **vaccine** can lead to lifespan extension, improved bone mineral density, reduced oxidative stress, and decreased expression of senescence-related gene.

9.WO/2026/213360CANCER **VACCINE** COMBINATION TREATMENTS

WO - 08.10.2026

Clasificación Internacional A61K 35/12Nº de solicitud PCT/US2026/022002Solicitante PHOTONPHARMA, INC.Inventor/a GOODRICH, Raymond P.

Provided herein are methods for the treatment of a disease or disorder, such as cancer, comprising administering to a subject a cancer vaccine and an anti-angiogenic agent. Also provided herein are related compositions for use in treatment of cancer. The cancer vaccine comprises inactivated whole cells, which may be prepared by exposing cells to UV light in the presence of riboflavin, a chemical process which renders the cells replication incompetent.

10.20260306614VACCINE COMPOSITIONS

US - 08.10.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19476020Solicitante SAIL BIOMEDICINES, INC.Inventor/a Emad ARAFA

Disclosed herein are nucleic acid vaccine compositions including one or more polynucleotides encoding one or more antigenic polypeptide, formulated within a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a nucleic acid vaccine, comprising reconstituting a film comprising purified NMP lipids in the presence of an ionizable lipid to produce a LNMP comprising the ionizable lipid, and loading into the LNMPs with one or more polynucleotides encoding one or more antigenic polypeptides.

11.20260306618A VACCINE AGAINST ERYSIPELOTHRIX RHUSIOPATHIAE AND PORCINE PARVO VIRUS

US - 08.10.2026

Clasificación Internacional A61K 39/23Nº de solicitud 19482058Solicitante INTERVET INC.Inventor/a Antonius Arnoldus Christiaan JACOBS

The invention pertains to the use of a vaccine comprising a non-replicating immunogen of *Erysipelothrix rhusiopathiae* and a non-replicating immunogen of porcine parvo virus, in prophylactically treating a pig against an infection with *Erysipelothrix rhusiopathiae* and an infection with porcine parvo virus, by injection of the first vaccine into the dermis of the pig.

12.20260294828CALIXARENE-BASED DELIVERY SYSTEM AND METHOD OF USE

US - 01.10.2026

Clasificación Internacional A61K 9/51Nº de solicitud 19479327Solicitante QUANTOOM BIOSCIENCES S.A.Inventor/a Aurélien VANDER STRAETEN

The current invention relates to a delivery system to deliver one or more cargo to one or more cells, wherein the cargo delivery system comprises at least a calixarene, a phospholipid, an additional lipid such as sterol. The invention further relates to a method of delivering cargo to a subject using the delivery system and a pharmaceutical composition comprising the delivery system. The invention also relates to the use of a calixarene in an immunogenic composition, wherein said composition comprises an immunogenic component encapsulated in a lipid nanoparticle (LNP) comprising said calixarene and wherein said LNP has an adjuvant effect in said immunogenic composition. The invention also relates to a vaccine, wherein

said **vaccine** comprises an immunogenic component encapsulated in a lipid nanoparticle, wherein said lipid nanoparticle comprises at least one calixarene molecule and said lipid nanoparticle acts as an adjuvant in said **vaccine**. The invention also relates to a method of preparing an immunogenic composition and a composition comprising a lipid nanoparticle (LNP) adjuvant comprising calixarene.

13. WO/2026/206447 METHODS OF DETECTING, IDENTIFYING AND QUANTIFYING WILD SPIKE PROTEIN AND COVID **VACCINE** SPIKE PROTEINS

WO - 01.10.2026

Clasificación Internacional C12Q 1/70Nº de solicitud PCT/US2026/013420 Solicitante WOLF OF ZION, INC. Inventor/a RUDDY, Kathleen T.

A method of detecting, identifying and quantifying a wild spike protein and/or virus **vaccine** spike protein in a patient by: (a) providing a patient sample that may include at least one spike protein (wild spike protein and/or a virus **vaccine** spike protein) with at least one corresponding synthetic RNA, wherein its sequence differs from natural nucleic acid sequences; (b) isolating RNA from the sample; (c) performing a reverse transcription polymerase reaction on the sample of RNA to obtain a lysed, reverse transcribed sample of cDNA utilizing at least one primer set from the group consisting of VAXX-specific primers, wild spike protein-specific primers and combinations thereof, and at least one probe set; (d) performing an amplification reaction on the lysed, reverse transcribed sample of cDNA to obtain an amplified analyzable sample of the cDNA; and, (e) performing a quantitative analysis. A custom computer program creates candidate primer lists.

14. WO/2026/209607 **VACCINE** COMBINATION, PREPARATION AND USES THEREOF

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2026/059134 Solicitante NANOBIOTIX (NANOBIOTIX S.A.) Inventor/a DEVALLIERE, Julie

The present invention relates to a pharmaceutical combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a nanoparticle whose surface exposes a carboxyl group ($-C(=O)-OH$). This nanoparticle is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the **vaccine** effect of the substance transported by the carrier. The nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below -10 mV, and a size of about 4 nm to about 500 nm. The invention also relates to such a combination for use as a medicament in a subject in need thereof, in particular for use as a **vaccine** in the treatment of a cancer, an infection, or an immune disease.

15. WO/2026/209612 **VACCINE** COMBINATION TO OBTAIN LONG-LASTING ANTIGEN-SPECIFIC IMMUNE MEMORY, PREPARATION AND USES THEREOF

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2026/059140 Solicitante NANOBIOTIX (NANOBIOTIX S.A.) Inventor/a DEVALLIERE, Julie

The present invention relates to a combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a lipoplex having a positive or a negative surface charge whose value, expressed as an absolute value, is between about 10 mV and about 70 mV, and a size between about 100 nm and about 600 nm. This carrier is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the vaccine effect of the substance transported by the carrier. Concretely, the nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below – 10 mV, and a size of about 4 nm to about 500 nm. This combination, designed to optimize the activation of antigen-specific effector immune cells and their differentiation into long-term memory cells, may be used as a medicament in a subject in need thereof, in particular as a prophylactic or therapeutic vaccine in the context of a cancer, an infection, or an immune disease.

16. WO/2026/209609 VACCINE COMBINATION, PREPARATION AND USES THEREOF

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2026/059136 Solicitante NANOBOTIX (NANOBOTIX S.A.) Inventor/a DEVALLIERE, Julie

The present invention relates to a pharmaceutical combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a nanoparticle whose surface exposes a carboxyl group ($-C(=O)-OH$). This nanoparticle is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the vaccine effect of the substance transported by the carrier. The nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below -10 mV, and a size of about 4 nm to about 500 nm. The invention also relates to such a combination for use as a medicament in a subject in need thereof, in particular for use as a vaccine in the treatment of a cancer, an infection, or an immune disease.

17. WO/2026/205509 VACCINE ADJUVANT, COMPOSITION FOR ENHANCING PRODUCTION OF ANTIBODIES, AND COMPOSITION FOR TLR-9 ACTIVATION

WO - 01.10.2026

Clasificación Internacional A61K 39/39Nº de solicitud PCT/JP2026/012825 Solicitante MEIJI HOLDINGS CO., LTD. Inventor/a ASAMI, Yukio

Provided are a vaccine adjuvant, a composition for enhancing the production of antibodies, and a composition for activating TLR-9 that include extracellular vesicles derived from a Gram-positive bacterium with a GC content of 30% or greater in the genome thereof, a nucleic acid derived from said extracellular vesicles, or a nucleic acid derived from said Gram-positive bacterium.

18. 20260306612 INFLUENZA ESTEM IMMUNOGENS

US - 08.10.2026

Clasificación Internacional A61K 39/145Nº de solicitud 19489344Solicitante The Scripps Research InstituteInventor/a William SCHIEF

The present invention relates to influenza immunogens and a vaccine platform for influenza viruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered hemagglutinin stem sequence and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.

19.WO/2026/200974DOSING REGIMENS FOR HBV TREATMENT

WO - 01.10.2026

Clasificación Internacional A61K 31/7105Nº de solicitud PCT/CN2026/085900Solicitante AUSPER BIOPHARMA CO., LTD.Inventor/a CHENG, Guofeng

Provided herein are methods, kits, and articles of manufacture useful for treating a hepatitis B virus (HBV) infection. In some embodiments the methods comprise administering to a subject an antisense oligonucleotide specific for an HBV target and an HBV vaccine and/or an immunomodulator. In some embodiments, the methods comprise administering an antisense oligonucleotide specific for an HBV target and a siRNA specific for an HBV target. In some embodiments the methods comprise administering to a subject an antisense oligonucleotide specific for an HBV target, a siRNA specific for an HBV target, and an HBV vaccine and/or an immunomodulator. The methods and kits described herein may be useful for treating chronic HBV infection.

20.20260311803COMPUTATIONAL METHODS FOR SELECTING PERSONALIZED NEOANTIGEN VACCINES

US - 08.10.2026

Clasificación Internacional G16B 20/20Nº de solicitud 19474041Solicitante Icahn School of Medicine at Mount SinailInventor/a Tim O'DONNELL

Systems and methods for identifying a personalized tumor vaccine are provided. Somatic variants for a subject are determined and RNA sequence reads from a tumor of the subject are obtained. From the RNA sequence reads, fusion proteins are determined, each fusion protein a fusion of a portion of a first protein and a portion of a second protein. Candidate neoantigens are selected, including a first subset of candidate neoantigens encoding somatic variants and a second subset of candidate neoantigens encoding residues of the portions of the first and second proteins. A score is determined for each candidate neoantigen using a scoring function including a first scoring term that upweights candidate neoantigens having a higher relative class I MHC affinity, given a class I HLA type of the subject. Two or more candidate neoantigens are selected for the tumor vaccine as a final set of neoantigens based on the respective scores.

21.WO/2026/210440A NOVEL CHIMERIC LIVE ATTENUATED VACCINE AGAINST DENGUE VIRUSES

WO - 08.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/IB2026/053310Solicitante VAXTHERA SASInventor/a OSORIO, Jorge E.

Disclosed herein is a dengue virus **vaccine** comprising an attenuated chimeric dengue virus selected from the group consisting of: (a) a first attenuated chimeric dengue virus comprising a dengue virus serotype 1 (DENV1) mosaic protein or fragment thereof; (b) a second attenuated chimeric dengue virus comprising a dengue virus serotype 2 (DENV2) mosaic protein or fragment thereof; (c) a third attenuated chimeric dengue virus comprising a dengue virus serotype 3 (DENV3) mosaic protein or fragment thereof; (d) a fourth attenuated chimeric dengue virus comprising a dengue virus serotype 4 (DENV4) mosaic protein or fragment thereof; and (e) a combination of any two or more of the first attenuated chimeric dengue virus, the second attenuated chimeric dengue virus, the third attenuated chimeric dengue virus, or the fourth attenuated chimeric dengue virus.

22. WO/2026/207453CANINE ADENOVIRUS **VACCINE** CONSTRUCTS

WO - 01.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2026/021302Solicitante SALK INSTITUTE FOR BIOLOGICAL STUDIESInventor/a O'SHEA, Clodagh

Recombinant replication-competent canine adenovirus (CAV) **vaccine** compositions engineered to contain one or more heterologous open reading frames (ORFs) encoding heterologous antigenic proteins, such as antigenic proteins from canine distemper virus (CDV) and/or canine parainfluenza virus (CPiV), are described. The heterologous ORFs are inserted at the site of a complete or partial deletion of an E3 region of the CAV. Immunogenic compositions that include one or more of the recombinant CAV vaccines are also described. The recombinant CAVs and immunogenic compositions thereof can be used to elicit an immune response against CAV, CDV and/or CPiV and/or to prevent or treat a CAV, CDV and/or CPiV infection.

23. 20260295036**VACCINE** FOR TREATING ALLERGIES

US - 01.10.2026

Clasificación Internacional A61K 39/35Nº de solicitud 19127971Solicitante WORG PHARMACEUTICALS (ZHEJIANG) CO., LTDInventor/a Alexander KARAULOV

A peptide consisting of 20 to 30 amino acid residues derived from amino acid position 120 to 171 of mature allergen Fel d 4 is provided as well as fusion proteins comprising said peptide. A vector includes a nucleic acid molecule encoding the peptide. A **vaccine** formulation includes the peptide is effective in prevention or treatment of a furry animal allergy.

24. 20260306607**VACCINE** COMPOSITIONS

US - 08.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19481466Solicitante Seqirus Inc.Inventor/a Douglas Widman

The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in **vaccine** compositions. In some examples, the RNA also encodes a chemoattractant, such as chemerin, C-X-C motif chemokine ligand 9 (CX-CL9), C-X-C motif chemokine ligand 10 (CXCL10) or C-X-C motif

chemokine ligand 11 (CXCL11). The present disclosure also relates to use of the RNAs and compositions in methods of inducing an immune response in a subject.

25. WO/2026/210006 COMBINATION THERAPY COMPRISING AN RNA CANCER **VACCINE** AND AN ANTI-HER3 ANTIBODY-DRUG CONJUGATE FOR CANCER TREATMENT

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2026/059874 Solicitante BIONTECH SE Inventor/a SAHIN, Ugur

The present invention relates to combination therapy using an RNA anti-cancer **vaccine** in combination with an anti-HER3 antibody-drug conjugate to reduce or prevent progression of cancer or to treat cancer.

26. 20260306615 COMBINATION **VACCINE**

US - 08.10.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19482706 Solicitante Seqirus Inc. Inventor/a Cheng Chang

The present disclosure relates to compositions comprising multiple antigens of interest for use in **vaccine** formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.

27. WO/2026/207046 PROCESS FOR PRODUCING NATIVE OUTER MEMBRANE VESICLES (NOMVS) FROM BACTERIA

WO - 01.10.2026

Clasificación Internacional C12N 1/21Nº de solicitud PCT/US2026/020680 Solicitante OMVAX, INC. Inventor/a MOE, Gregory R.

Disclosed herein is a combination **vaccine** based on outer membrane vesicles (OMVs) with overexpressed recombinant antigens that is broadly protective against *Neisseria meningitidis* (Nm) and *Neisseria gonorrhoeae* (Ng). The OMVs were produced from strains with the acyl transferase LpxL1 knocked out to attenuate endotoxin activity. Factor H binding protein (FHbp) mutants with reduced Factor H (FH) binding from subfamilies A and B were overexpressed in the Nm strains. The Ng strain also had reduction modifiable protein knocked out. The combination **vaccine** maintained broad serum bactericidal activity (SBA) with human complement against diverse Nm and Ng strains grown in the presence of CMP-NANA, showing no significant reduction in SBA compared to the respective individual vaccines even though the dose of each was decreased by half. Further disclosed are processes for producing outer membrane vesicles (OMVs) from bacteria that acquire iron from human transferrin comprising growing the bacteria in culture medium comprising recombinant human transferrin; compositions comprising outer membrane vesicles (OMVs), bacteria that acquire iron from human transferrin, and recombinant human transferrin.

28. 20260297137 UNIVERSAL AVIAN FLU **VACCINE** (AIV)

US - 01.10.2026

Clasificación Internacional C07K 14/005Nº de solicitud 19094937Solicitante DEI BiopharmaInventor/a Matthias Magoola

The universal **vaccine** of the present invention can induce one or more targeted immune responses against a broad range of AIV subtypes by incorporating their antigen-producing sequences for cross-protection against various subtypes of AIV. In another embodiment, the invention is manufactured by recombinant or RNA technology, either for in vitro manufacturing or vivo administration, and administered by parenteral or inhalation route.

29.20260295037SAPONIN DMLT ADJUVANTS AND RELATED USES

US - 01.10.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19120270Solicitante Q-VANT BIOSCIENCES, INC.Inventor/a Elizabeth NORTON

A composition, preferably an immune adjuvant system, for vaccines containing a saponin component and a dmLT component. The combination of the saponin component and the dmLT component shows a synergistic effect in the treatment of various conditions, illnesses and diseases. The methods of use for prophylactic use or therapeutic treatment are disclosed. Exemplary adjuvant compositions include a double-mutant heat-labile toxin adjuvant derived from an *Escherichia coli* enterotoxin and a saponin, optionally with an additional **vaccine** component (e.g., an antigen), particularly when used in a **vaccine**.

30.WO/2026/213404PROPHYLACTIC NEO-ANTIGEN VACCINATION TO ENHANCE IMMUNE SURVEILLANCE IN ADVANCED ALK+ NONSMALL CELL LUNG CANCER

WO - 08.10.2026

Clasificación Internacional C07K 14/82Nº de solicitud PCT/US2026/022075Solicitante THE JOHNS HOPKINS UNIVERSITYInventor/a LAM, Vincent K.

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for cancer, in particular, lung cancer. In particular embodiments, the present invention comprises a neoantigen peptide **vaccine** in combination with ALK TKI for advanced ALK+ NSCLC. In more specific embodiments, the **vaccine** targets about 7-10 of the most prevalent resistance alternations in ALK (e.g., primarily single points mutations and a deletion), representing approximately 80-90% of second generation TKI resistance mutations. The present invention forms the basis of a new treatment paradigm for ALK+ patients and, in further embodiments, for neo-antigen specific immunotherapies in other targetable oncogenic-driven tumors.

31.WO/2026/204005INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, AND PROGRAM

WO - 01.10.2026

Clasificación Internacional G16H 20/10Nº de solicitud PCT/JP2026/006313Solicitante NEC CORPORATIONInventor/a MIURA Daiki

This information processing device comprises: a first acquisition means for acquiring first authentication information associated with a cancer **vaccine**; a second acquisition means for acquiring genome information

obtained by analyzing a specimen collected from a target patient before administration of the cancer vaccine; a conversion means for converting the genome information into second authentication information; and a comparison means for comparing the first authentication information with the second authentication information.

32. 20260306623 VACCINE ADJUVANTS

US - 08.10.2026

Clasificación Internacional A61K 39/385Nº de solicitud 19482978Solicitante Seqirus Inc.Inventor/a Douglas G. Widman

The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidin or a fragment thereof. The present disclosure also relates to use of the RNAs, polynucleotides or compositions in methods of inducing an immune response in a subject.

33. WO/2026/209996 COMBINATION THERAPY COMPRISING AN RNA CANCER VACCINE AND AN ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE FOR CANCER TREATMENT

WO - 08.10.2026

Clasificación Internacional A61K 47/68Nº de solicitud PCT/EP2026/059854Solicitante BIONTECH SEInventor/a SAHIN, Ugur

The present invention relates to combination therapy using an RNA anti-cancer vaccine in combination with an anti-B7-H3 antibody-drug conjugate to reduce or prevent progression of cancer or to treat cancer.

34. 3080090 MALARIA VACCINE

ES - 01.10.2026

Clasificación Internacional C12N 15/09Nº de solicitud 17869200Solicitante Sumitomo Pharma Co., Ltd.Inventor/a FUKUSHIMA, Akihisa

35. 20260297141 TP0751 CHIMERA-CONTAINING VACCINE

US - 01.10.2026

Clasificación Internacional C07K 14/20Nº de solicitud 19479497Solicitante UVIC INDUSTRY PARTNERSHIPS INC.Inventor/a Caroline E. Cameron

Provided are chimeric Tp0751 (99-237) peptides containing one or more non-native epitopes that replace all or of part of one or more loops 1-8 of the native Tp0751 (99-237) peptide. The non-native epitopes can be from one or more sexually transmitted infections (STIs), such as *Treponema pallidum*, *Chlamydia*, or *Neisseria gonorrhoeae*. Also provided are nucleic acid molecules that encode the chimeric Tp0751 (99-237) peptides. Methods of using the chimeric Tp0751 (99-237) peptides to stimulate an immune response, for example to treat syphilis or other sexually STIs are provided.

36. WO/2026/208185 USE OF CCR5^{HI} INNATE IMMUNE MEMORY CELL IN PREPARATION OF IMMUNOTHERAPEUTIC DRUG FOR TREATING SEPSIS

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2025/137377Solicitante CHILDREN'S HOSPITAL OF SOOCHOW UNIVERSITYInventor/a ZHOU, Huiting

Disclosed is use of a CCR5^{hi} innate immune memory cell in the preparation of an immunotherapeutic drug for treating sepsis. Provided is a CD45⁺CD11b⁺Ly6G⁻Ly6C⁺CCR5^{hi} monocyte, which is an innate immune memory cell that is produced by trained immunity induced by a combination of the Bacillus Calmette-Guérin vaccine and bacterial lipoprotein and has a protective effect against sepsis. By means of single-cell sequencing analysis and functional verification, the cell subpopulation characteristics thereof are accurately identified, and the functional mechanism thereof is clarified, thereby filling the key gap of "the effector cell identity being unclear and the action target being unclear" in the prior art and providing a cell-level theoretical basis and technical solutions for targeted immunotherapy for sepsis. The present invention is expected to achieve a better therapeutic effect in clinical practice.

37.WO/2026/213508IMPROVED CHLAMYDIA VACCINE COMPOSITIONS AND METHODS OF USE THEREOF

WO - 08.10.2026

Clasificación Internacional A61K 39/118Nº de solicitud PCT/US2026/022233Solicitante VAXCYTE, INC.Inventor/a ROZZELLE, James

Provided herein are compositions containing chlamydial protease-like activity factor (CPAF) polypeptide and QUIL-A and uses thereof for immunization.

38.20260306602DEVELOPMENT OF CARBOHYDRATE-BASED ANTI-SALMONELLA VACCINES

US - 08.10.2026

Clasificación Internacional A61K 39/112Nº de solicitud 18998478Solicitante Board of Trustees of Michigan State UniversityInventor/a Xuefei Huang

Provided herein are vaccine compositions comprising *Salmonella* antigens conjugated to a capsid, wherein said capsid comprises wild type or native sequence, or said capsid may comprise at least one mutation, such as a non-natural mutation; such compositions being useful in the treatment and prevention of a *Salmonella* infection (salmonellosis), gastroenteritis, typhoid fever, and/or paratyphoid fever; and may be effective against multiple strains of *Salmonella*.

39.20260306613PREFUSION-STABILIZED HUMAN PARAINFLUENZA VIRUS 3 F PROTEINS

US - 08.10.2026

Clasificación Internacional A61K 39/155Nº de solicitud 19146737Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a Jason McLELLAN

Provided herein are engineered parainfluenza virus fusion protein (PIV F) polypeptides. In some aspects, the engineered PIV F polypeptides exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered PIV F polypeptides as diagnostics, in screening platforms, and/or in vaccine compositions.

40. WO/2026/201149 NEW MULTIVALENT RECOMBINANT MDV VECTOR **VACCINE**

WO - 01.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/CN2026/086594 Solicitante GUANGZHOU KINGMIAO ANIMAL HEALTH CO., LTD. Inventor/a SONG, Chaoyi

The present invention provides novel recombinant Marek's disease virus (MDV), which involves a novel insertion site for heterologous genes and/or expression cassettes, and/or efficiently co-expresses multiplexed heterologous antigens by optimizing the heterologous antigenic expression regulatory elements, combinations of the expression regulatory elements and their linkage to the antigens, and/or combinations of multiple insertion sites. Also provided are the use of the recombinant MDV in vaccines, and methods of constructing the same.

41. 20260306624 A NOVEL NON-STOICHIOMETRIC MULTI-ELEMENT ADJUVANT (NSMA) AND COMPOSITION THEREOF

US - 08.10.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19485016 Solicitante MAGVITAE INNOVATIONS INC Inventor/a Manzoor Koyakutty

The present invention broadly relates to the field of immunology. Particularly, the present invention relates to a non-stoichiometric multi element adjuvant (NSMA) as immunomodulatory material, a method for preparing the same, a composition comprising the non-stoichiometric adjuvant. Also, the present invention relates to non-stoichiometric multi-element adjuvant (NSMA) doped with various ions and application of non-stoichiometric adjuvant in various forms of **vaccine**, immunotherapy and theranostics (diagnosis and therapy).

42. 20260295034 CORONAVIRUS S2 IMMUNOGENS

US - 01.10.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19489384 Solicitante The Scripps Research Institute Inventor/a William SCHIEF

The present invention relates to coronavirus immunogens and a **vaccine** platform for coronaviruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered pathogen S2 subunit and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.

43. 20260295029 INFLUENZA EHEAD IMMUNOGENS

US - 01.10.2026

Clasificación Internacional A61K 39/145Nº de solicitud 19489371 Solicitante The Scripps Research Institute Inventor/a William SCHIEF

The present invention relates to influenza immunogens and a **vaccine** platform for influenza viruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered

hemagglutinin lateral patch sequence and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.

44. 20260306619 NATURAL ATTENUATED STRAIN OF INFECTIOUS LARYNGOTRACHEITIS VIRUS WITH GOOD SAFETY AND GOOD IMMUNOGENICITY AND USE THEREOF

US - 08.10.2026

Clasificación Internacional A61K 39/245Nº de solicitud 19106818 Solicitante INSTITUTE OF ANIMAL HUSBANDRY AND VETERINARY MEDICINE, FUJIAN ACADEMY OF AGRICULTURAL SCIENCES Inventor/a Bo HOU

Provided is a natural attenuated strain of infectious laryngotracheitis virus attenuated strain (ITLV) with good safety and good immunogenicity. The natural attenuated strain, designated as ILTV FJ19, has been deposited in the China Center for Type Culture Collection on Nov. 29, 2023 with a deposit number of CCTCC NO: V2023109, the deposit address is No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province. Experiments have shown that the avian infectious laryngotracheitis virus ILTV FJ19 strain has a stable passaging ability, may adapt to inoculation via the allantoic cavity route, has good safety and good immunogenicity when inoculated to 14-day-old SPF chickens. The strain may be used through eye-drop vaccination or oral administration, making it a candidate strain for attenuated live **vaccine** against ILTV.

45. 3080448 ORAL TUMOR **VACCINE**

ES - 05.10.2026

Clasificación Internacional C12N 1/21Nº de solicitud 16814103 Solicitante National University Corporation Kobe University Inventor/a SHIRAKAWA, Toshio

46. 20260306600 SARCOMA CANCER VACCINES AND USES THEREOF

US - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19481504 Solicitante MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor/a Christopher A. Klebanoff

The present disclosure provides **vaccine** compositions comprising recombinant SS 18::SSX fusion peptide epitopes and at least one cancer-testis antigen (CTA) epitope, or nucleic acids (e.g., mRNA, cDNA) encoding the same, and methods for using the same to treat sarcoma (e.g., synovial sarcoma) in a subject in need thereof.

47. 3325398 LIPID NANOPARTICLES COMPRISING GINSENOSE OR DERIVATIVE THEREOF, AND USE THEREOF

CA - 08.10.2026

Clasificación Internacional A61K 9/51Nº de solicitud 3325398 Solicitante GENOMICTREE, INC. Inventor/a AN Sungwhan

The present invention relates to lipid nanoparticles comprising ginsenoside or a derivative thereof, and use thereof, and, specifically, to: lipid nanoparticles containing vegetable ginsenoside or a derivative thereof

included in ginseng or red ginseng, instead of animal cholesterol for the delivery of therapeutic or vaccine nucleic acids; nucleic acid-inorganic nanoparticles in which lipid nanoparticles encapsulating the nucleic acid-inorganic nanoparticle, and a preparation method therefor; and a nucleic acid delivery composition comprising same.

48. WO/2026/213426 METHANOGENS FOR CELL-BASED VACCINES

WO - 08.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2026/022102Solicitante ARKEA BIO CORP.Inventor/a DUNN, Matthew

The present invention relates to cell-based vaccine compositions and methods that reduce methane and/or hydrogen production in animals. The present invention relates to the treatment of diseases that are associated with methanogens. The present invention also relates to methods of growing hydrogenotrophs in safe anaerobic conditions.

49. 20260295025 COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE

US - 01.10.2026

Clasificación Internacional A61K 39/02Nº de solicitud 19401907Solicitante Valneva Austria GmbHInventor/a Nicole Bézay

The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipS1D1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.

50. 20260306601 COMPOSITIONS AND METHODS FOR GENERATING IMMUNITY TO BACTERIAL INFECTION

US - 08.10.2026

Clasificación Internacional A61K 39/02Nº de solicitud 19490833Solicitante Syntiron LLCInventor/a Leah Randles

The present disclosure relates, in part, to a polypeptide of formula (I), or a salt or solvate thereof, and a vaccine composition thereof further comprising at least one pharmaceutically acceptable excipient. The present disclosure further relates to isolated mRNA and/or isolated polynucleotides encoding the polypeptide of formula (I), vectors and/or LNPs comprising the same, and pharmaceutical compositions thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a bacterial infection, and/or generating immunity to infection by one or more pathogenic bacteria, in a subject in need thereof, the method comprising administering to the subject at least one composition of the present disclosure. In certain embodiments, the bacterial infection is a urinary tract infection, sepsis (e.g., neonatal sepsis), or pneumonia.

51. 4817599 VERFAHREN ZUR VERKAPSELUNG VON MYCOBACTERIUM BOVIS BCG-IMPFSTOFFBAKTERIEN IN EINEM ALGINATTRÄGER ZUR BEKÄMPFUNG EINER HELICOBACTER PYLORI-INFEKTION

EP - 07.10.2026

Clasificación Internacional A61K 9/16Nº de solicitud 26166123Solicitante UNIV LODZKIInventor/a GONCIARZ WERONIKA

52.20260295024KITS FOR TRICHINELLA VACCINATION BASED ON A PRIME-BOOST SEQUENTIAL IMMUNIZATION REGIMEN

US - 01.10.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19679577Solicitante JILIN UNIVERSITYInventor/a Xiaolei LIU

Provided is a kit for a *Trichinella* vaccination, the kit including into two parts, a first part being a *Trichinella* recombinant protein **vaccine** that includes a *Trichinella* recombinant protein with an amino acid sequence as shown in SEQ ID NO:2, and a second part being a recombinant adenovirus expressing a protein with an amino acid sequence as shown in SEQ ID NO:1.

53.20260306658METHODS OF SENSITIZING TUMORS TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

US - 08.10.2026

Clasificación Internacional A61K 47/69Nº de solicitud 19358600Solicitante UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor/a Elias Sayour

The present disclosure provides methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI) in a subject and methods of treating a subject with an immune checkpoint inhibitor (ICI)-resistant tumor. The methods comprise administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Also provided are methods of increasing the number of activated plasmacytoid dendritic cells (pDCs) in a subject in need thereof, comprising administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Combination therapy with anti-PD-L1 mAb. Related methods of treatment and methods of preparing a dendritic cell **vaccine** are additionally provided.

54.3324076RECOMBINANT POLIOVIRUS-LIKE PARTICLE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF

CA - 08.10.2026

Clasificación Internacional A61K 39/13Nº de solicitud 3324076Solicitante CANSINO BIOLOGICS INC.Inventor/a YAN Qiaoling

Provided are a recombinant poliovirus-like particle immune composition, a preparation method therefor, and use thereof. The recombinant poliovirus-like particle immune composition comprises type I, type II, and/or type III poliovirus-like particles, wherein the type I, type II, and/or type III poliovirus-like particles have a suitable particle content. The prepared recombinant poliovirus-like particle immune composition and **vaccine** have a simple constituent and a weak side effect, and have significant advantages in the aspects of safety, immune efficacy, stability, and adaptability relative to existing inactivated vaccines and attenuated vaccines.

55.2026234074TLR4-TLR7 LIGAND FORMULATIONS AS **VACCINE** ADJUVANTS

AU - 01.10.2026

Clasificación Internacional A61K 39/145Nº de solicitud 2026234074Solicitante The Regents Of The University Of CaliforniaInventor/a CARSON, Dennis A.

56.WO/2026/199476NEW MULTIVALENT RECOMBINANT MDV VECTOR **VACCINE**

WO - 01.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/CN2025/085812Solicitante GUANGZHOU KINGMIAO ANIMAL HEALTH CO., LTD.Inventor/a SONG, Chaoyi

The present invention provides novel recombinant Marek's disease virus (MDV), which involves a novel insertion site for heterologous genes and/or expression cassettes, and/or efficiently co-expresses multiplexed heterologous antigens by optimizing the heterologous antigenic expression regulatory elements, combinations of the expression regulatory elements and their linkage to the antigens, and/or combinations of multiple insertion sites. Also provided are the use of the recombinant MDV in vaccines, and methods of constructing the same.

57.WO/2026/213357VACCINES AGAINST TOXICITY FROM ALPHA-2-ADRENERGIC RECEPTOR AGONISTS EXPOSURE

WO - 08.10.2026

Clasificación Internacional C07D 279/06Nº de solicitud PCT/US2026/021997Solicitante UNIVERSITY OF WASHINGTONInventor/a PRAVETONI, Marco

Compositions, systems and methods for xylazine-based hapten-carrier conjugate vaccines are described herein. A hapten can be based on a xylazine structure. A xylazine-based hapten can be conjugated to a carrier molecule. A xylazine-based hapten can be used in a **vaccine** for inducing a humoral response in the recipient.

58.3081070RECOMBINANT **VACCINE** AGAINST HELMINTHS INPICHIA PASTORIS

ES - 08.10.2026

Clasificación Internacional C07K 14/435Nº de solicitud 18741098Solicitante Fundação Oswaldo CruzInventor/a SIMPSON, Andrew J G

59.20260306610SYSTEMS AND METHODS FOR DELIVERY OF VIRAL ANTIGENS

US - 08.10.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19631969Solicitante Veergen Inc.Inventor/a Gustavo Garcia, Jr.

Systems and methods for generating viral vectors, including systems and methods for generating Dengue **vaccine** are described. Generally, a viral vector can comprise structural proteins from a non-dengue *Orthoflavivirus* species and a genetic code for nonstructural proteins from dengue virus or a different *Orthoflavivirus* species. Viral vectors can be produced to yield vaccines to stimulate immune response to the *Orthoflavivirus* species providing genetic code for nonstructural proteins.

60. 20260295009 HUMORAL MODULATION IN VACCINATED AND VIRALLY INFECTED SUBJECTS WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)

US - 01.10.2026

Clasificación Internacional A61K 38/19Nº de solicitud 19480710 Solicitante PARTNER THERAPEUTICS, INC. Inventor/a Ila JOSHI

The present disclosure relates to the treating or preventing a viral infection in a subject who has received a viral **vaccine** with granulocyte-macrophage colony-stimulating factor.

61. 20260309709 ACE2 INHIBITION ASSAY FOR EVALUATION OF **VACCINE** IMMUNOGENICITY

US - 08.10.2026

Clasificación Internacional G01N 33/569Nº de solicitud 18998471 Solicitante NOVAVAX, INC. Inventor/a Joyce S. PLESTED

An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.

62. 20260306603 LIPID NANOPARTICLES FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS

US - 08.10.2026

Clasificación Internacional A61K 39/04Nº de solicitud 19141236 Solicitante Akagera Medicines, Inc. Inventor/a Ross Fulton

Aspects of the present disclosure provides for improved *Mycobacterium tuberculosis* **vaccine** compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.

63. WO/2026/207443 CANINE ADENOVIRUS ASSEMBLY METHODS

WO - 01.10.2026

Clasificación Internacional C12N 15/86Nº de solicitud PCT/US2026/021285 Solicitante SALK INSTITUTE FOR BIOLOGICAL STUDIES Inventor/a O'SHEA, Clodagh

Methods for the modular assembly of canine adenovirus (CAV) genomes, referred to as CAVSLIC and CAVsembly, are described. The modular assembly platform allows a CAV genome to be split into functional modular plasmid units that can be engineered and systematically and rapidly assembled in different combinations. The modular units are assembled using multi-site recombination or a seamless cloning method

to create synthetic CAV vectors or fully replication-competent virus that can be produced to high titers for gene therapy, oncolytic therapy and vaccine applications.

64.4816384MULTIVALENTE IMPFSTOFFZUSAMMENSETZUNGEN

EP - 07.10.2026

Clasificación Internacional C07K 14/31Nº de solicitud 24898320Solicitante AUCKLAND UNISERVICES LTDInventor/a CLOW FIONA

65.4818322TOLLWUTIMPFSTOFFIMMUNOGENZUSAMMENSETZUNG

EP - 07.10.2026

Clasificación Internacional C12N 15/47Nº de solicitud 24895314Solicitante ZHONGSHAN HOSPITAL FUDAN UNIVInventor/a XU JIANQING

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búsqueda: vaccine.ti. AND @PD>="20261001"<=20261012 21 records

Document ID	Title	Inventor	Applicant Name
US 20260306616 A1	Spike Protein Based Genetic Vaccines	Hasan; Syed Saif et al.	University of Maryland, Baltimore
US 20260306618 A1	A Vaccine Against Erysipelothrix Rhusiopathiae and Porcine Parvo Virus	JACOBS; Antonius Arnoldus Christiaan	INTERVET INC.
US 20260306620 A1	Tumor Neoantigen Vaccine System Specifically Marking Heterologous Protein, And Use Thereof	YANG; Yong et al.	China Pharmaceutical University
US 20260306602 A1	Development Of Carbohydrate-Based Anti-Salmonella Vaccines	Huang; Xuefei et al.	Board of Trustees of Michigan State University, University of Maryland, Baltimore
US 20260309709 A1	Ace2 Inhibition Assay for Evaluation of Vaccine Immunogenicity	Plested; Joyce S. et al.	NOVAVAX, INC.

US 20260311803 A1	Computational Methods for Selecting Personalized Neoantigen Vaccines	O'Donnell; Tim et al.	Icahn School of Medicine at Mount Sinai
US 20260306614 A1	Vaccine Compositions	ARAFA; Emad et al.	Sail Biomedicines, Inc.
US 20260306604 A1	Mucosal Vaccines Against Tuberculosis	Varadarajan; Navin et al.	University Of Houston System
US 20260306605 A1	Inhaled Adenovirus Vector Vaccine, Preparation Method Therefor and Use Thereof	ZHAO; Xiaolong et al.	Cansino Biologics Inc.
US 20260306600 A1	Sarcoma Cancer Vaccines and Uses Thereof	Klebanoff; Christopher A. et al.	Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, Sloan-Kettering Institute for Cancer Research
US 20260306608 A1	Vaccines Against African Swine Fever Virus, And Methods of Using Same	Weiner; David	The Wistar Institute of Anatomy and Biology
US 20260306607 A1	Vaccine Compositions	Widman; Douglas et al.	Seqirus Inc.
US 20260306615 A1	Combination Vaccine	Chang; Cheng et al.	Seqirus Inc.
US 20260306623 A1	Vaccine Adjuvants	Widman; Douglas G. et al.	Seqirus Inc.
US 12751954 B2	Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds	Smith; Christopher W. et al.	Principia Biopharma Inc.
US 12752003 B2	Lipidated FLIPr and uses thereof in vaccine	Chen; Hsin-Wei et al.	National Health Research Institutes

US 20260295027 A1	Orally-Delivered Vaccines for Domesticated and Wild Animals to Prevent Pathogen Spread Using Recombinant Probiotic Bacteria	FOY; Brian D. et al.	Colorado State University Research Foundation
US 20260297137 A1	Universal Avian Flu Vaccine (Aiv)	Magoola; Matthias	DEI Biopharma
US 20260295028 A1	Nanoparticle-Based Influenza Virus Vaccines and Uses Thereof	Kanekiyo; Masaru et al.	The USA, as represented by the Secretary, Department of Health and Human Services, University of Washington
US 20260295036 A1	Vaccine for Treating Allergies	KARAULOV; Alexander et al.	Worg Pharmaceuticals (Zhejiang) Co., Ltd
US 20260297141 A1	Tp0751 Chimera-Containing Vaccine	Cameron; Caroline E. et al.	Uvic Industry Partnerships Inc., University of Washington

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
 Randelys Molina Castro rmolina@finlay.edu.cu
 Claudia Camejo Salas ccamejo@finlay.edu.cu
 Yamira Puig Fernández yamipuig@finlay.edu.cu

